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Abstract
This thesis is about the economic evaluation of interventions for air pollution control. It is
structured around three major components. First, a critical analysis of current methods for
health impact quantification in the environmental health literature. Second, the development
of a Markov model of the health impacts of long-term exposure to air pollution, using the
quality-adjusted life year as health metric, in order to evaluate the cost-effectiveness of
reducing air pollution in England. Third, evidence synthesis and COPD incidence estimation
by severity stage, in order to parameterize the model developed.
I demonstrate that the current approach to quantifying the health benefits from air
pollution reduction leads to substantially biased estimates. By ignoring interactions between
morbidity and mortality impacts, including differential susceptibility to risk by health status,
it overestimates the change in morbidity cases and underestimates life expectancy effects.
I also show that current European guidelines for uncertainty analysis in assessments of air
pollution control interventions underestimate decision uncertainty and may misguide air
quality strategies.
My Markov model fully captures, for the first time, the lifetime impact of air pollution
exposure on individuals’ quality and length of life, and identifies the joint health care budget
impact of a reduction in chronic morbidity and premature death. Air quality improvement
has important health implications. In London, investing up to £500 million to reduce
fine particulate concentrations by 1 µg/m3 (i.e. by 7%) is highly likely to be cost-effective,
whether the investment is funded by the NHS or through taxation. If this improvement were
to cost more than that, however, funding through taxation is more likely to be cost-effective
than funding via the NHS, since consumer willingness to pay for a QALY is higher than the
estimated NHS expenditure required to deliver one QALY. The optimal level of pollution
reduction, as well as the decision about whether and for how long to delay investments, is
therefore expected to depend on the source of financing.
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Preface
On completion of my Baccalaureat, I hesitated between Medical and Business
studies and finally opted for the latter, driven by the perspective to travel
around the world and work abroad. I was seventeen back then...
The highroad for entry to leading Business schools in France is through
two or three years of “classes preparatoires” which pave the way for the com-
petitive entry exams to each school. The preparation consists of fast-pace in-
tensive learning of a range of subjects such as: maths, programming, history,
philosophy, languages, in short, everything but business studies. It is also
characterised by a particular teaching approach where getting negative marks
and being told that you are “as thick as clotted cream” is not uncommon, but
solely designed to spur excitement towards learning more and working even
harder. I guess it worked for me as, at the time, I felt I had never learned so
much in all my life. The working methods which I acquired during those two
years of preparation proved to be precious throughout the entire course of my
academic studies.
After completing my business studies, I settled for a committed job in the
city of London as admittedly, over the years I had compromised on my wish
to travel the world. Whilst the position was stimulating, I soon realised deep
down that I had no real enthusiasm for what I was doing, although this would
take up a great amount of my time and energy.
At that point I began to think seriously about something I had always felt a
great concern for: our natural environment, but yet until then, had not really
considered orienting my career towards. So after two years in asset manage-
ment I enrolled on the MSc in Environmental Economics at the University of
York. I am glad I dared to take this step.
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In the course of familiarising with the concept of ecosystem services, I be-
came very interested in the economic implications of the linkages between our
natural environment and human health. This PhD thesis is the result of my
desire to nurture this interest. It focuses on one particular aspect: the air we
breathe. I hope however, to have the opportunity in the future to work on
many other interconnections between our health and natural ecosystems and
the economic benefits of rebuilding or maintaining these relationships, espe-
cially in a context where due to man-made global warming the Earth’s climate
is set to change at an increasing pace.
I wish to thank my parents for supporting my decisions and for being there
for me, during moments of doubt and frustration. Most importantly, I wish to
thank my partner Daniele who strongly encouraged me to re-orient my career
and shared with me both the exciting and difficult moments of this PhD.
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Chapter 1
Introduction
Environmental threats, in a broad sense, are estimated to be responsible
for 23% of premature deaths globally (Pru¨ss-U¨stu¨n & Corvala´n, 2006). My
PhD research aims to support decision-making pertaining to the evaluation of
environmental health interventions (EHI), which are government interventions
designed to improve population health by reducing environmental hazards.
This thesis draws from quantification techniques used in the health economics
literature, in order to address a number of methodological challenges associ-
ated with the quantification of health benefits and costs of EHIs and proposes
a complementary approach to the economic evaluation of this type of inter-
ventions.
To achieve this objective, I chose to focus on EHIs of outdoor air pollu-
tion control. This choice was underpinned by the following three rationales.
First, outdoor air pollution is ubiquitous, i.e. everybody is exposed to it to
some extent. As a result, it is a major driver of ill-health globally, ranking as
the 9th risk factor out of a total of 43 by attributable burden of disease for
the year 2010 (Lim et al., 2012). Whilst the greatest health burden is borne
by countries in East and South Asia, which are typically characterised with
high concentrations of air pollutants, outdoor air pollution remains an impor-
tant public health issue in developed countries, insofar as no safe level of air
pollution has been identified. In England, which is the focus of this thesis,
chronic exposure to current levels of air pollution was recently estimated to be
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responsible for 25,000 premature deaths annually (Gowers et al., 2014).
Second, the costs of abating air pollution are considerable. For instance,
in the US, the Environmental Protection Agency estimated that the annual
costs of the National Ambient Air Quality Standards exceeded $ 80 billion
annually (US EPA, 1999). This puts decision-makers under great pressure to
assess whether further air quality efforts are worthwhile, and bestow particular
economic importance to improvements in the validity and accuracy of estimates
of the health benefits associated with air pollution control.
Third, quantification of health impacts associated with a reduction in pop-
ulation exposure to an given environmental hazard requires quantitative evi-
dence of associations between exposure and health effects. The health impacts
of exposure to outdoor air pollution have been intensively quantified by epi-
demiological studies (Medina et al., 2013). Interventions of air pollution con-
trol are therefore perfect candidates to support the analysis and development
of an alternative approach to economic evaluation of EHIs. Whilst outdoor
air pollution is constituted by a mixture of pollutants, particulate matter is
considered to adversely affect population health more than any other air pol-
lutant (WHO, 2014) and accordingly, this thesis focuses on fine particulate air
pollution (PM2.5).
My research contributes to knowledge pertaining to the economic evalua-
tion of air pollution control interventions in several ways: (i) by evaluating
and identifying two major limitations associated with the traditionally used
method to health benefit quantification, including its impact on predictions’
validity; (ii) by developing an approach based on Markov modelling that fully
captures, for the first time, air pollution’s joint impact on quality and length of
life and on health care costs; (iii) by performing systematic searches and sta-
tistical analyses of the epidemiological evidence base pertaining to a selected
set of health endpoints and (iv) by developing an approach to address both
underdiagnosis and late diagnosis issues that characterise chronic obstructive
pulmonary disease, so that the public health benefits of reducing the risk of
developing this disease as a result of air quality efforts are correctly quantified;
(v) by providing estimates of impacts that inform decision-making about the
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UK air quality strategy.
This thesis is structured as follows. Chapter 2 reviews the literature rel-
evant to the economic evaluation of air pollution control interventions. It is
structured in three parts pertaining to: (i) the epidemiological evidence base,
with a focus on study design and statistical approaches to effect estimation;
(ii) decision-making tools used in the environment and health policy fields and
their respective theoretical underpinnings; (iii) the methodology to quantify
health benefit and valuations approaches currently used in economic evalua-
tions of air pollution control interventions.
Chapter 3 pertains to the first essential step to policy evaluation: impact
quantification. This chapter is addressed to the wide audience of health im-
pact assessment practitioners for environmental policies. It focuses on the
limitations associated with the current approach to quantification, where mor-
bidity and mortality are quantified separately and argues for a simultaneous
quantification of impacts using Markov modelling.
Chapter 4 relies on the simultaneous approach to quantification advocated
in Chapter 3 and develops a Markov Model to refine the understanding of air
pollution control benefits. It assesses life expectancy gains but also improve-
ments in quality of life, using the quality-adjusted life year (QALY) as health
metric, and evaluates the total health care budget impact of a decrease in both
morbidity and premature mortality. This is the first study to fully capture par-
ticulate air pollution’s influence on the individual’s baseline quality of life, life
expectancy and level of susceptibility to adverse effects, which are crucial to
perform a cost per QALY analysis of air pollution control interventions.
Chapters 5 and 6 aim at charaterising parameter uncertainty pertaining to
the estimation of the health benefits and health care resource impacts of air
pollution control. The obtained parameters are fed into the Markov model de-
veloped in Chapter 4. Chapter 5 develops a coherent probabilistic framework
to estimate the age-specific annual probability of being diagnosed at a given
stage of COPD and applies it to the general population of England. Chapter
6 performs a systematic review and two meta-analyses of the association be-
tween long-term exposure to particulate air pollution and respectively all-cause
mortality and lung cancer.
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Chapter 7 presents the results from the application of the model developed
in Chapter 4 to the UK, in order to support the UK air pollution strategy. It
evaluates the cost-effectiveness of air pollution reduction in London, whether
such an intervention would be funded by the NHS or via general taxation.
Finally, Chapter 8 concludes the thesis. Its aims are fourfold: (i) to restate
the overall structure of the thesis; (ii) to underline the contributions of the
work undertaken; (iii) to highlight its limitations and (iv) to outline some
avenues for further research.
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Chapter 2
Review of literature
2.1 The adverse health effects of outdoor air pollution
2.1.1 Outdoor air pollution: background
Air pollution results from the release in the atmosphere of a mixture of: (i)
gases and vapour-phase compounds, such as nitrogen oxides (NOx), sulphur
dioxide (SO2), ammonia (NH3), volatile organic compounds and (ii) particu-
late matter, which is a mixture of liquid and solid compounds (Brook et al.,
2010). These compounds are either emitted directly in the atmosphere or result
from the atmospheric interaction of primary air pollutants with sunlight and
water vapour. Particulate matter for instance, is constituted both by directly
emitted elemental and organic carbon and by secondarily formed pollutants
resulting from chemical reactions between SO2, NOx, NH3 and organic gases
in the atmosphere (US EPA, 2012).
Air pollution is mostly the by-product of human activity (WHO, 2014).
Primary air pollutants are essentially generated by fossil fuel combustion for
power generation and transportation, but also result from various industrial
processes (e.g. cement plants, smelters, paper and still mills) as well as road
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dust, fertiliser use, livestock farming and biomass and waste burning (US EPA,
2012).
The awareness of the deleterious health impacts of air pollution at popu-
lation level, and not only as a cause of occupational disease, started to grow
in the 20th century, following a series of acute episodes of air pollution when
unfavourable weather conditions increased the concentrations of air pollutants
emitted from nearby factories (Jun, 2009). In particular, the upsurge in death
rates in the Meuse valley (Belgium) during a 4-day long sulphuric fog in De-
cember 1930 (Firkey, 1936) and the increase in death rates and respiratory
symptoms in Monongahela valley (Pennsylvania) during a short episode of
heavy smog in 1948 (Schrenk et al., 1949) provided the first pieces of evidence
on the potential toxicity of air pollution at community level. These events
were followed by London’s great smog in December 1952, which is estimated
to have led to 3,000 premature deaths in the three weeks following the event
and to 12,000 premature deaths until a year later (Bell & Davis, 2001). This
serie of acute air pollution episodes greatly contributed in arousing awareness
of the harmful effects of air pollution and spurred governments in enacting
the first national pieces of air pollution legislation, e.g. UK Clean Air Acts of
1956 and 1968, US Clean Air Act of 1970 which introduced the first National
Ambient Air Quality Standards.
Much of the epidemiological effort on identifying the health risk posed by air
pollution has focused on particulate matter (PM). Particulates are constituted
by hundreds of chemicals and greatly vary in size and shape (US EPA, 2012).
They are classified in terms of their aerodynamic diameter range. The three
size fractions are PM10, i.e. particles less or equal to 10 µm in diameter; PM2.5,
i.e. particles less or equal to 2.5 µm in diameter and PM0.1, i.e. particles less
or equal to 0.1 µm in diameter. PM10 are commonly referred to as coarse
particles, PM2.5 as fine particles and PM0.1 as ultra fine particles.
The effect of particles less or equal to 10 µm in diameter have been inten-
sively investigated since they cannot be filtered by the nose and upper airways
and thus, penetrate into the respiratory system, while the fine fraction also
pass into the blood stream (Marchwinska-Wyrwal et al., 2011). PM2.5 are
expected to be more harmful than PM10 since they have a longer life period,
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penetrate deeper into the human organism as well as into indoor environments
and carry more toxic compounds, e.g. sulphates, nitrates, acids, metals (Pope
III & Dockery, 2006). While PM0.1 are expected to be the most harmful, due
to the lack of monitoring of these particulates, to date the evidence base for
this pollutant is essentially based on laboratory-based toxicological studies.
2.1.2 Epidemiological studies: challenges and design typology
Challenges
Statistical analysis for causal inference of air pollution health effects in
human is challenging for two main reasons. First, since controlled randomisa-
tion of individuals to air pollution exposure is possible only under very strict
and limiting conditions, statistical analysis is overwhelmingly based on ob-
servational studies. The latter require extensive covariates adjustment and
sophisticated modelling techniques to control for factors that may confound
the association between air pollution exposure and health effect, where the
choice of confounding variables will depend on study design (Dominici et al.,
2003). Second, exposure measurement error appears inevitable as individual
exposure to air pollution exposure is typically proxied by levels of ambient
concentrations. Although exposure misclassification is not expected to pose a
threat to studies’ internal validity as participants should theoretically have an
equal likelihood to be assigned an inaccurate estimate of exposure, it affects
studies’ statistical power and can lead to imprecise estimates of health effects
(Raaschou-Nielsen et al., 2013).
The choice of epidemiological study design is motivated by the time-scale
of exposure to be investigated, namely short-term or long-term i.e. cumula-
tive. The latter determines the temporality of the health effect to be esti-
mated: acute or chronic and the source of variation in air pollution exposure
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to be exploited: temporal and/or spatial. In practice four main types of epi-
demiological study designs have been used to build evidence of air pollution
effects: time series, case-crossover, cross-sectional studies and cohort studies.
The health outcomes investigated by the first epidemiological studies were
typically death and hospitalisations. In recent years, however, continuous out-
comes such as changes in lung function (Eisner et al., 2010) and in levels of
coronary atherosclerosis (Adar et al., 2013) for instance, have also been in-
vestigated. Study design and the nature of health outcome investigated (e.g.
binary or continuous) drive the choice of statistical method for data analysis.
Studies of short-term changes in pollution
Time-series and case-crossover studies measure the change in daily counts
of deaths and rare morbidity events (e.g. hospitalisations) over a time window
of a few days, following a short-term peak in pollutants concentrations.
Time-series associate daily population-averaged exposure levels to count of
health outcomes, where the bias from data aggregation is expected to be small
if health effects are small and the frequency of disease outcome is low (Wake-
field & Salway, 2001). Whilst the statistical designs of the earliest time-series
were simple with count data being modelled using Poisson regression, adequate
control for time-dependent covariates (e.g. seasonality, weather) increasingly
became a primary concern. Since the mid-1990’s, generalised additive models
using non parametric smoothing have been extensively used to control for nat-
ural time-dependent fluctuations in mortality that would confound estimates
of air pollution adverse effect (Pope III & Dockery, 2006).
The case crossover design consists in matching individuals’ exposures at
time of death/morbid event with exposures during one or more control periods
in a retrospective case-control design, where each case represents his/her own
control. It exploits the individual’s variation in exposure over time using con-
ditional logistic regression. Unlike time-series, case crossover studies control
for seasonality and temporal trends in mortality by design through carefully
chosen control periods, rather than by statistical modelling with smooth func-
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tions (Dominici et al., 2003). Since the case-crossover design relies on events
at the individual level, as opposed to population-averaged counts of events, it
may be useful to investigate individual-level effect modification or susceptibil-
ity. The main drawback of this design, however, is that results can be sensitive
to the choice of periods used as controls (Pope III & Dockery, 2006).
Studies of long-term cumulative exposure
Whilst information about the acute health effects of pollution peaks is im-
portant, the understanding of the cumulative impact of long-term air pollution
is key to evaluate air pollution public health burden. The analysis of health
impacts from long-term exposure to air pollution typically exploits spatial vari-
ation in exposure between geographical areas over time. Two main types of
study design have been used by epidemiologists to study both binary and con-
tinuous health outcomes associated with cumulative exposure to air pollution:
cross-sectional studies and cohort studies.
Cross-sectional studies associate data on individuals health status (e.g. dis-
ease prevalence) and pollution concentration levels measured at a single point
in time. Whilst these studies are informative, they proxy long-term pollu-
tion exposure with actual air pollution concentrations (Brunebreef & Holgate,
2002) and oversimplify long term impacts (Sunyer, 2001). Consequently, al-
though cohort studies are expensive and time consuming, they are considered
the best source of epidemiological evidence of the long effects of exposure to
pollution (Pope III & Dockery, 2006)
Cohort studies associate long-term exposure with health outcomes by ex-
ploiting cumulative variation in individuals’ exposure between geographical
locations. Prospective cohort studies are preferred for their ability to control
for individual risk factors measured at enrolment, such as age, smoking his-
tory including passive smoking, occupational exposure to pollutants, drinking
habits, diet, BMI and so forth. Unlike cross-sectional studies, cohort stud-
ies consist in following individuals over time to measure the time to adverse
health event. The statistical analysis of time-to-event typically relies on the
27
Cox proportional hazard model, with the baseline hazard function being strat-
ified by sex, age and, in the US, race. In addition to adjusting for individual
risk factors, controls for area-specific potential confounding factors has been
increasingly performed, although they do not seem to significantly alter esti-
mates of effect (Krewski et al., 2009; Crouse et al., 2012).
As mentioned earlier, exposure measurement error is inherent in using es-
timates of exposure based on measures of pollutant concentrations captured
by fixed monitors. To obtain finer spatial contrasts in exposure, most co-
hort studies use geographic information systems-based statistical methods to
account for small-scale spatial variations in pollution concentrations. These
methods, which fall into three categories: (i) interpolation methods, (ii) land
use regression models or (iii) dispersion modelling are described in Chapter 6.
Natural experiment studies
The body of epidemiological evidence on the health effects of air pollution
exposure is also built on natural experiments using a before/after study design
and, when a control group is available, a difference in differences approach. In
addition to a number of studies of unplanned events such as strikes (Pope III,
1996; Pope III et al., 2007; Parker et al., 2008), planned interventions resulting
in either abrupt or progressive changes in air pollution concentrations have
been intensively investigated.
Studies of planned actions are commonly referred to as “accountability stud-
ies”. They aim to identify one or more causal effects in the “accountability
chain” that links regulatory actions to various policy-relevant outcomes. The
causal chain has at least five sequential stages: (1) regulatory action or any
other planned action, (2) change in air pollutants emissions levels, (3) change
in ambient air quality, (4) change in exposure/dose, (5) human health response
(HEI, 2003). Most accountability studies however, have focused on the link-
ages between (3) the change in ambient air quality and (5) human health (van
Erp & Cohen, 2009).
As underlined by the reviews of van Erp & Cohen (2009); Bell et al. (2011);
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Giles et al. (2011) and van Erp et al. (2012), very diverse past interventions of
outdoor air pollution reduction have been analysed. Examples of intervention
include: (i) emission restrictions in cities hosting Olympic games (Friedman
et al., 2001; Lin et al., 2011); (ii) local regulations such as the ban on domestic
coal use in Dublin in 1990 (Clancy et al., 2002) or restrictions on fuel sulphur-
content in Hong Kong in 1990 (Hedley et al., 2002); (iii) the introduction of
measures to decrease traffic congestion (Currie & Walker, 2011; Kelly et al.,
2011); (iv) national policies such as the Clean Air Act in the US (US EPA,
1997, 1999, 2011).
Retrospective analyses of past interventions of air pollution control are of-
ten confronted with issues such as potential unmeasured confounding by oth-
ers health stressors than pollution, the choice of appropriate time period be-
fore/after intervention and of control groups and limited data availability on
both air quality and health outcomes (van Erp et al., 2012). A recent study
of the impact of the congestion charging scheme on air quality in London
(Kelly et al., 2011) further underlines such challenges. Investigators found it
extremely difficult to attribute changes in air pollution concentrations to the
congestion charge as other traffic interventions were implemented in parallel
to its introduction.
Nevertheless, natural experiment studies do provide compelling evidence
about the actual health benefits associated with past decrements in air pollu-
tion and valuable information regarding the decrease in health risk over time.
For instance, the ban on domestic coal use in Dublin in 1990, was found to
result in a 36 µg/m3 (70%) decline in black smoke (a former measure of PM).
This was associated with a significant decrease in cardiovascular deaths (-
10.3%, 95%CI -12.6 - 8%) and respiratory deaths (- 15.5%, 95%CI -19.1 -
11.6%) in the first year after the ban (Clancy et al., 2002). Importantly, no
rebound in cardio-pulmonary mortality was observed in the subsequent years.
With regards to infant health, Currie & Walker (2011) found that the intro-
duction of an electronic toll collection in the northeastern states of the US
(E-ZPass), which led to a sustained reduction in traffic congestion, was asso-
ciated with reduced premature birth (by 6.4 - 8.6%) and low birth weight (by
7 - 9.3%) in babies of mothers living within 2 kilometers from a toll plaza,
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relative to babies of mothers living 2-10 km from a toll.
2.1.3 Epidemiological evidence: a selection of key findings
Preliminaries
Whilst there remains numerous uncertainties, epidemiological studies per-
formed over the last decades have enabled to shed light on a number of adverse
health impacts associated with exposure to air pollutants, particulate pollu-
tion in particular. This section discusses some key results from a selection
of studies, in order to give a flavour of the range of mortality and morbidity
effects associated with respectively acute and chronic exposure to particulate
matter. Thorough reviews of epidemiological evidence and suspected mecha-
nistic pathways may be found in Anderson et al. (2012); Spiric´ et al. (2012);
Brook et al. (2010); US EPA (2009, 2004b).
Although a number of epidemiological studies have investigated the health
effects of air pollution exposure on children, especially with regard to lung
development - see Shannon et al. (2004) and Eisner et al. (2010) for a review
- most studies have focused on adults. Nevertheless, more recently, epidemi-
ological studies investigated air pollution impacts on fetal health and found
association with low birth weight, premature birth and event a greater risk of
autism (Pedersen et al., 2013; Raz et al., 2014).
Measure of excess risk
The effect of air pollution exposure on health is typically measured as a
relative risk (RR), a hazard ratio (HR), or less commonly, as an odds ratio
(OR). A ratio equal to 1 means that there is no association between hazard
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exposure and adverse event. The RR is the ratio of risks, i.e. of probabilities,
of adverse health event among the exposed and non-exposed group. For time-
to-event data, HRs are a more appropriate measure as they are derived from
instantaneous event rates in each group, conditional on survival at time t.
Studies using the logistic regression to analyse data, such as case crossover
studies typically express results with odds ratios. The latter are ratios of the
probability of event occurrence and the probability of non-occurrence of event.
Since odds and probabilities are related, where Odd = Pr/(1−Pr), the relative
risk is a function of the odd ratio and of the probability of event occurrence
in the unexposed group Pr0, such that RR = OR/(1 − Pr0 + Pr0OR). If
Pr0 ≤ 10% and OR value is comprised between 0.5 and 2.5, the OR is quasi
equivalent to a RR (Sistrom & Garvan, 2004).
Evidence from studies of short-term exposure
Since the 1990’s, more than 100 single-cities daily time series and case cross-
over studies exploiting relatively small changes in daily levels of air pollution
have been carried out (Pope III & Dockery, 2006). The results of many of
these studies have been pooled in meta-analyses, e.g. Levy et al. (2000); Steib
et al. (2003), to improve the accuracy of effect estimates. Furthermore, in
order to address potential city selection bias, multi-city daily time-series were
conducted, the largest and most notorious ones being the National Morbidity
Mortality and Air Pollution Study (NMMAPS) in the US and Air Pollution
and Health (APHEA) in Europe. Further description and discussion of these
studies can be found in Brunebreef & Holgate (2002).
Overall evidence from studies of short-term exposure of air pollution sug-
gests that a 10 µg/m3 increase of ambient concentrations of PM10 and PM2.5
in the preceding 1 to 5 days before event, is associated with an increase in
mortality by 0.4% to 1% and does not support the hypothesis of a threshold
to health effects (Brook et al., 2010). In this context, a threshold refers to a
level of air pollutant concentration, below which no health impact is found.
As underlined by Pope III & Dockery (2006), given that relatively small in-
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crements in air pollution over a few days is unlikely to lead to a large increase
in daily mortality, the fact that studies of short-term exposure consistently
found a small but significantly positive effect at relatively low concentrations
is impressive. In addition, numerous time-series and case crossover studies
consistently found that short-term elevations in particulate pollution were as-
sociated with respiratory and cardio-vascular hospital admissions (US EPA,
2004b; Mustafic et al., 2012).
Evidence from studies of long-term exposure
Mortality:
The two most prominent prospective cohort studies of mortality, which have
been extensively reanalysed under the lead of the Health Effects Institute and
which follow-up duration has been extended several times are: the Harvard Six
Cities (HSC) cohort and the American Cancer Society (ACS) cohort. The HSC
cohort was constituted by 8,096 white adults aged between 25 and 74 years at
enrolment, who were randomly sampled between 1974 and 1977 from six US
cities characterised with large spatial contrasts of air pollution. The first study
of the HSC cohort (Dockery et al., 1993) had 14-16 years of follow-up whereas
the latest extended analysis (Lepeule et al., 2012) relied on a follow-up period
of 33 years. The ACS cohort was based on the ACS Cancer Prevention Study
II (CPS II), an on-going prospective study of mortality based on 1.2 million
of adults aged at least 30 years old (with at least one family member aged 45
years or more) who voluntarily enrolled in 1982. Risk factor data from CPS
II was linked with ambient PM2.5 concentrations for 359,000 subjects from 61
metropolitan areas for the period 1979-1983 and for 500,000 subjects from 116
metropolitan areas for the period 1999-2000. The latest analysis of the ACS
study has a follow-up of 18 years (Krewski et al., 2009).
Many other cohort studies of mortality were conducted both in the US and
in other parts of the world (Canada, Europe, China). The complete list and
a description of such studies is presented in Chapter 6. These studies over-
whelmingly suggest that concentrations of PM2.5 are significantly associated
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with an excess risk of premature mortality, in particular from cardiovascular,
pulmonary and lung cancer causes. For instance, based on the latest extended
analysis of the ACS cohort, Krewski et al. (2009) reported that a 10 µg/m3 in-
crement of PM2.5 is associated with a 6% (95% CI of HR: 1.04 - 1.08) increase
in all-cause mortality, a 24% (95% CI of HR: 1.19 - 1.29) increase in death
from ischaemic heart disease and a 13% (95% CI of HR: 1.06 - 1.23) increase
in death from lung cancer.
In general, risk estimates from cohort studies of mortality are an order of
magnitude higher than effect estimates from studies of short-term exposure to
air pollution. This is an important finding as it contradicts with the hypoth-
esis of short-term harvesting, according to which air pollution would solely
impact the frailest individuals by bringing their deaths only a few days for-
ward. Indeed, if harvesting explained most of air pollution effect, then impacts
on death rates in the long run would be negligible, which is clearly not the
case (Pope III & Dockery, 2006).
Extended analyses of cohort studies and repeated cross-sectional analyses
have also provided an opportunity to evaluate the change in health risk associ-
ated with long term changes in air pollution. Pope III et al. (2009) found that
reductions in particulate pollution across various US counties over a two-decade
period (1980s and 1990s) were associated with half to a full year increase in life
expectancy, after controlling for changes in socio-economic, demographic, and
proxy smoking variables. The observed changes in life expectancy appeared
consistent with indirect estimates based on cohort studies results. Laden et al.
(2006); Schwartz et al. (2008) exploited the fact that concentrations during the
extended follow-up period of the Harvard Six Cities cohort were lower than
during initial analysis. Their studies suggested that the excess mortality risk
of air pollution was essentially associated with exposures as short as one to
two years before event and thus, were relatively quickly reversible.
Finally, epidemiological studies also found that, at particulate concentration
levels present in developed countries (e.g. between 5 and 35 µg/m3), health
effects increase linearly with increments in exposure and no threshold below
which there would be no adverse effect on health was found (Pope III et al.,
2011; Lepeule et al., 2012; Crouse et al., 2012).
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Morbidity:
Cohort studies were also used to investigate the impact of air pollution
on the development of chronic respiratory and cardiovascular conditions. For
instance, Abbey et al. (1995) used data from the Health and Adventist and
Smog Study (ASHMOG) to look at the development of new cases of chronic
bronchitis associated with PM2.5 exposure (RR of 1.81, 95%CI: 0.98 - 3.25 per
45 µg/m3 increment in PM2.5). Miller et al. (2007) exploited data from the
Women’s Health Initiative to analyse the effect of air pollution exposure on the
risk of first cardiovascular events for menopausal women (HR of 1.24, 95%CI:
1.09 - 1.41 per 10 µg/m3 increment in PM2.5). In the US, the Multi-Ethnic
Study of Atherosclerosis and Air pollution (MESA-Air) was launched in 2004
in order to investigate the progression of cardiovascular disease associated with
air pollution exposure over a 10-year period. In 2008, the European Study of
Cohorts for Air Pollution Effects (ESCAPE), involving more than 30 cohorts of
studies across Europe, was launched with a view to investigate the relationship
between long-term exposure to PM and NO2, with several morbidity health
endpoints.
The relatively few cohort studies of morbidity have been complemented by
a number of cross-sectional studies. For instance, Zemp et al. (1999) relied
on the Swiss study on air Pollution and lung disease in adults (SAPALINDA)
to investigate the association between long term exposure to PM10 (proxied
by PM10 data for the year 1993) and the prevalence of reported respiratory
symptoms across eight areas in Switzerland characterised with differing levels
of air pollution. The authors found that an 10 µg/m3 increment in average
annual level of PM10 concentration was associated with an OR of 1.33 (95%
CI: 1.14 - 1.55) for breathlessness day or night. Schikowski et al. (2005) used
consecutive cross-sectional studies performed between 1985 and 1994 in seven
areas of Germany as part of the Study on the Influence of Air pollution on
Lung function, Inflammation and Ageing (SALIA) to assess the role of air
pollution on the development of chronic obstructive pulmonary disease among
55 year old women and found a OR of 1.33 (95%CI: 1.03 - 1.72) associated
with a 7 µg/m3 increment in five years mean of PM10.
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2.1.4 Epidemiological evidence: main conclusions
The adverse effects of outdoor air pollution in health have been documented
since the early 20th century and have led to the first major regulatory interven-
tions of air pollution control by the second half of the 20th century. Although
the body of epidemiological evidence is extensively underpinned by observa-
tional studies, study designs and statistical approaches to data analysis have
been greatly refined and adverse effects on the cardio-respiratory systems have
consistently been found across studies. This strongly supports the hypothesis
that exposure to air pollution causes adverse health effects.
Whilst the effects of acute exposure were the focus of the first wave of
epidemiological studies, which relied on time-series and case crossover designs,
over the last decades, large-scale expensive cohort studies have been conducted
to investigate the effects from long-term cumulative exposure. Findings from
cohort studies of mortality, which have primarily focused on adults of the
general population: (i) contradict the hypothesis of short-term harvesting,
according to which air pollution would solely impact the frailest individuals
by bringing their deaths a few days forward; (ii) support the hypothesis that at
concentrations prevailing in developed countries, health effects increase linearly
with increase in exposure; (iii) suggest the absence of a concentration threshold
below which there would be no health effect.
Finally, as underlined by section 2.1.3, which aimed at providing a brief
overview of the range of health effects associated with both acute and long-
term exposure to air pollution, the body of epidemiological evidence keeps on
growing. This bestows particular importance on systematic reviews and meta-
analyses of epidemiological findings, in order to ensure that decision-making
pertaining to air quality targets is based on all available relevant evidence.
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2.2 Evaluating air pollution control interventions: the-
oretical background
2.2.1 Interventions’ key characteristics
In light of epidemiological findings mentioned in section 2.1.3, and of the fact
that air pollution exposure is ubiquitous, interventions of air pollution control
clearly represent public health interventions (Reisnik & Zeldin, 2005). Whilst
possibilities of adapting to air pollution such as locating densely populated
areas away from busy roads should not be neglected (Giles et al., 2011), owing
to the high dispersion of air pollutants, abating emissions appears to be the
key response to the environmental health threat of outdoor air pollution.
Pollution results from the release in the environment of a pollutant load
that, by far, exceeds the waste assimilative capacities of natural ecosystems.
Air pollution abatement will therefore also improve ecosystems’ health, for
instance by reducing the deposition of acidic particles and polycyclic organic
matter, which damage trees, lakes and their aquatic life (US EPA, 2004a).
Consequently interventions of air pollution control overlap with environmental
policies, which aim to protect public health against the harmful effects of
environmental degradation and prevent, reduce or mitigate the negative effects
of human activities on ecosystems (McCornick, 2001).
Improving air quality is costly. In the US, for instance, the EPA estimated
that nationwide pollution abatement costs were in the range of about $80
billion per year (US EPA, 1999). Typically interventions of air pollution control
are expected to be associated with a high up-front costs. For example, the UK
Department of Transport recently pledged to commit a minimum of £200
million to support the early market for ultra low emission vehicles, in order
to help achieve London’s ultra low emission zone (Department for Transport,
2014).
This substantial use of scarce resources requires to assess whether further
efforts in decreasing air pollution are expected to be worthwhile if compared
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with other courses of action such as “business as usual”. The comparative
analysis of costs and consequences of alternative actions, with view to support
the choice between competing uses of scarce resources, constitutes an economic
evaluation (Drummond et al., 2005).
However, should actions taken to reduce outdoor air pollution be evaluated
as public health interventions or as environmental interventions? In light of
the overlap between these two types of interventions, the economic evalua-
tion of air pollution control somewhat lies at the intersection of environmental
economics and health economics. The two disciplines, however, have been de-
veloped for different decision contexts and as a result, have differing theoretical
foundations.
2.2.2 Differing decision contexts
Environmental interventions
Goods and services derived from natural ecosystems, such as clean air,
often have no property rights attached to them and their misuse and result-
ing damages to third parties cannot be compensated by a market transaction
(Freeman et al., 1984). Environmental policies are generally designed to cor-
rect for such market failures since if left uncorrected, they may lead to socially
harmful over-exploitation and degradation of natural resources, as illustrated
by Hardin (1968)’s “Tragedy of the Commons”. The latter involved herdsmen
using a common pasture for grazing their cattle. Individually, the herdsmen
would have no incentive to prevent overgrazing since they would not themselves
benefit from holding back their own cattle. However, the collective impact of
their self-interested strategies proved disastrous to their community in the long
run.
Pollution, like any other uncompensated externality, creates a wedge be-
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tween the private costs and the social costs of production and consumption
and ultimately, a loss of social welfare (Pigou, 1920). Some economists, argued
that externalities could be internalized via bargaining over pollution rights be-
tween polluters and their victims (Coase, 1960). However, air pollution vic-
tims are typically too large in number and too different in terms of income
and geography to be able to organise themselves as a single agent for bargain-
ing. Therefore it is now widely acknowledged that government intervention for
pollution-control is a necessity (Mendelsohn, 2002; Ostrom, 2003).
Environmental interventions generally aim to internalize the external costs
of pollution into private costs. This can be done via command and control
polices, such as air pollution targets, quotas and bans or market based policies,
such as Pigouvian taxes or tradeable pollution permits. As a consequence,
EHIs of air pollution are typically regulatory interventions whose costs are
expected to primarily fall on the polluter.
The objective of the economic evaluation of environmental policies is to as-
sess policies’ efficiency in addressing externalities, by evaluating whether their
social benefits are worth seeking given their social opportunity cost embedded
in the best possible alternative use of resources (Boardman et al., 2006). There
are two good reasons to suppose that the socially optimal level of air pollution
is above zero: (1) pollution controls typically have non-zero opportunity costs
and (2) natural ecosystems typically provide waste-sink services that can cope
with a certain level of pollution (Turner et al., 1994). Therefore, economic
evaluations of pollution-control EHIs also aim to inform questions pertaining
to the optimal scale of pollution-control programmes, whereby the socially op-
timal level of pollution is reached when the marginal abatement cost equals
its marginal benefit.
Public health interventions
The World Health Organisation defines public health as: “all organized
measures to prevent disease, promote health, and prolong life among the pop-
ulation as a whole” (WHO, 2015). The scope of public health interventions
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is extremely broad, including for instance vaccination, occupational safety,
healthy-behaviour promotion and their impacts typically go beyond health
care budgets. Nevertheless, presumably due to historic links between medical
and public health services, public health evaluations have often been carried
out using a health care evaluation paradigm (Wanless, 2004; McDaid & Needle,
2009).
Public expenditure on health care is generally designed as an alternative
to market provision, rather than as a way of regulating market provision to
correct for market failure. It is typically justified as a way of addressing equity
concerns (e.g. difficulties that the poor and the sick would face in buying
health insurance) and market failures due to informational asymmetries.
The fact that relevant public sector entities are endowed with a budget
to achieve health implicitly suggests that population health is a worthwhile
output, and that the role of economic evaluation is to identify the most cost-
effective way to produce it. From this point of view, that however is not
shared by all (Pauly, 1995), economic evaluations of health care programmes
do not seek to maximise social welfare but aim to optimally allocate a pre-
determined health care budget across competing programmes (Gold et al.,
1996; Drummond et al., 2005).
2.2.3 Decision-support tools
Cost Benefit Analysis
Different objectives require different decision-support tools. Assessing whether
an environmental policy achieves a socially optimum level of pollution con-
trol requires to compare, at the margin, the present value of all benefits and
costs accruing to society. As a consequence, the economic evaluations of envi-
ronmental policies have extensively relied on the cost-benefit analysis (CBA)
39
framework.
CBA values all opportunity costs and benefits using the common money
metric. In welfare economics, a good is considered valuable insofar as it gen-
erates utility to some individuals who, assuming the traditional axioms of
consumers preferences (completeness, reflexivity and transitivity), will be will-
ing to trade consumption for it. Therefore individuals’ preferences for goods
are revealed in the market-place by their willingness to pay (WTP) for them
and the appropriate social value of a programme’s benefits is the sum total
of individuals’ WTP for it (Boardman et al., 2006). Alternatively, especially
in the context of a reduction in the good or service to be valued, individual’s
preferences can be revealed by individuals’ “willingness to accept” the loss of
benefits against compensation.
CBA is grounded in neoclassical welfare economic theory. It is often justi-
fied in terms of the Kaldor-Hicks compensation test, from which the potential
Pareto efficiency rule was derived as a decision rule for accepting policies. The
Kaldor-Hicks criterion suggests that a policy represents a potential Pareto im-
provement, and thus will increase efficiency, as long as those who will win
from the implementation of a policy could potentially compensate those who
will lose, while still being better-off (Boardman et al., 2006). An alternative
justification for CBA is in terms of a utilitarian social welfare function (SWF)
representing a social objective of maximising the sum total of individual wel-
fare. Either way, the basic idea is that a policy should be adopted as long as
its net social benefits are positive.
Cost Effectiveness Analysis
Economic evaluations of public health interventions and health care tech-
nologies have commonly relied on cost-effectiveness analysis (CEA), which con-
sists in comparing the incremental costs of an intervention to its incremental
health benefits. CEA is commonly considered from a social decision making
point of view, as a tool to maximize an explicit societal objective, such as
maximizing the present value of population health, subject to an exogenous
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budget constraint (Paulden & Claxton, 2012). For public health, such ap-
proach is exemplified by WHO’s CHOICE 1 initiative, which is intended to
support the allocation of limited resources across public health interventions.
Consequently, health outcomes are commonly combined into a single compos-
ite index, such as disability-adjusted life years (DALYs) or quality-adjusted
life years (QALYs), in order to compare the cost-effectiveness of competing
interventions and support resource allocation (Drummond et al., 2005).
QALY and DALY encapsulate morbidity and mortality effects in one single
indicator by multiplying life expectancy estimates with health-related quality
of life weights that characterise health states or disability conditions (Gold
et al., 2002). The DALY was developed to compare the health burden of dis-
eases or risk factors globally. Whilst the DALY has also been recommended for
economic evaluations of public health interventions in low- and middle-income
countries (Gates foundation’ reference case, NICE International (2014)), the
QALY has been routinely used for economic evaluations of public health in-
terventions and health care technologies in high income countries (Drummond
et al., 2005; ISPOR, 2013). The QALY will therefore be the focus of the
present thesis, which relies throughout on a UK case study.
Computation of the QALY requires two elements. The first is quality of life
weights associated with a particular health condition. By convention, health-
related quality of life weights (HRQoL) are anchored on a interval scale from 1
(perfect health) to 0 (death) and health states considered to be worse than dead
have a negative value. Several methods may be used to obtain the HRQoL
scores of health-related quality of life. The three main approaches are: (i)
visual analogue scales, where individuals rank in a line the various health
states representing the health-related quality of life continuum; (ii) time trade-
off, where individuals have to choose between living a certain period of time
with a given health condition versus living a shorter period of time but in a
improved state of health; (iii) standard gamble, where individuals are required
to choose between living a given health state or living in a better health state
with a particular risk of death (Gold et al., 2002). To compute a QALY,
disease duration is multiplied by its attached HRQoL score, so that living
1CHOosing Interventions that are Cost-Effective
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with a condition associated with quality weight x for T years amounts to Tx
QALYs. The QALY therefore assumes linear substitution between quality and
quantity of life and has interval scale properties such that, for example, a gain
from 0.2 to 0.5 is equally valuable as a gain from 0.6 to 0.9. (Gold et al., 2002).
Finally, it should be underlined that QALY-based CEA was initially referred
to as cost-utility analysis. However since CUA can be seen as a type of CEA
(Drummond et al., 2005), nowadays most authors do not specify the distinction
between the two. Accordingly, this thesis solely uses the term CEA.
2.2.4 Monetizing health benefits
In a CBA framework
Individuals’ WTP to obtain a good such as clean air, or alternatively to
avoid damages such as pollution, is an estimate of the change in consumer
surplus measured by the Hicksian demand function (Boardman et al., 2006).
For instance, the WTP for better air quality or for improved health represents
the income that could be taken from a person so that her utility would get
back to its level before the improvement (equivalent variation). Since neither
health nor environmental services are traded in markets, their WTP value (or
shadow price) can be either revealed through consumers’ trade-offs in surrogate
markets (e.g. via hedonic pricing methodology) or elicited through contingent
valuation or choice modelling surveys, which involve hypothetical scenarios.
For health risk, the risk-wage trade-offs observable in the labour market
have been extensively researched in hedonic models in order to derive a value
of statistical life (VSL) from wage premiums for risks of death by occupational
accident. VSL corresponds to individuals’ aggregated WTP for a small change
in survival probabilities (Chestnut & de Civita, 2009). VSL values, however,
appear to be context specific and their estimates vary greatly (Drummond
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et al., 2005). Recent meta-analyses found mean VSL values ranging from re-
spectively $ 2.8 million (Miller, 2000) to $ 6.7 million (Viscusi & Aldy, 2003).
This wide range of VSL values partially stems from the difficulty to control
for workers’ lack of full information or cognitive bias regarding job risk, self-
selection according to differing levels of risk aversion and labour markets im-
perfections such as unions’ bargaining powers (Boardman et al., 2006).
In this context, although they are potentially prone to bias associated with
the use of hypothetical scenarios, contingent valuation studies (which focus on
the non-market good as a whole) and choice experiments (which focus on spe-
cific attributes of the non-market good), provide a complementary source of
valuation for specific improvements in health. These stated-preferences meth-
ods however, do also exhibit huge variation in estimates. Further discussion on
the strengths and weaknesses of revealed and stated preferences can be found
in Fujiwara & Campbell (2011).
Alternatively, when there is not enough information to derive a demand
function for a good, there exists a set of another techniques, which do not aim
to measure true changes in social welfare but still provide useful information
for CBA. These techniques, referred to as damage or production-function ap-
proaches, rely on observable market information and include replacement cost,
averted expenditure and cost-of-illness studies. Whilst cost of illness studies
can encompass direct medical costs (physician service, hospital care and drugs)
and productivity costs (loss workdays), they do not account for the value of
pain and psychological suffering, quality of life impacts (e.g. restricted lifestyle)
and typically ignore caretakers expenditures. Therefore, they are expected to
understate the true changes in social welfare (Bell et al., 2008).
In a CEA framework
The use of a composite health index such as the QALY is sufficient to
compare the cost-effectiveness of health care technologies, based on their in-
cremental cost effectiveness ratio (ICER), e.g. £x/QALY . However, in order
to drive investment or dis-investment decisions, health care technologies’ cost-
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effectiveness performances need to be compared against a benchmark, known
as cost-effectiveness threshold or cut-off value. The application of a decision-
rule, whereby a health care technology costing more than the agreed cut-off
value for every QALY it delivers should not be funded, effectively consists in
applying a monetary value to health (Phelps & Mushlin, 1991).
According to the social-decision making perspective, the value of health
is revealed by the health care budget constraint, which represents the health
displaced by a given investment (Claxton et al., 2006). The NHS budget
constraint can be seen as a partial expression of a latent social welfare function,
and its shadow price corresponds to how much society is willing to pay for
health that is generated by a collectively funded health care system (Claxton
et al., 2007). In the UK, NICE uses a cost-effectiveness threshold range of
£20,000 - 30,000 per QALY gained for health care technology assessments
(NICE, 2013). However, recent empirical work suggests £13,000/QALY may
be a more correct benchmark (Claxton et al., 2013).
As an alternative to this supply-sided approach to health valuation, a
branch of health economics has applied welfare economic methods to obtain
WTP values for a QALY, a recent review of which can be found in Ryen &
Svensson (2014).
Ultimately, the choice of source of money value to monetize QALY impacts
in CEA should be driven by the opportunity cost of intervention. If the latter
is borne by the NHS, then the money value of a QALY should be informed
by the cost-effectiveness of the health care to be displaced by the investment,
as embedded in the budget constraint (Claxton et al., 2007). By contrast, if
the intervention is funded by raising new tax revenue, private consumption
will be displaced and thus, the source of valuation should be the utility loss of
foregone private consumption that is equivalent to the willingness to pay for a
QALY (Ryen & Svensson, 2014).
Value judgments embedded in the choice of monetization approach
There appears to be two main ways of valuing health benefits in economic
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evaluation: either by relying on the budget constraint of the health care system
(supply-sided approach) or by relying on consumers’ willingness to trade con-
sumption for health that is revealed or elicited by their trade-offs in surrogate
or hypothetical markets (demand-sided approach). While the former assumes
that the health care budget is optimally defined by a socially-legitimate au-
thority. The latter is too underpinned by value judgments.
There are indeed a number of issues pertaining to the application of stan-
dard welfare economic theory as a source of societal value of outcomes. Firstly,
as aggregated WTP is dependant on society’s wealth distribution, if costs and
benefits are borne by people in different wealth groups associated with differing
marginal utilities of money, the application of the potential Pareto principle
could lower aggregate utility (Boardman et al., 2006). This issue can how-
ever, be addressed by using a common general population value for benefits or
by deriving distributional weights from the elasticity of marginal utility, e.g.
by expressing the marginal utility of each quantile of the income distribution
as a percentage of the average marginal utility, thus moving towards a social
welfare justification of CBA (Fleurbaey et al., 2013).
Secondly, the economic axioms of rationality that define individuals as
utility-maximisers have repeatedly been shown to be often violated by a large
body of work in experimental economics. Furthermore, even if the assumption
of individuals’ transitive preferences were not violated, (Arrow, 1951) demon-
strated that the aggregation of two or more individuals’ preferences between
three or more alternatives may fail to maintain an transitive social ordering of
options.
Finally, the necessary conditions for achieving a first-best Pareto optimum
are generally not fulfilled in some sectors of the economy due to second-best
distortions, such as uncorrected externalities, monopolistic power etc. In such
case, the theory of second-best asserts that seeking first-best Pareto optimality
may reduce social welfare instead of increasing it, especially if there is insuf-
ficient information about the degree and direction of the divergence of the
second-best optimum (Ng, 2004).
Whilst these limitations do not suggest the need to forsake welfare economic
theory and its application altogether, they highlight that, just as the claim of
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optimality of public agencies’ existing budget allocations is rooted on social
value judgements, so too are welfarist prescriptions for social choice (Claxton
et al., 2007). In other words, valuing health in terms of its consumption value
(collective WTP) or at the shadow price of the budget constraint imposed on
the health care system, inevitably implies social value judgments.
2.3 Economic evaluations of interventions of air pollu-
tion control
2.3.1 Ex-ante accountability studies
In addition to the large number of retrospective evaluations of past inter-
ventions of air pollution control (section 2.1.2), the health effects associated
with hypothetical policies of air pollution reduction have also been intensively
evaluated. These ex-ante modelling studies are also qualified as accountability
studies. Examples include impact analyses of complying with WHO guidelines
in Hong Kong (Hedley et al., 2008), of reducing emissions from the industry
and power sector in the Yangtze Delta River in China (Zhou et al., 2010),
of curbing urban transit bus emissions in the US (Cohen et al., 2003) and so
forth.
Unlike retrospective accountability studies, which focus on estimating the
actual levels of reduction in pollutant air concentrations and associated health
effects, ex-ante accountability studies of proposed interventions commonly in-
clude an economic evaluation as they aim to spur or justify regulatory action
(Hunt, 2011).
Ex-ante accountability studies of proposed national environmental regula-
tions are referred to as regulatory impact assessments. The latter are required
in most OECD countries for major regulatory initiatives and typically con-
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sist of a CBA (Scapecchi, 2008). As a result, the literature on economic
evaluations of air pollution control essentially consists of CBAs of proposed
air-quality targets and sector-specific emission control measures at national or
inter-governmental level. In Europe, a CBA was conducted to analyse pollu-
tion control scenarios as part of the Clean Air for Europe (CAFE) programme
(Holland et al., 2005b) and the European Environment Agency assessed the
impact on Europe’s air quality of a selection of measures targeting the trans-
port and energy sectors (Kuenen et al., 2010). In the US, the Environmental
Protection Agency has performed CBAs of environmental policies since Pres-
ident Reagan’s 1981 order. In particular, it conducted CBAs for planned
amendments to the 1990 Clean Air Act (US EPA, 1999, 2011) and for pro-
posed revisions to the National Ambient Air Quality Standards for Particulate
Matter (US EPA, 2006, 2012).
Although, in a CBA framework, the health benefits of air pollution control
are expected to be considered alongside wider economic impacts including on
ecosystems health and associated benefits (e.g. crop yields), most of these
impacts are commonly too difficult to monetize, and are instead considered
qualitatively in a separate analysis. Consequently, similarly to evaluations of
public health interventions, ex-ante studies of air pollution control are pri-
marily centred on health benefits. Productivity gains associated with health
benefits are, however, also considered in some regulatory impact assessments
in terms of reduced loss of working days and/or restricted activity days.
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2.3.2 Method to quantify health impacts
Key principles
Ex-ante accountability studies of proposed interventions of air pollution
control follow the health impact assessment (HIA) approach to perform pro-
jections of expected health benefits. HIA is defined as “a combination of
procedures, methods and tools used to evaluate the potential health effects of
a policy, programme or project.” (WHO, 1999). Since HIA may also rely on
qualitative evidence, quantitative evaluation of impacts is also referred to as
quantitative risk assessment (QRA) in the HIA literature.
Projections of health effects in HIA are based on a set of health impact
functions, which are parameterised with results from epidemiological studies.
The health impact function combines separately for each health endpoint of
interest: (i) the size of the potentially affected population; (ii) the baseline
endpoint incidence rate; (iii) the change in the concentration of outdoor air
pollutant and (iv) the change in incidence of health endpoint per unit change
in ambient concentration of outdoor air pollutant, also known as the coefficient
of the concentration-response function.
Health effects in HIA are commonly expressed in attributable cases of se-
lected morbidity or mortality endpoints, e.g. premature death, hospitalisation
etc, without any aggregation of impacts in a summary metric (Briggs, 2008).
Impact computation
The functional form of a health impact function will depend on the statisti-
cal model used to analyse epidemiological data. For air pollution, a log-linear
relationship is typically used to model the incidence rate of health endpoint y,
for air pollution concentration x:
log(y) = βx+ log(α)
48
where β is the slope coefficient of the concentration-response function and α
is the background incidence rate of endpoint y under no pollution.
The change in y, 4y = y − y0 associated with a change in pollution 4x =
x− x0, can be therefore obtained as follows:
log(y)− log(y0) = log(α)− log(α) + β(x− x0)
y
y0
= exp(β(x− x0))
y
y0
− 1 = exp(β(x− x0))− 1
4y = y0(exp(β4x)− 1) (2.1)
Whilst epidemiological studies estimate β, i.e. the slope coefficient of the
concentration-response function, as mentioned in section 2.1.3, they typically
report risk estimates (RE). The latter are ratios of risks (RR) of rates (HR)
or of odds (OR) of experiencing an adverse health effect, for a given change
in pollutant concentration levels x. For PM concentrations, typically RE are
computed for 4x = 10µg/m3.
It is straightforward to show that under a log-linear functional form, RE4x =
exp(β4x). For instance, if we use the specification of the Cox proportional
hazard which is used to analyse time to event data in cohort studies (see section
2.1.2), we can model the hazard function of individual i over time as:
hi(t) = h0(t) exp
(
βxi +
∑
i,j
γjzi,j
)
with h0(t) representing the baseline hazard function which is left unspecified,
x representing the average cumulative level of exposure to pollution, β the
dose-response coefficient, zj representing confounding variables and γj their
related regression coefficients.
Now, if we consider two individuals i and i′ who are similar in all respect
excepted in their level of cumulative level of exposure to pollution xi and x
′
i,
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the ratio of their hazards can be expressed as:
RE4x =
hi(t)
h′i(t)
RE4x =
h0(t) exp(βxi + c)
h0(t) exp(βx′i + c)
with c =
∑
i,j
γjzi,j =
∑
i′,j
γjzi′,j
Simplifying for h0(t), we obtain:
RE4x = exp(β(xi − x′i))
RE4x = exp(β4x)
Equation 2.1 can therefore be rewritten as:
4y = y0(RE4x − 1) (2.2)
Where (RE4x − 1) is also referred to as the % change in incidence of health
endpoint y0 for a 4x increment/decrement in air pollution.
It should be underlined that linearity in health effects in response to a
change in air pollution exposure, as indicated by equations 2.1 and 2.2 has
been repeatedly found solely in studies conducted in developed countries, i.e.
with PM concentrations ranging between 5 to 35 µg/m3 (see section 2.1.3).
Attempts to extrapolate the shape of concentrations-response functions for
concentrations far beyond those observed in North America and Western Eu-
rope were performed by Pope III et al. (2011) and Burnett et al. (2014), based
on studies of health effects from active and passive smoking and household use
of solid cooking fuel. Pope III et al. (2011)’ results, which suggest a steeper
increase in risk at low exposure levels than at higher concentrations (supra-
linear function), were used in the 2010 Global Burden of Disease study (Lim
et al., 2012).
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2.3.3 Economic evaluations in practice
A 3-step process
Economic evaluations of ex-ante accountability studies of proposed inter-
ventions of air pollution control consist of three core steps. The latter have
been systematised by some softwares, such as Benefits Mapping and Analysis
Program (BenMAP) from Abt Associates, which is used by the US EPA for
the assessment of air pollution control policies (US EPA, 2006, 2011, 2012). In
the UK, the Department for Environment Food and Rural Affairs (DEFRA)
refers to this 3-step approach as the “full-impact pathway” (DEFRA, 2013).
Step 1:
The first step involves the modelling of the change in air pollution con-
centrations to which the target population is exposed, based on the expected
change in emissions associated with policy scenarios. This typically requires
sophisticated GIS-based dispersion modelling tools, e.g. CMAQ, RAINS etc.
An extensive description of such tools and of the algorithms underpinning them
may be found in Yerramilli et al. (2011).
Step 2:
The second step consists of a quantitative health impact assessment, us-
ing the method to impact computation described above. Typically effects
are computed per year, by applying epidemiological risk estimates to annual
background rates of endpoint incidence. The most comprehensive regulatory
impact assessments of proposed interventions of particulate air pollution con-
trol consider the following health endpoints: (1) premature deaths (or life ex-
pectancy impacts see section 2.3.4), (2) chronic bronchitis, (3) hospital admis-
sions for cardio-pulmonary causes, (4) upper and lower respiratory symptoms,
(5) asthma exacerbations and (6) restricted activity days. For Europe, the
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World Health Organisation (WHO) has recently compiled a report of recom-
mended coefficients of concentration-response function for each of these health
endpoints, as part of the HRAPIE 2 project (WHO, 2013).
Most regulatory analyses place particular emphasis on mortality effects, as
recommended by WHO (2013). The latter are estimated based on risk esti-
mates from cohort studies of long-term exposure, which capture the effects
from both short-term peaks and long-term background exposure to pollution
(Ku¨nzli et al., 2001). As mentioned in section 2.1.3, cohort studies of air pollu-
tion have investigated the mortality effects of long-term air pollution exposure
on both all natural causes of death and specific causes of death. However, in
order to avoid under-estimating the overall mortality burden (see Chapter 3
for further details), WHO recommends to use all-causes of death risk estimates
in evaluations of air pollution control interventions (WHO, 2013).
In contrast to mortality impacts, with the exception of chronic bronchitis,
morbid endpoints are typically considered only for acute exposure, i.e short-
term peak in pollution above daily recommendation measures. It follows that,
although the reduction in life expectancy associated with the development
of chronic conditions associated with long-term exposure is expected to be
captured in overall the mortality effect (Ku¨nzli et al., 2001), long-term quality
of life impacts are completely ignored.
Step 3:
In a third step, in accordance with welfare theory roots of CBA which is the
preferred decision tool of regulatory impact assessments (see section 2.3.1), the
attributable change in each health endpoint is monetized using WTP (VSL)
values for relevant health risk reduction. When WTP values do not exist, for
instance for hospital admissions, cost of illness estimates are used. However
as mentioned in section 2.2.4, since cost of illness estimates do not account for
quality of life impacts from restricted lifestyle, pain and psychological suffering,
their use is equivalent to setting quality of life impacts to zero.
It is worth highlighting that in most studies, mortality benefits drive the
overall benefits (WHO, 2013). This is not surprising given that: (i) mortality
2Health Risks of Air Pollution In Europe.
52
impacts are the primary focus of such analyses; (ii) morbidity effects are com-
monly monetized using cost of illness estimates which as mentioned in section
2.2.4, do not account for quality of life impacts from restricted lifestyle, pain
and psychological suffering.
As mentioned in section 2.2.4, WTP values for health risk reduction, be it
revealed or stated, vary greatly. This results in substantial differences in gov-
ernments’ recommended values for monetizing health impacts. For instance,
Scapecchi (2008)’s comparison of recommended values (mean estimates, ex-
pressed in 2006 $) for monetizing mortality impacts from PM exposure showed
that the VSL estimates for the US and Canada were much higher (respectively
$ 7,4 and 6 million) than those recommended at EU level ($ 1,8 million). In
the UK, the DEFRA-commissioned study of Chilton et al. (2004) suggested a
VSL of about $ 6 million.
Example: DEFRA’s damage costs
Based on this 3-step impact pathway approach, in the UK, DEFRA pro-
duced standardised damage costs estimates per tonne of pollutant emitted
(DEFRA, 2011, 2015), in order to support the evaluation of small-scale pro-
posals (below £50 million).
The health endpoints and the magnitude of effects considered in damage
costs computations are in line with recommendations from the UK Commit-
tee on the Medical Effects of Air Pollutants (COMEAP), which independently
advises the government on matters concerning the health effects of air pollu-
tants. For particulate matter, the health endpoints included are: (i) mortality
effects associated with chronic exposure and (ii) hospital admissions for cardio-
respiratory causes following acute exposure, i.e. following a short-term peak
in pollutants concentrations over a few days (DEFRA, 2013).
Health impacts were computed for different densities of population e.g.
“Central London”, “Urban medium” or “Rural” and monetized based on WTP
values or cost of illness estimates. For instance, according to DEFRA’s damage
costs calculator, an annual reduction of one tonne of PM emission in central
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London is expected to yield an annual gain of £2.4 million (in 2015 prices).
By contrast, the same reduction in a small rural area would be expected to
provide an annual monetized benefit of £375,000 (in 2015 prices).
Dealing with uncertainty
In addition to considering uncertainties inherent to the modelling of air pol-
lution concentrations, many large scale ex-ante studies consider uncertainty in
key parameters, typically concentration-response coefficients and VSL/WTP
values, via probabilistic sensitivity analysis (PSA). This consists in fitting a
probability distribution to each uncertain input parameter, where uncertainty
is indicated by the 95% confidence interval, and to propagate joint parameter
uncertainty in total aggregated benefits via Monte Carlo simulations. The lat-
ter are readily integrated in software packages such as previously mentioned
BenMAP or @RISK (Palissade Corporation).
If one takes into account the nature of the data used for estimating param-
eters as well as parameters’ logical bounds, only a few distributions remain
that are appropriate candidates for a given type of parameter (Briggs et al.,
2006). Typically, the beta and Dirichlet distributions will be appropriate to
model transition probabilities derived from respectively binomial and multi-
nomial data, whereas the gamma distribution will be appropriate for costs
and dis-utilities and the log-normal distribution will be adequate for relative
risks (Briggs et al., 2006). By contrast the use of the triangular distribution,
which simply requires a maximum, a minimum and a mode, has been largely
discouraged since it is not statistically related to the estimation process of the
data and thus, very difficult to parametrize correctly (Briggs et al., 2006).
Interestingly, probabilistic sensitivity analyses in past evaluations of air
pollution control have departed from the above recommendations, which may
bring their quality into question. For instance, the US EPA fitted triangular
distributions to model utility parameters and WTP values in past regulatory
analyses of air pollution control policies (US EPA, 2006, 2012). For the CBAs
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of Clean Air for Europe (Holland et al., 2005b) and Revisions of the E.U.
Gothenburg Protocol (Holland et al., 2011), triangular distributions were fitted
to baseline incidence rates of health endpoints.
It should be underlined that recently published European guidelines for
uncertainty analysis in health impact assessment and cost benefit analysis of
air pollution control policies (Holland, 2014) do not suggest to rule out the
triangular distribution. On the contrary, they recommend to use the latter for
background mortality and morbid endpoint incidence rates as well as for risk
estimates when “there is great confidence in central estimates but adoption of
a normal distribution would imply that ranges were based on more data than is
the case” (pp 41). Alternatively, guidelines suggest to chose among two other
distributions for risk estimates. The normal distribution is recommended in
the case of a higher probability of values towards the range midpoint than
towards its extremes, whereas the uniform distribution is recommended when
all values in the range are thought to be of equal probability. Uncertainty
pertaining to WTP values for mortality risk reduction are recommended to be
dealt with in univariate sensitivity analysis.
2.3.4 Controversies in impact quantification
Years of life lost (YLL) vs. counts of premature deaths
A major controversy in impact quantification pertained to whether prema-
ture deaths should be differentiated based on the amount of remaining life
expectancy. This question is of particular relevance for interventions of air
pollution control since their benefits are not expected to fall equally between
age-groups. Indeed, although Krewski et al. (2000) and Pope III et al. (2002)
found that the excess risk of mortality associated with air pollution exposure
is almost uniform with age, as baseline mortality rates strongly increase with
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age, the absolute number of air pollution-related premature deaths is expected
to fall disproportionally among the elderly population.
A common argument against measuring benefits in counts of avoided pre-
mature deaths is that such approach would wrongly make air pollution control
compare on a equal footing with, for instance, improvements in traffic safety,
although the two are expected to vary an order of magnitude in terms of
amount of life gained per person (McMichael et al., 1998; Rabl, 2003). The
importance to consider the loss of life expectancy instead of the number of
premature deaths to measure air pollution health impact is summarised in
Bellander (2001)’s remark that “excess deaths are deaths that occur earlier
than expected. The important question is how much earlier?” (pp 69).
Nowadays, while the number of avoided premature deaths remains in use
to measure mortality impacts, it is now commonly considered alongside life
expectancy effects, i.e. years of life gained (Hunt, 2011; WHO, 2013). However,
the debate as to how to value reductions in mortality risk either as statistical
lives (VSL) or alternatively, as statistical life years (VOLY) remains open,
mainly because of the absence of consensus on the age-dependency of VSL
(Hubbell, 2006; Chestnut & de Civita, 2009). During some time, the US EPA
applied a 37% discount to the value of statistical live of individuals above 70.
However, after public outcry at this “senior discount”, the US EPA dropped
age difference in VSL in 2003.
Quality-adjustment to life year gains
Another important controversy pertains to whether a quality adjustment
should be applied to gains in life expectancy (Hubbell, 2006). One obvious
rationale for the application of HRQoL weight to life year gains is measure-
ment accuracy. Indeed, as previously mentioned, it is now largely agreed that
potential health gains should reflect that death can only be postponed but not
avoided, i.e. that what matters is life expectancy effects. In the same line of
thought, it can be argued that when evaluating the extra years of life to be
gained from air pollution reduction, one should take into account that individ-
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uals benefiting from air pollution reduction may not be in perfect health.
The discussion about the use of quality-adjusted life years (QALY) to assess
air pollution control started about a decade ago. It stemmed from the US Office
of Management and Budget’s decision that both a CBA and CEA should be
undertaken for policies expected to greatly impact public health and safety
(US OMB, 2003) and from the US Institute of Medicine’s recommendation
that “Regulatory CEAs that integrate morbidity and mortality impacts should
use the QALY to represent net health effects” (US Institute of Medicine, 2006)
(pp 161).
The controversy about the use of QALY to assess air pollution control
was greatly fuelled by Harris (1987)’s double jeopardy argument, which states
that allocating a restricted budget based on a QALY-maximizing approach
would systematically discriminate against those who have a low quality of
life and small life expectancy due to preexisting health conditions. Whilst
the double-jeopardy argument does not apply for interventions that improve
quality of life, provided recipients have the same life expectancy, it is true that
life-lengthening interventions will maximise QALY gains if they are targeted
to individuals with the highest quality of life and/or life expectancy (Singer,
1995). In other words, the return on investment in postponing the deaths
of ill or disabled people is lower than the return on investment in extending
the lives of healthy people. However, it has been forcefully argued that this
finding is not unfair or unjust, but merely results from the application of the
most rational approach to maximize population health from available scarce
resources (Singer, 1995; Claxton & Culyer, 2006).
Interestingly, although the QALY has been widely used in economic evalu-
ations of public health interventions and health care technologies (Drummond
et al., 2005), the issue of double-jeopardy appears to have represented a hur-
dle to the political acceptance of QALY in the evaluation of environmental
policies, especially in the US. As remarked by Singer (1995), what seemed to
stir controversy is not so much to discriminate recipients of a potential in-
tervention based on their remaining life-expectancy, and thus their age, but
based on differences in their baseline quality of life, as reflected by their health
condition.
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This led the US EPA to propose an innovative approach to measuring the
impacts of air pollution reduction on quality and length of life. The agency
decided to use a double-baseline of quality adjustment scores to compute sep-
arately the gain in quality of life from reduction in morbidity and the gain
in non-quality adjusted life years. For instance, in its analysis of revisions of
PM National Ambient Air Quality Standards, the agency used a HRQoL score
of 0.95 as baseline for the general population when computing quality of life
decrements associated with the incidence of chronic bronchitis and myocardial
infarction due to PM exposure but in parallel, it used a HRQoL score of 1 as
baseline when computing life expectancy effects (US EPA, 2006).
This double baseline of HRQoL weights however, no longer satisfies the
linear substitution between quality and length of life that characterises the
QALY. The resulting health measure is therefore no longer a QALY but a
Morbidity Inclusive Life Year (MILY). The main issue with the MILY is that
it cannot support the comparison of air quality policies with other public health
interventions. In addition, to date, there has not been any attempt at valuing
a MILY or to provide a cut-off value for MILY-based cost-effectiveness assess-
ment. This is problematic since, as mentioned earlier, to support decision-
making about resource allocation, consequences need to be monetized in one
way or another in order to be compared with costs (Drummond et al., 2005).
Finally, the construction of the MILY somehow presents a lack of consistency.
Indeed while life year gains are adjusted with a HRQoL of 1, which implies
perfect health, they are computed based on the life expectancy for the general
population, which itself reflects the population prevalence of chronic condi-
tions. Based on these considerations, the MILY does not appear adequate to
support the evaluation of air pollution control interventions.
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2.4 Conclusions
2.4.1 Context: decision frameworks
By pertaining to both the fields of public health and environmental eco-
nomics, the economic evaluation of air pollution control interventions lies at
the intersection of two disciplines which, due to the specificity of their deci-
sion contexts, are rooted on different theoretical frameworks and use different
decision tools. The evaluation of environmental policies traditionally relies on
CBA, which is grounded in welfare economics and seeks economic efficiency.
By contrast, the evaluation of public health interventions has typically followed
the health care evaluation paradigm rooted in decision science, where CEA is
used to allocate constrained resources with view to satisfy most efficiently an
explicit societal objective.
Whilst the two intellectual traditions are different, their decision tools do
share a common ground in practice. Firstly, although economic evaluations of
air pollution control traditionally rely on WTP-based CBA, similarly to public
health evaluations, they are primarily centred on health benefits. Secondly,
both CBA and CEA involve monetization of health output, either in terms of
collective WTP or at the shadow price of the budget constraint imposed on
the health care system, and either approach to valuation inevitably relies on
social value judgments.
2.4.2 Research gaps
This review contributed to identify several limitations associated with the
current approach to quantifying the health benefits of air pollution control and
the uncertainty surrounding the cost-effectiveness of such interventions.
First economic evaluations of air pollution control rely on the HIA method
to health impact quantification where the change in each health endpoint at-
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tributable to the intervention under assessment is computed separately and the
total aggregated effect is obtained via monetization. Such an approach ignores
any interactional effects between morbidity and mortality impacts. This is
expected to be a source of inaccuracy in impact estimates since morbidity and
mortality do interact in a number of ways. In particular, morbidity may affect
baseline life expectancy but also susceptibility, i.e. physiological reaction, to
air pollution exposure.
Second, the morbidity effects considered are primarily associated with acute
exposure and are commonly monetized using cost-of illness estimates which,
given that they do not encompass any disutility effects, are equivalent to at-
tributing a zero value to quality of life impacts. It follows that the long-
term quality of life impacts associated with the development of chronic cardio-
respiratory conditions have been largely ignored so far.
Third, in a context where the application of a quality-adjustment to life year
gains from environmental policies has long been controversial, the most elabo-
rated approach to encompassing quality of life effects alongside life expectancy
impacts from air pollution reduction (US EPA’s MILY) is inappropriate to
support resource allocation.
Fourth, whilst economic evaluations of air pollution control interventions
have placed substantial emphasis on dealing with parameter uncertainty, its
impact on decision uncertainty, i.e. whether an intervention is cost-effective
or not, and the value of reducing parameter uncertainty have not been evalu-
ated yet. In addition, current European guidelines to probabilistic sensitivity
analysis may need to be challenged.
2.4.3 Role of decision analytical modelling
The four limitations previously identified suggest that there is potentially
substantial value in rethinking the current method to evaluating air pollu-
tion control interventions, by drawing on health modelling techniques and
frameworks for characterising decision uncertainty currently used in health
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care decision-making.
To construct a decision model that accurately reflects all the relevant costs
and outcomes associated with competing interventions, it can be useful to
consider a conceptual model before implementing the chosen modelling ap-
proach. Conceptual modelling can be broken down in two sequential steps:
problem-oriented modelling and design-oriented modelling (Tappenden, 2012)
Problem-oriented modelling aims to embrace the complexity of the decision-
problem and of the overall system in which it exists (Tappenden, 2012). For
example, in order to assess interventions aimed at tackling obesity in the UK,
the Foresight Project developed a series of causal loop models that mapped
the interplay of a large numbers of causal factors (e.g. physical activity, diet,
genetic make-up) within the wider cultural, environmental and social contexts
(Vandenbroeck et al., 2007). In the case of air pollution, such analysis would
for instance, underline the productivity effects related to work absences associ-
ated with exacerbations during acute exposure. In addition, potential linkages
with physical activity may need to be considered, whereby air pollution may
reduce individuals’ willingness to undertake outdoor exercise, depending on
their perception of air pollution as a health risk and their level of discomfort
associated with exposure.
Design-oriented modelling subsequently sets boundaries to the depth of the
analysis and considers alternative credible model structures based on consid-
erations of feasibility, that are themselves based on evidence requirements and
resources available in terms of person-time, expertise and so forth (Tappenden,
2012). The main benefit of undertaking this two-stage conceptual modelling
is to provide a benchmark against which the appropriateness of the simplified
structure of the final model may be evaluated in a transparent and accountable
manner.
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2.4.4 Reflecting uncertainty in decisions
Finally, it should be underlined that at the core of model development lies
the intertwined concepts of choice as well as uncertainty. Indeed, in imple-
menting a chosen model structure, assumptions are taken which require value
judgements. In addition the evidence base may be uncertain. It is important
to reflect any uncertainty in the evidence - referred to as parameter uncer-
tainty - and assumptions - referred to as structural uncertainty - and explore
how these may impact the decision.
Structural uncertainty steams from the fact that it is not possible to know
for sure ex-ante whether the choices underpinning the structure of the hard
implemented model (e.g. selection of relevant impacts, of appropriate simpli-
fications) are right or wrong, i.e. whether they will substantially affect the
model’s capacity to usefully inform the decision problem (Tappenden, 2012).
Parameter uncertainty, which was discussed in section 2.3.3, also depends
on a string of modelling choices, including but not restricting to deciding which
parameters are relevant and which source of evidence should characterise them
(Tappenden, 2012). Such choices will be a particular focus on this thesis
which, following an assessment of currently available evidence, will undertake
the estimation of a subset of parameters required to parameterise the model
of the health effects from air pollution exposure.
Importantly, the consequences of parameter and structural uncertainty are
intrinsically linked since the structure of the model will determine the relation-
ship of parameters between one another and their relative influence on final
outcomes.
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Chapter 3
Quantitative impact assessment:
why morbidity and mortality
impacts need to be
simultaneously considered
3.1 Introduction
This chapter challenges the current approach to quantification in health
impact assessment of environmental health interventions, such as air pollution
control.
Health impact assessments aim to predict the effects of projects, programmes
or policies - hereafter also referred to as interventions - on population health
and health inequalities. They are widely used to inform environmental policy
and other public policies outside the health care sector and are championed by
the World Health Organisation under the rubric of “Healthy Public Policy”,
which calls for explicit consideration of health and equity matters in all policy
areas (WHO, 1986; Kemm, 2001).
To achieve this objective, health impact assessments are expected to provide
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predictions that are valid (Veerman et al., 2007; Bathia & Seto, 2011) and
that add value to the decision-making process pertaining to the design and/or
implementation of interventions (Davenport et al., 2006; Kemm, 2001). This
is often best done through quantitative risk assessment (QRA), which provides
a more precise description of impacts and their magnitude and also supports
economic evaluation, which is a key input to decision-making (Veerman et al.,
2005; Fehr et al., 2012).
QRA has often been carried out to evaluate interventions that affect health
by modifying exposure to environmental risk factors, air pollution in particular
(Medina et al., 2013). As mentioned in Chapter 2, the quantification method
consists in applying, for each health endpoint, a health impact function that
links together: (i) the relevant epidemiological risk estimate, (ii) incidence data
and (iii) the change in risk factor exposure and its distribution within the target
population (O’Connell & Hurley, 2009; Bathia & Seto, 2011; Medina et al.,
2013). This provides the change in number of cases of a selection of morbidity
and mortality endpoints, attributable to the intervention under evaluation.
For instance, in the assessments of large-scale programmes of air pollution
control, such as Clear Air for Europe (Holland et al., 2005a), Revisions of
the E.U. Gothenburg Protocol (Holland et al., 2011) and Revisions to the
US National Ambient Air Quality Standards for particulate matter (USEPA
2006; USEPA 2009), commonly reported health impacts included numbers of
premature deaths and/or of life years lost, counts of cardio-respiratory hospital
admissions, numbers of cases of chronic bronchitis and so forth.
Morbidity and mortality are, however, known to interact in a number of
ways. In particular, a chronically sick person is expected to have a shorter
life expectancy than a healthy person. Additionally, morbidity can influence
individuals’ susceptibility to the harmful effects of environmental hazards.
The objective of this chapter is twofold: it aims (i) to demonstrate the im-
portance of encompassing interactions between morbidity and mortality im-
pacts in QRA of environmental health interventions; and (ii) to show how
to handle these interactions via simultaneous quantification of effects using
Markov modelling, which is used extensively to support decision-making in
the health care sector. This work is based on the example of outdoor air pol-
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lution that is one of the environmental risk factors for which health effects
have been most intensively quantified over the recent years (Medina et al.,
2013). Study findings, however, are expected to apply to any environmental
risk factor associated with both morbidity and mortality effects.
The work consists of four main components. First, I briefly recall the cur-
rent approach to QRA, which has been described in greater detail in Chapter 2
and is hereafter referred to as the “separate” approach. Second, I identify lim-
itations associated with the latter and advocate simultaneous quantification of
morbidity and mortality impacts. Third, I outline two approaches to applying
the Markov modelling technique to QRA. Fourth, I illustrate the advantages
of the simultaneous approach to quantification, based on an illustrative inter-
vention of air pollution reduction in London.
3.2 Traditional approach to QRA: the separate approach
The change in annual number of cases of health endpoint y that is at-
tributable to an intervention that modifies the exposure of a target population
of size N to environmental hazard h is obtained by the following health impact
function, assuming a log-linear concentration-response function:
4y = y0(RE4h − 1)N (3.1)
where:
4h represents the change in exposure to hazard h;
4y represents the change in annual incidence of endpoint y;
y0 is the annual incidence rate of endpoint y at hazard levels h0;
RE4h is the ratio of risk of experiencing endpoint y in the group exposed to
4h compared to the unexposed group.
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The application of static health impact functions to quantify health impacts
over a given period of time is however especially problematic when applied to
quantify a change in mortality risk since death can be postponed but not per-
manently avoided. It has indeed been forcefully argued that what matters is
not the number of attributable premature deaths, but time to death advance-
ment (McMichael et al., 1998; Ku¨nzli et al., 2001; Brunekreef et al., 2007).
As a result, life expectancy impacts have been increasingly considered along-
side premature deaths in QRA (O’Connell & Hurley, 2009). They are com-
puted using the life-table method, which consists of comparing survival curves
calculated from annual probabilities of death accumulated over time. The
modification of age and gender-specific probabilities of death by the relevant
mortality risk estimates allows one to derive a modified survival curve that can
be compared against the baseline survival curve (Miller & Hurley, 2003). The
weighted area between the two curves, with weights representing the age and
sex distribution of the target population, is the average life expectancy impact
associated with the change in risk factor exposure (Rabl, 2003).
Whilst the life-table method greatly improves upon health impact functions
with regards to the quantification of life expectancy impacts, there remains a
second and different set of issues that arise when morbidity and mortality
impacts are quantified separately, which is the focus of this chapter.
3.3 Two key limitations of the separate approach
3.3.1 Overestimation of the change in morbidity cases
There is a straightforward interaction between morbidity and mortality ef-
fects: the longer people live, the more likely they are to experience additional
morbidity events, and conversely if their life expectancy is shortened.
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Understandably it is not common practice to exhaustively account for the
potential morbidity impacts associated with a change in mortality risk in a
given target population. However, if a risk factor is associated with adverse
impacts on both mortality and a selection of morbid conditions, the described
interactional effect implies that the true change in number of cases of morbid
endpoints of interest, net of the mortality impact, will always be lower than
the “crude” change computed separately from the mortality effect.
We shall examine this relationship using the example of outdoor air pol-
lution that is positively associated with a greater risk of dying prematurely
from all-causes and of developing chronic conditions such as chronic bronchi-
tis (Anderson et al., 2012; US EPA, 2009). Under a decrement in exposure
to air pollution, the crude decrease in number of cases of chronic bronchitis,
resulting from a reduced risk to develop this disease, is expected to be partly
compensated by additional cases of chronic bronchitis taking place during the
extended length of life enjoyed by individuals of the target population. Con-
versely, under an increment in air pollution exposure, the crude increase in
cases of chronic bronchitis is expected to be partly compensated by the short-
ening of an individual’s average lifespan, during which they can develop this
disease.
The magnitude of the overestimation bias in the change in cases of morbid
endpoint y under the separate approach will be determined by the interaction
between three main factors: (i) the target population’s baseline probability of
developing condition y, i.e. disease incidence; (ii) the relative magnitude of the
risk factor’s impact on the risk of death and on the risk of developing condition
y; (iii) the analysis time-horizon. Indeed the longer the time-horizon, the more
mortality impacts will matter when assessing the morbidity effects associated
with a given intervention. The overestimation bias is therefore difficult to
estimate a priori. However, modelling results based on a case study of air
pollution reduction in London over a time horizon of 60 years, presented in
section 3.5, shows that it can be substantial.
67
3.3.2 Limited ability to characterise the distribution of life ex-
pectancy impacts
By causal pathways
The computation of an intervention’s impact on life expectancy separately
from morbidity effects has two main limitations. The first pertains to the
limited ability to identify the contribution of each morbid endpoints, i.e. each
causal pathway, to the overall life expectancy impact.
Whilst cause-specific mortality risk estimates can help address this problem,
their use is typically not recommended for health economic evaluation as it
may lead to an under-estimation of the total mortality burden (WHO, 2013).
Indeed, the effect of a severe disease on lifespan usually goes beyond death
from this particular disease and includes an overall weakening of the general
health condition, e.g. co-morbidities, that may lead to premature death from
other causes. These premature deaths may not be captured by the narrower
focus of cause-specific risk estimates. Second, the validity of cause-specific
mortality risk estimates may be adversely affected by misclassification of causes
of death in mortality registration. Background national statistics on all-cause
mortality are therefore expected to be of greater precision than cause-specific
death rates (Mathers et al., 2005). Finally, at least in the case of air pollution,
cause-specific risk estimates are deemed more appropriate for meta-analysis,
which is key to incorporate all relevant evidence and to decrease parameter
uncertainty (WHO, 2013).
Between health-stratified population subgroups
Second, the life expectancy impact attributable to interactions between the
presence of pre-existing morbid conditions, i.e. health status, and hazard ex-
posure cannot be identified. Morbidity indeed typically affects mortality in
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two main ways. Firstly, it can increase the individual’s baseline probability
of death. For instance, subjects with chronic obstructive respiratory disease,
especially in the severe or very severe stages of the disease, have a higher prob-
ability of death (Mannino et al., 2006). Secondly, it can enhance individuals’
predisposition to experience adverse effects associated with hazard exposure,
hereafter referred to as greater susceptibility to exposure. For instance, sur-
vivors of a myocardial infarction were found to have a higher excess risk of
death associated with air pollution exposure than individuals of the general
population (Zanobetti & Schwartz, 2007).
A potential approach to encompassing interactions between health status
and mortality may be to: (i) split the target population into subgroups whose
health state has a known influence on baseline mortality risk and/or suscep-
tibility to risk factor’s adverse effects and (ii) apply the life-table method
to each subgroup. However, in addition to being cumbersome, when assess-
ing air pollution control interventions, such an approach would be incomplete
and underestimate health benefits. Indeed, air pollution not only affects peo-
ple differently according to their health status but, as it increases the risk
of developing chronic conditions, also impacts upon the risk on entering each
susceptibility-stratified subgroup. Consequently, simply applying the life-table
method to each subgroup would fail to capture air pollution’s influence on in-
dividuals’ health distribution over time, and its interaction with health-related
differential susceptibility. As a result, such an approach would underestimate
total health benefits.
Reasons why the distribution of impacts matters
The ability to characterise the distribution of life expectancy impacts is
extremely pertinent to implementing the concept of Healthy Public Policy.
The latter indeed embraces concerns for both health and equity and places a
particular emphasis on distributional analysis (WHO, 1999, 2005, 2008).
Firstly, combining knowledge of the distribution of life expectancy impacts
by causal pathway and between population subgroups stratified by health sta-
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tus, with evidence on social gradients in health outcomes (O’Neill et al., 2003)
is key to finely characterise the distribution of health effects across socio-
economic subgroups. It is therefore a crucial component of health inequality
analysis.
Secondly, knowledge of impact distribution is paramount to the construction
of summary measures of population health (SMPH), which require to adjust life
expectancy estimates with health- or disability-related quality of life weights
(Gold et al., 2002). Although SMPH are not used widely in health impact
assessments (Briggs, 2008), they were suggested as a complementary metric to
support resource prioritisation (Veerman et al., 2005).
Thirdly, instead of simply adding numbers of cases of morbid events, un-
derstanding the impact of morbid events on individuals’ baseline probability
of death as well as on their susceptibility to suffer from further adverse effects,
helps provide an much more accurate picture of the morbidity health burden
attributable to a given environmental health hazard.
Finally, distributional information is also pertinent to economic analyses,
which are often performed for regulatory assessments. For instance, extending
the life of a person with a medical condition or extending the time period
during which a person remains healthy is expected to have opposite impacts
on health care budgets.
3.4 Simultaneous quantification of health impacts using
Markov modelling
3.4.1 Markov modelling: Description
The argumentation developed in section 3.3 makes a case for accounting
for morbidity and mortality interactions, via simultaneous quantification of
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these impacts. This can be performed using Markov models, which have a
long history of use in medical decision-making and health care technology
assessment (Sonnerberg & Beck, 1993; Briggs et al., 2006).
Markov models simulate the incidence of health events over the individual’s
lifetime via pathways to and from a set of mutually exclusive and exhaustive
health states, such as “healthy”, “diseased”, “dead”. The use of an absorbing
state, i.e. a state that cannot be left once entered such as “ dead”, makes the
Markov process finite (Sonnerberg & Beck, 1993).
The main strength of Markov models is to consider all relevant health effects
simultaneously and thus to capture interactions between impacts. In addition,
Markov models are especially suitable to QRA as they are dynamic projec-
tions tools. As such, unlike static health impact functions, they can allow for
dynamics in population demographics as well as in the pattern of change in
health risk, where the latter may vary by age and/or calendar time after inter-
vention implementation. Whilst life-tables also allow for such dynamics, they
can only evaluate life expectancy impacts. Furthermore, Markov models are
particularly suited to model health effects that can repeat over time for a same
individual as is often the case for morbidity effects, such as hospitalisations
(Sonnerberg & Beck, 1993).
In a Markov model, pathways between health states are parameterised by
probabilities of transiting between states, called transition probabilities (TP).
Whilst Markov processes are continuous, they are typically evaluated using
a discrete time approximation by expressing TP for a discrete time period
know as a cycle, where the sum of cycles represents the time horizon for effect
quantification.
Each TP represents the probability of transiting to a particular state of
the model during a cycle, conditional on being in a given health state at the
beginning of the cycle. This allows to differentiate an individual’s probability
of experiencing future health events according his/her current health status.
TP are also typically stratified by age and gender and expressed as a function
of numbers of cycles elapsed to reflect the time-dependency of health events
(Briggs & Sculpher, 1998).
To estimate the total change in population health associated with an in-
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tervention that increases or reduces population exposure to an environmental
hazard such as air pollution, the Markov model structure should be composed
of two arms: a “Baseline” arm, populated with baseline TP and (ii) an “Inter-
vention” arm for which, similarly to a health impact function, baseline TP are
multiplied with relevant epidemiological risk estimates, scaled to the expected
change in hazard. For a decrement in hazard exposure, scaled risk estimates
are hereafter referred to as risk reduction estimates (RRE) throughout the
thesis.
Each arm of the model should then be evaluated across all cycles, either via
first order Monte Carlo simulation which follows the unique pathways taken
by a large number of individuals, or via cohort simulation where a cohort of
individuals are followed altogether throughout the model (Briggs & Sculpher,
1998). At the end of all cycles, one can obtain the total life years spent by each
individual, or by the overall cohort, in each health state of the model, along
with the total count of health events experienced. Comparison of results for
each arm provides the intervention’s attributable change in counts of health
events and in total life years spent in each health state.
3.4.2 Applying Markov modelling to QRA
Modelling approach
Two main approaches to applying Markov modelling in QRA are presented
below. They essentially differ in the scope of morbidity-mortality interac-
tions encompassed and thus, in the way life expectancy impacts are modelled.
The choice between the two approaches should be driven by the nature and
availability of epidemiological data, as well as by the potential presence of
policy-focus on some disease or susceptible populations subgroups.
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- Full modelling of morbidity-mortality interactions:
A first approach consists in modelling the full range of diseases that are as-
sociated with hazard exposure and/or that enhance individuals’ susceptibility
to adverse health events. In this case, the life expectancy impact of a change in
hazard exposure is fully mediated via the change in the risks of entering health
states that represent life-shortening diseases and/or susceptibility-enhancing
conditions. The mortality risk of individuals who do not enter those health
states is therefore unchanged under an increment or decrement in hazard ex-
posure.
Although this “full modelling” approach best characterises the distribution
of life expectancy impacts by morbidity pathways and between population sub-
groups, it requires a good knowledge of the range of morbid impacts associated
with the risk factor of interest. It is therefore quite resource intensive and may
not be adequate if gaps in epidemiological evidence are known to be large.
- Focused modelling of morbidity-mortality interactions:
The second approach, hereafter referred to as “focused modelling”, consists
in focusing on a restricted set of life-shortening and/or susceptibility-enhancing
morbid condition(s) that are most strongly supported by epidemiological evi-
dence, or that are of particular policy interest.
Importantly, in this case, the mortality effect of hazard exposure - if the
latter is associated with all-cause mortality - will typically need to be mod-
elled via all the model pathways, such that both the individuals who enter
the disease state(s) and those who do not, face a change in death risk (with
potentially differing magnitude) under exposure change.
Whilst the modelling of health impacts is easier to implement under the
“focused modelling” approach, for model parameterisation to be accurate, the
risk estimate of mortality associated with hazard exposure may need to be
adjusted. Indeed, the Markov model structure implies that individuals who
do not enter the disease state X, cannot die from cause x. Therefore, to
be coherent and to avoid potential double-counting of life expectancy effects,
the risk estimate of mortality that applies to the probability of death of those
individuals who are not in state “X” should pertain to all other causes of death
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than cause x. Whilst the required information may not be available from the
epidemiological literature, a mean estimate of excess risk can be derived using
the risk estimate of all-cause mortality and the risk estimate of mortality from
cause x. A method to do so is presented in Appendix A.
Model structure
To assess the overall life expectancy impact of an intervention that modifies
population exposure to a risk factor, only one “Intervention” arm, fitted with
all relevant and appropriately scaled risk estimates is required (i.e. arm I4 of
Figure 3.1 in section 3.5.1).
However, disentangling health effects by morbidity pathways and across
population subgroups requires additional “Intervention” arms, where risk es-
timates apply only on selected transition paths (e.g. arms I1, I2, I3 of Figure
3.1 in section 3.5.1). To identify the health effect attributable to the change
in the risk of a particular health event, inter-arms comparisons should involve
two arms that solely differ on the basis of that particular risk being modified.
3.5 Illustration
3.5.1 Description and method
This section illustrates how Markov modelling-based simultaneous quantifi-
cation of morbidity and mortality impacts can address the previously outlined
limitations of the traditional “separate” approach to QRA. It is based on an
illustrative intervention that is expected to decrease immediately and perma-
nently concentrations of fine particulate air pollution (PM2.5) by 1µg/m
3 in
London.
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For illustrative purposes, quantification of the whole range of health effects
associated with PM2.5 exposure (Anderson et al., 2012; Brook et al., 2010; US
EPA, 2009) was out of scope. Consequently, the “focused modelling” approach
described in section 3.4.2, focusing on coronary heart disease (CHD) - ICD I20-
25 - as a chronic morbid endpoint alongside all-cause mortality impacts, was
followed to model the health benefits of air pollution reduction.
The model, which is illustrated in Figure 3.1, uses a simple 3-state structure:
“Without CHD”, “With CHD”, “Dead”. This implies that, for a given age
and gender, health status is defined as having CHD or not. This structure was
duplicated four times such that the “Baseline” arm could be compared against
four “Intervention” arms I1 to I4, which differ according to the transition paths
to which risk reduction estimates apply.
- Arm I1 only accounts for the reduced risk of developing CHD;
- Arm I2 only accounts for the reduced risk of premature mortality among
individuals without CHD;
- Arm I3 encompasses simultaneously the reduced risk of developing CHD
and the reduced risk of premature mortality among individuals without CHD;
- Arm I4 accounts simultaneously for the reduction in all risks of health
events affected by the intervention: (i) the risk of developing CHD, (ii) the
risk of death among individuals without CHD and (iii) the risk of death among
individuals with CHD.
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Figure 3.1: Diagram of 5-arm Markov model developed for evaluating the illustrative inter-
vention.
Abreviations: AOC = all other causes; AC = all causes; CHD = coronary heart disease, CHD = without
CHD, Dev. = developing. Each oval represents a Markov state and full arrows indicate allowed transitions
between them.
Risk reduction estimates RREa, RREb, RREc are epidemiological risk estimates scaled to a 1µg/m
3
decrement in PM2.5 concentrations and are defined in Table 3.2. RREa applies to P (Dev.CHD), RREb to
P (DeathAOC|CHD) and RREc to P (DeathAC|CHD).
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Table 3.1 describes the various inter-arms comparisons that were performed
to disentangle life expectancy impacts attributable to the reduction in each
risk. It underlines how modelling results address the two limitations of the
“separate” approach outlined in section 3.3.
Arms Inter-arms comparisons’ output
compared
Correct estimation of the change in morbidity cases (section 3.1.)
(B − I3) Avoided CHD cases under the simultaneous approach to quantification (1)
(B − I1) Avoided CHD cases under the separate approach to quantification
(I1 − I3) Overvaluation bias associated with the separate approach
Distributional analysis of life expectancy impacts (section 3.2.)
(I3 − I2) Life year (LY) gain due to reduced risk of developing CHD
(I2 −B) LY gain due to reduced mortality risk in individuals “Without CHD”
(I4 − I3) LY gain due to reduced mortality risk in individuals “With CHD”
Intervention’s total life expectancy impact in the target population
(I3 − I2) + (I2 −B) + (I4 − I3) = (I4 −B)
Table 3.1: Inter-arms comparisons: limitations addressed and modelling output.
(1) In the present case, since CHD is chronic, comparing the baseline arm (B) against arm I4 or arm I3
provides exactly the same number of avoided CHD cases.
The target population was defined as the currently alive population of Lon-
don aged 40 to 90 years (2011 census) followed until they reached 100 years
or died. As a result, the analysis time horizon is 60 years. The modelling
parameters, which consist of risk reduction estimates, death probabilities and
CHD incidence and prevalence are detailed in Table 3.2. Since: (i) the present
study focuses on the expected morbidity and mortality impacts and (ii) the
structure of each arm of the model is linear, a deterministic analysis relying on
the mean values of each parameter was performed. The model was evaluated
in Matlab.
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Mean values (2)
Name Definition (1) Source 4PM2.5 = −1µg/m3
cycle 0 CHD Prevalence
P (Dev.CHD)
cycle 1-60 CHD Incidence UK GPRD (3)
N.A.
P (DeathAOC|CHD) Probability of death Own computations
from all other based on death rates
causes than CHD, in England (ONS, 20131)
if without CHD and hazard ratios of
P (DeathAC|CHD) Probability of death
excess death from N.A.
from all causes, CHD provided by
if with CHD (Whiteley et al., 2005)
RREa RRDev.CHD Gan et al. (2011) 0.988
RREb HRDeathAOC|CHD Own computations 0.995
(see Appendix A)
RREc
(4) age ≤ 64 HRDeathAC Pope III et al. (2002) 0.994
age ≥ 65 HRDeathAC|CHD Zanobetti and 0.971
Schwartz 2007
Table 3.2: Modelling parameters for parameterisation of the 5-arm model.
Abreviations: AOC = all other causes; AC = all causes; CHD = coronary heart disease, CHD = without
CHD, Dev. = developing.
(1) All probabilities are expressed for a one-year period. They are stratified by one-year age group and
gender. To be combined with risk reduction estimates (RRE), transition probabilities were converted into
rates and the resulting product was converted back to probabilities to parametrize intervention arms. RRE
values unconditional on health status hold for the general population.
(2) Mean risk estimates rescaled to a 1µg/m3 decrement in PM2.5 concentration. Rescaling method and
original values provided in the epidemiological literature are presented in Appendix B.
(3) Obtained from open-access model DYNAMO-HIA.
(4) HRDeathAC|CHD, which captures CHD-subgroup’s specific susceptibility to PM2.5 mortality effect,
only applies to individuals with CHD aged 65 and above in order to be in line with Zanobetti & Schwartz
(2007)’s study population.
3.5.2 Results
The results are presented for each gender and 1-year age group of the cur-
rently alive London adult population, over the 60 years modelling period. Per-
centage values given are population-weighted.
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Overestimation bias in quantification of avoided CHD cases
Figure 3.2 contrasts the numbers of avoided cases of CHD under pollution
decrement obtained by the separate approach (results represented by the full-
line curve) as opposed to the simultaneous approach (results represented by the
dotted curve). The comparison of those results - which is equivalent to directly
comparing arm I1 against arm I3 - shows the impact of extending individuals’
life expectancy, simultaneously to reducing their risk of developing CHD, on
the total number of CHD cases expected to be avoided in the target population.
The interactional effect between the morbidity and mortality impacts of
air pollution reduction is the strongest for younger age-groups, who are those
who enjoy the reduction in mortality risk for the longest period, i.e. who have
the largest life expectancy gain. As a result, the size of the bias in counts of
CHD cases associated with the separate approach is the largest among younger
age-groups and slowly decreases as a function of age. An implication of this
finding is that the longer the time horizon of analysis, the greater the bias
in quantification of morbid cases will be, as differences accumulate over time.
Across all age-groups and a time horizon of 60 years, the bias is not negligible:
under the separate approach, counts of avoided CHD cases is overestimated
by about one fifth for each gender.
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Figure 3.2: Number of avoided CHD cases in current London population under the separate
and the simultaneous approaches to quantification.
Abreviations: B, I1 and I3 stand for “Baseline” and “Intervention” arms I1 and I3, as represented in
Figure 3.1.
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Distributional analysis of life expectancy impacts by causal pathways and be-
tween health-stratified population subgroups
Figure 3.3 illustrates how simultaneous quantification of morbidity and mor-
tality impacts can characterise the distribution of life expectancy impacts by
causal pathways and between population subgroups stratified by demograph-
ics and health status, presently defined by the presence of the CHD condition
or not. In line with the fact that life expectancy gains are cumulative over
a lifetime, the younger age groups gain the most from the intervention. The
small irregularities in the pyramidal distribution of life year (LY) gains solely
mirror the peculiarities of London’s population distribution (see Appendix C).
Figure 3.3 was obtained by performing three inter-arms comparisons defined
in the lower-section of Table 1. It provides three main modelling insights.
Firstly, individuals “With CHD”, i.e. those who had CHD at baseline or who
developed it in their remaining lifetime, are expected to reap about a quarter
of the intervention’s total LY gain (respectively 25% and 23% of total LY
gain accruing to males and females populations across all ages). It should be
underlined that this finding reflects epidemiological evidence that individuals
with CHD aged above 65 years old are more susceptible to air pollution adverse
effects than the rest of the general population (see section 3.5.1).
Secondly, about a fifth of the intervention’s total LY gain steams from
reducing the risk of CHD incidence (respectively 22% and 16% of total LY
gain accruing to males and females populations across all ages). A corollary of
these two findings is that the CHD pathway is expected to be a major driver of
the intervention’s overall life expectancy impact. Indeed, respectively 47% and
39% of the intervention’s total LY gain accruing to male and female populations
is generated by preventing or decelerating the development of CHD and/or by
staying alive longer once suffering from it.
Thirdly, the relative contribution of each risk reduction to total LY gain
strongly depends on age and gender. For instance, the LY gain associated
with a reduced risk of CHD incidence accounts for 26% of the total LY gain
accruing to individuals aged 40 as opposed to 10% of the total LY gain accruing
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to individuals aged 75. Indeed, as individuals get older, their probability of
already having developed CHD before intervention implementation becomes
greater and moreover, their risk of developing other life-shortening diseases
than CHD becomes more prevalent. Finally, gender differences pertaining to
the share of LY gain attributable to the CHD pathway corroborate results
of Figure 3.2, where the absolute numbers of avoided CHD cases is lower for
females than males. It is explained by the lower baseline incidence of CHD in
females before menopause.
Figure 3.3: Distribution of the intervention’s life year (LY) gain by causal pathway and
between age- gender- and health status-stratified subgroups.
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3.6 Discussion
The present work challenges the traditionally used approach to quantifi-
cation in health impact assessments of environmental interventions such as
air pollution control regulations, where morbidity and mortality impacts are
quantified separately. It demonstrated that, by ignoring interactions between
morbidity and mortality impacts, this “separate” approach undermines the
validity of health predictions and cannot provide policy-relevant information
pertaining to the distribution of life expectancy impacts.
As illustrated with a case study of air pollution reduction in London, the
simultaneous quantification approach has two major benefits. First, it pro-
vides a correct estimate of the intervention-related change in cases of morbid
endpoints in the target population, rather than systematically overestimating
this impact. The size of the overestimation bias associated with the “separate”
approach will depend on several factors, in particular the relative magnitude
of the risk factor’s impact on mortality and morbidity risks. Over long time
horizons, as typically used in HIA of air pollution control interventions, the
bias may be substantial. Over a 60-year time horizon for instance, the “sep-
arate” approach was found to lead to an overestimation by one fifth of the
number of CHD cases expected to be avoided following pollution abatement
in London.
Secondly, by encompassing interactions between health effects, including
health-related differential susceptibility to hazard exposure, the simultaneous
quantification approach can characterise the distribution of life expectancy
effects by causal pathways and across population subgroups stratified with
different levels of health. This more refined understanding of the distribution
of health effects is expected to have a least three main applications. First, in
a context where the reduction of health inequalities is viewed as an essential
component of the implementation of Healthy Public Policy (WHO, 1999, 2005,
2008), such distributional information, when combined with evidence of social
gradients on health, can support health inequality analysis. Second, it is crucial
to the computation of summary measures of population health, which require
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to adjust life expectancy estimates by health (or disability)-related quality of
life weights. Whilst not widely used in HIA , these measures allow to compare
the performance of diverse interventions and provide an accurate picture of
morbidity on length and quality of life, thus going beyond simple adding up
of numbers of cases. Finally, encompassing interactions between health effects
as also particularly relevant for budget impact analysis especially with regards
to health care resource use.
Markov models were suggested as a quantification tool to perform simulta-
neous quantification of morbidity and mortality impacts in quantitative health
impact assessments. In addition to capturing interactions between health ef-
fects, which was the focus of this chapter, it is worth underlining that Markov
modelling also allows for dynamics in population demographics and health
risks over time. Consequently it addresses the static feature of health impact
functions, which are currently used to quantify morbidity impacts.
Markov models are also particularly suited to model repeating health effects
as well as to attach costs and utilities to health states in order to compute
summary measures of population health, such as QALYs and DALYs. As
a result, they have been used extensively for decision-making in the health
care sector. By contrast, to the exception of recently developed Markov-based
generic software DYNAMO HIA (Lhachimi et al., 2012), Markov models have
very little history of use in health impact assessments of environmental health
interventions. A potential reason for the limited application of Markov models
in quantitative health impact assessment may be their greater complexity than
the current tools of the separate approach i.e. health impacts functions and
life-tables. In this respect, the “focused modelling” approach illustrated in this
chapter appears particularly attractive.
Notwithstanding the level of refinement in the quantification of predicted
health impacts, it is worth stressing that quantitative risk assessment, be it
performed under the “separate” or the presently advocated simultaneous ap-
proach, is underpinned by a set of assumptions which impact on predictive
validity should always be considered. In particular it is assumed that epidemi-
ological results from various studies are applicable to the target population of
the intervention under assessment (Bathia & Seto, 2011). It should however
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be noted that, by taking into account individuals’ heterogeneity in suscep-
tibility to health effects as a result of their health status, the simultaneous
approach may help reduce extrapolation of epidemiological findings. Finally,
whilst input parameters to quantification (e.g. mortality and disease incidence
statistics) are typically assumed to be stable over time, secular trends, be
it purely contextual or induced by the interventions themselves, may further
widen the gap between predictions and reality (Bathia & Seto, 2011).
3.7 Conclusion
In a context where health impact assessment has become a major compo-
nent of the implementation of Healthy Public Policy, the present work chal-
lenges the current approach to impact quantification, which assesses morbidity
and mortality impacts separately. Two main limitations pertaining to predic-
tions’ validity and informational content were identified. To address these
limitations, a simultaneous approach to quantification that captures interac-
tions between impacts was advocated. Markov modelling was selected to im-
plement the simultaneous approach and to illustrate its superiority, a simple
3-state Markov Model was constructed to evaluate an illustrative intervention
of air pollution reduction in London. By improving predictions’ validity and
policy-relevant informational content, the simultaneous modelling approach to
quantitative risk assessment in HIA is expected to help contribute to public
health protection more effectively.
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Chapter 4
A Markov modelling approach
to the estimation of QALY gain
and health care costs impacts of
air pollution control
4.1 Introduction
Chapter 3 demonstrated that the current approach to quantitative health
impact assessment of environmental health interventions such as air pollu-
tion reduction presents two important limitations: by quantifying morbidity
and mortality impacts separately, it undermines predictive validity and cannot
charaterise the distribution of life expectancy impacts by causal pathways and
among population subgroups with different levels of health. A simultaneous
approach to quantification, that captures interactions between morbidity and
mortality health effects, was therefore advocated.
Markov models were selected to apply this approach to quantitative health
impact assessment, owing to their numerous attractive features. More specifi-
cally, since they were developed to represent stochastic processes, Markov mod-
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els are particularly suited to modelling the dynamic progression of diseases and
their interactions with health events, such as death, in a given target popula-
tion. Additionally, they also allow for dynamics in population demographics
and in the pattern of change in health risk associated with a intervention, thus
addressing the static feature of commonly used health impacts functions.
As mentioned in Chapter 2, the morbidity effects considered in evalua-
tions of air pollution control interventions are primarily associated with acute
pollution exposure. Consequently, the long-term quality of life impacts associ-
ated with a reduction in chronic morbidity, following a sustained decrement in
background air pollution, are typically ignored. However, in light of increasing
political attention to strategies to improve air quality (Medina et al., 2013),
it is of particular interest to refine the understanding of the long-term health
benefits of such interventions, by evaluating quality of life gains alongside life
expectancy effects.
The health metric designed to encompass impacts on both quality and
length of life dimensions is the quality-adjusted life years (QALY). Although
the QALY has been rarely used in HIA (Briggs, 2008), its use has been advo-
cated for assessments of environmental health interventions in order to support
resource prioritisation (Ponce et al., 2001; US Institute of Medicine, 2006). In
particular, as the QALY routinely supports health care resources allocation
(Drummond et al., 2005), its use in the assessment of air pollution control in-
terventions would allow policy-makers to compare the latter with health care
interventions, for which cost-effectiveness decision rules are in place.
Constructing a QALY requires the application of a quality-adjustment to
life year gains using health-related quality of life (HRQoL) weights. However,
as mentioned in Chapter 2, adjusting life years gains for quality of life has been
controversial and past attempts at doing it have been simplistic. In this con-
text, this piece of work aims to demonstrate that the Markov-modelling based
simultaneous approach to quantification presented in Chapter 3 represents a
step forward for QALY-based cost-effectiveness assessments of air pollution
control.
The aims of this chapter are threefold: (i) to review existing attempts at
estimating the QALY gain of air pollution control and to outline the advan-
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tages of the Markov-modelling based simultaneous approach to perform such
analysis (ii) to analyse and translate the rich body of epidemiological evidence
on the adverse health effects of long-term exposure to fine particulate air pol-
lution (PM2.5) into chronic conditions associated with known effects on life
expectancy and quality of life; (iii) to construct a Markov model that captures
the main characteristics of the chronic conditions identified and that relies on
the latest most relevant epidemiological evidence, as was feasible at the time of
project realisation. This implies that the risk estimates that will parameterise
the model will be more up to date than the estimates used in Chapter 3.
The underpinning objective is to apply the developed model to quantify
the QALY gain and health care cost impact of reducing PM2.5 concentrations
in England and Wales and London, in order to support the UK air quality
strategy. The present chapter however, solely focuses on the construction
and parameterisation of the model. Estimation of a subset of key parameters
required to parameterise the model will be dealt with separately in Chapters
5 and 6. Modelling findings will be presented and discussed in Chapter 7.
4.2 Benefits of the simultaneous approach to quantifi-
cation in QALY analysis
4.2.1 Limitations of past QALY analyses
The QALY is obtained by multiplying the period of time spent in a given
health state by health-related quality of life (HRQoL) weights associated with
that state (Gold et al., 2002). There are two related elements to take into
account when assessing the QALY gain of air pollution reduction. First, the
lower the baseline quality of life and/or remaining lifespan of targeted indi-
viduals are, the smaller the QALY gain from postponing their deaths will be.
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Second, epidemiological evidence suggests that air pollution is associated with
both premature mortality and the development of chronic cardio-respiratory
conditions (Anderson et al., 2012). A subset of population individuals affected
by a poor health condition and thus, a low quality of life and a short life
expectancy, is therefore attributable to cumulative exposure to air pollution.
Ignoring air pollution’s influence on individuals’ quality of life and life ex-
pectancies at baseline, i.e. under current pollution levels, will consequently
greatly underestimate the QALY gain of air pollution control. Although this
issue has been acknowledged (Hubbell, 2006), it has not been adequately ad-
dressed. Using the life-table method, Coyle et al. (2003) simply applied HRQoL
weights for the general population to life year gains from a lower risk of pre-
mature mortality and completely ignored quality of life gains associated with
reduced morbidity. Cohen et al. (2003) used a similar method but assumed
that all the individuals who would die prematurely from air pollution suf-
fered from a preexisting coronary or respiratory condition without however,
accounting for air pollution’s role in driving a subset of them to such health
state. Such an approach further contributed to underestimating the QALY
gain of air pollution control.
Whilst Hubbell (2006) partly accounted for air pollution’s impact on quality
of life via the development of chronic bronchitis, he did not use the resulting
level of quality of life as a baseline to adjust life years gains from decreased
mortality risk. This use of a double baseline of HRQoL weights to assess
respectively morbidity and mortality effects, as was done by the US EPA to
create the MILY (see Chapter 2), no longer allows a linear substitution between
quality and quantity of life and thus, clearly departs from the QALY.
A second major limitation shared by all the above-mentioned studies - and
by all past HIAs of air pollution control interventions in general - is that no
study has accounted for the fact that individuals suffering from a compromised
health condition have been found to be more susceptible to air pollution expo-
sure than the general population (Zanobetti et al., 2008; Zanobetti & Schwartz,
2007; Tonne & Wilkinson, 2013). As argued and illustrated in Chapter 3,
health-related differing susceptibility to air pollution drives the distribution
of adverse impacts among population subgroups stratified by health status.
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Such a knowledge is crucial to accurately adjust life expectancy estimates
with HRQoL weights and ignoring it, as was done by past QALY analyses of
air pollution control interventions, is expected to lead to inaccuracy in impact
estimates.
4.2.2 Advantages of the simultaneous approach
The two major limitations of past QALY analyses stem from the fact that
they relied on the traditional “separate” approach to impact quantification in
HIA that was criticised in Chapter 3. These limitations can be addressed by
encompassing interactions between morbidity and mortality impacts via the
simultaneous approach to impact quantification, using Markov modelling as a
quantification tool.
Markov modelling consists in following individuals’ health condition over
time by simulating their trajectories to and from a set of mutually exclusive and
exhaustive health states. It provides two core advantages to QALY analysis.
First, individuals’ quality of life and life expectancies are no longer treated
as exogenous parameters. Instead, they are endogenously determined as a
function of individuals’ current health states, where air pollution influence in
driving them to their respective states of health is fully accounted for. Second,
individuals’ change in susceptibility to air pollution exposure over time, as a
consequence of a degraded health condition that may, or may not, be associated
with air pollution exposure is encompassed. Thanks to these two features, the
lifetime impact of air pollution exposure on individuals’ quality and length of
life is fully captured.
In addition, from an economic perspective, the proposed approach can quan-
tify both the health care savings from a reduced occurrence of morbidity events,
as well as the health care costs from extending the lives of individuals with
chronic medical conditions. As a consequence, the total health care budget
impact of reducing air pollution can be evaluated.
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4.3 Modelling the QALY and health care costs impacts
of air pollution exposure
4.3.1 Preliminaries
Chapter 2 discussed the importance of undertaking conceptual modelling
(problem-oriented and design-oriented), in order to produce a benchmark against
which to assess the credibility of the final model to be implemented. In this
analysis a conceptual model has not been formally implemented, however ele-
ments that are relevant to the construction of a conceptual model are consid-
ered in sections 4.3.2 to 4.3.4 and section 4.4.2.
4.3.2 System boundaries: scope of analysis
As mentioned in Chapter 2, the impacts associated with air pollution expo-
sure go beyond the increase in morbidity and mortality cases directly related
to exposure but include productivity effects due to work absences following
acute effects and potentially, wider effects on physical activity outdoors for
those living in urban areas.
Nevertheless, the core objective of the present work is to apply for the first
time, the Markov modelling technique to quantify the quality of life effects
associated with the development of adverse health conditions under air pollu-
tion exposure. Consequently, the scope of impacts considered as relevant for
the present analysis was restricted to direct effects on morbidity and mortality
and associated health care costs.
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4.3.3 Relevant health effects
Chapter 2 underlined two main categories of health effects which are related
to the timing of exposure: acute effects associated with short-term peaks in
pollution exposure versus chronic conditions developed as a result of sustained
exposure.
The present analysis aims to quantify the impact on life expectancy, quality
of life and health care resources of sustainably reducing PM2.5 concentrations
over the individual’ remaining lifetime. Given such timescale, only chronic
health effects were considered relevant. Whilst the life expectancy impacts
associated with acute exposure are encompassed in risk estimates of excess
mortality from cumulative exposure (Ku¨nzli et al., 2001), this choice implies
that quality of life effects from morbid events triggered by acute exposure, such
as respiratory exacerbations, are therefore not presently taken into account.
Short-term quality of life effects from excacerbations are however, not expected
to drive quality of life impacts over a lifetime.
4.3.4 Target population for the intervention
Air pollution has been found to affect individuals in every stage of life: (i) in
utero, whereby maternal exposure to air pollution exposure has been associated
with an excess risk of low birth weight in babies (Dadvand et al., 2013) and
most recently, with a greater odds of developing autism (Raz et al., 2014); (ii)
during childhood in particular by affecting children’ lungs development (Eisner
et al., 2010; Shannon et al., 2004) and (iii) in adulthood, whereby the sick and
elderly have been identified as susceptible subgroups (Peled, 2011; US EPA,
2009).
The latest findings with regards to impacts in utero are however, extremely
recent and may need further validation. Children are expected to be particu-
larly susceptible to air pollution impacts due to more time spent outdoors, a
higher air intake per body weight and bodies in developmental phase (Shannon
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et al., 2004; US EPA, 2009; Peled, 2011). However, evidence of effects in chil-
dren primarily pertains to respiratory exacerbations following acute exposure,
which are outside the present scope of analysis, or to subclinical respiratory
conditions (such as reduced lung growth), which are not well characterised
with incidence and prevalence statistics.
On these grounds, the present analysis focuses on chronic health impacts
experienced in adulthood. Importantly, since chronic respiratory impacts in
adults partly derive from the worsening over time of subclinical conditions
developed since childhood (Eisner et al., 2010; Peled, 2011), the long-term
damaging impact of PM exposure on children’s lung development should to
some extent, be encompassed in the analysis.
4.3.5 Inclusion/exclusion of relevant chronic health impacts in adults
As mentioned in Chapter 2, evidence requirements represent a key compo-
nent of the feasibility assessment when considering alternative credible model
structures. In the present case, the documented morbidity effects of partic-
ulate matter (PM) exposure had to be translated into well-defined chronic
conditions for which population prevalence, incidence and survival statistics,
as well as HRQoL scores and health care cost data, were available.
Epidemiological studies suggest a positive association between long-term
exposure to fine particulate air pollution and incidence of myocardial infarc-
tion (Lipsett et al., 2011; Puett et al., 2009), coronary revascularization (Miller
et al., 2007) and acute and sub-acute forms of coronary heart disease (Cesaroni
et al., 2014), in individuals of the general population without heart disease at
enrolment. In addition, further evidence suggests exposure to PM is also re-
lated to early stages of heart diseases by increasing coronary atherosclerosis
(Adar et al., 2013; Ku¨nzli et al., 2010; Allen et al., 2009). Whilst long-term
exposure to PM exposure has also been associated with stroke (Miller et al.,
2007), to date the epidemiological evidence supporting such an association
remains weak (Brook et al., 2010). Based on this body of evidence and con-
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straints in terms of required data, the cardiovascular impacts of air pollution
exposure were modelled using coronary heart disease (CHD) - ICD-10 I20-I25
- as health endpoint.
A number of studies have also shown positive associations between PM ex-
posure and respiratory symptoms (Schindler et al., 2009; Zemp et al., 1999),
including those of chronic bronchitis (Abbey et al., 1995) or lung function
decrements (Downs et al., 2007), all of which are associated with chronic ob-
structive pulmonary disease (COPD). Although the body of evidence linking
PM exposure and COPD development remains incomplete (Schikowski et al.,
2013), such association is likely as reduced pulmonary growth in childhood
and adolescence - for which the link with PM exposure is now established -
increases the incidence of COPD later in life (Eisner et al., 2010). The COPD
disease pathway (ICD-10 J40-J44) was therefore chosen to model the chronic
respiratory impacts of PM exposure.
Lung cancer (ICD-C33-34), which has repeatedly been found to be associ-
ated with chronic PM exposure (Hamra et al., 2014), was considered as a third
morbidity endpoint.
The life shortening impact of particulate air pollution exposure was mod-
elled using mortality risk estimates for all causes of death, as recommended
by WHO (2013) for health impact assessments (HIA) of air pollution control
interventions. However, unlike past HIAs and QALY analyses of air pollution
control, the mortality risk estimates used in the present analysis are stratified
by health status. Indeed, although epidemiological research on health-related
susceptibility to air pollution remains limited, it is generally recognised that
individuals who are already in a compromised health condition are expected to
suffer a disproportionate share of air pollution mortality burden than healthier
individuals (Peled, 2011; US EPA, 2009). More especially, a few studies found
that individuals with a chronic respiratory or cardiac condition are at a greater
risk of a pollution-related death (from all causes) than the general population
(Zanobetti & Schwartz, 2007; Zanobetti et al., 2008; Tonne & Wilkinson, 2013).
To conclude, the health impacts of a sustained decrement in exposure to
particulate air pollution were modelled by assessing the reduction in the risks
of developing COPD, CHD and lung cancer and in the risk of death from all
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causes, while allowing for greater susceptibility to premature death in individ-
uals suffering from COPD and CHD.
4.4 Model structure
4.4.1 Markov models: key features
Markov models were previously described in Chapter 3. They have two key
structural components: (i) mutually exclusive and exhaustive health states
and (ii) transition probabilities (TP) which, in discrete time approximation,
are expressed for a cycle. TP represent the probability of transiting to a
particular state of the model during a cycle, conditional on being in a given
health state at end of the previous cycle. They are typically stratified by age
and gender and expressed as a function of the number of cycles elapsed, to
reflect the time-dependency of health events.
Additionally, Markov models are based on the Markovian assumption that
knowledge of the past development of the Markov process is redundant for
predicting its future development as only the present matters (Kulkarni, 2011).
In other words, only the knowledge of the state in which the individual is at
the end of cycle “c-1” is necessary to predict his/her probability to transit to
other states during cycle “c”. When this assumption appears unrealistic, for
instance when survival is a function of the time spent with a condition, tunnel
states, which are health states in which individuals can only spend one cycle,
can be introduced into the model to allow TP to depend on previous health
history.
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4.4.2 Disease pathways
The model was built around three disease pathways - one for each chronic
morbid condition defined in section 4.3.5 - alongside the states “dead” and
“healthy”, where the latter represents a health state exempt of any of the
three conditions. As the analysis timeframe is the individual’s lifetime, the
cycle period was set to one year. Due to data gaps pertaining to co-morbidity
risks, the model assumed competitive risk between the three diseases pathways.
In other words, an individual cannot suffer from two conditions at the same
time. By ignoring co-morbidity effects, the estimates of health benefits from
air pollution reduction are therefore expected to be slightly conservative. This
will be further discussed in Chapter 8. In addition, each disease pathway was
underpinned by the following structural assumptions:
COPD
As health care cost, quality of life decrements and survival probabilities greatly
depend on the level of airflow obstruction, the COPD pathway was structured
around the four severity stages: GOLD 1 to GOLD 4, defined by the Global ini-
tiative for chronic Obstructive Lung Disease (GOLD, 2014). Although COPD
is treatable, it is not reversible and slowly worsens over time. Moreover, the
disease is often diagnosed in late stages (GOLD, 2014). To reflect these char-
acteristics, the COPD pathway was designed as unidirectional - i.e. without
allowed transitions back to “healthy” or to a less severe state - and upon entry
into the disease pathway, no jump of severity stage was allowed. By contrast,
to reflect the reality of late diagnosis, transitions from the state “healthy”
to the first three severity levels of the disease were allowed (see Figure 4.1).
Further justifications of the structure of the COPD pathway is provided in
Chapter 5.
Unlike the majority of existing population models of COPD (Najafzadeh
et al., 2012; Hoogendoorn et al., 2011, 2005) that are centred around smoking
as disease risk factor, the present model does not account for exacerbations of
the disease, i.e. a worsening of symptoms for a few days. The reason is that
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the impact of air pollution on COPD exacerbations is expected to be solely
related to acute exposure, whereas the present model focuses on the chronic
health effects associated with long-term exposure.
CHD
Although CHD also has different levels of severity that will influence quality
of life and life expectancy, in the absence of a widely accepted classification
by severity stages, the CHD disease pathway was composed of only one state.
The CHD pathway was also designed as unidirectional, since CHD is a chronic
condition that requires long-lasting disease management.
Lung cancer
Lung cancer is one of the deadliest cancers, from which most individuals die
in the first years of the disease (ONS, 2011). Whilst 5-year lung cancer sur-
vivors remain at risk of cancer recurrence, most recurrences (about 80%) occur
about two years after surgical resection (Maeda et al., 2010). Consequently,
it was assumed that after five years spent alive with the condition, individ-
uals would transit back to the state “healthy”, from where they would face
the same risks of adverse health events and enjoy the same quality of life as
individuals of the general population of same age and gender. To capture the
time dependence of survival probabilities in lung cancer patients, the disease
pathway was structured around five tunnel states. Each five state enables to
differentiate lung cancer patients whether they have been suffering from the
disease for respectively one, two, three, four and five years.
Figure 4.1 represents the Markov model structure, built around the three
disease pathways, as a state transition diagram. Ovals represent health states
and arrows represent the allowed transitions between them.
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Figure 4.1: Model’s structure around the three disease pathways.
Abbreviations: COPD = chronic obstructive pulmonary disease; CHD = coronary heart disease; lung
cancer = lung cancer. Ovals represent health states and arrows, allowed transition between them.
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4.4.3 Intervention arm and risk reduction estimates
Building from Chapter 3
As explained in Chapter 3, to evaluate an intervention such as air pollu-
tion reduction, the model requires: a “baseline” arm populated with baseline
TP to be compared against (ii) an “intervention” arm for which, similarly
to a health impact function, baseline TP are combined with risk reduction
estimates (RRE). The latter are epidemiological risk estimates scaled to the
intervention-related exposure decrement. Since TP are non-linear function of
time, the multiplication of TP with RRE is carried out on the transition rate
scale. Adjusted transition rates are then converted back to probabilities to
parameterise the intervention arm.
Chapter 3 presented two approaches to the application of Markov modelling
methodology to quantitative risk assessment, which differ in the scope of the
morbidity-mortality interactions encompassed and in the way life expectancy
impacts are modelled. Like the “full-modelling approach”, the present model
aims at encompassing thoroughly the chronic morbidity effects associated with
long-term PM exposure and their impacts on life-expectancy, including their
influence on individuals’ susceptibility to dying prematurely due to PM expo-
sure. However, since air pollution has been associated with a positive excess
risk of all-cause mortality, a lower risk of death under pollution decrement was
also applied to those “healthy” individuals who did not enter any disease path-
way. Importantly, as advocated in Chapter 3 when describing the “focused”
modelling approach, to avoid double-counting of life expectancy effects, the
change in mortality risk for those “healthy” individuals exclusively pertains to
all the other causes of death than the ones modelled (see parameter RREg in
Table 4.1).
Finally, as the present objective is to assess the total QALY and health care
resource impacts of reducing particulate air pollution, as opposed to disentan-
gling impacts by causal pathways and population subgroups as was done in
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Chapter 3, only one intervention arm fitted with all relevant and appropriately
scaled risk estimates was built.
Risk estimates: sources and application
Although the model is to be applied to evaluate an intervention of air pol-
lution control in the UK, risk estimates were taken from studies performed
in various developed countries, mainly in North America and Europe, with
only one risk estimate derived from a UK study (Tonne & Wilkinson, 2013).
However, this is unlikely to be a major limitation since developed countries
are characterised with a similar range of PM2.5 concentrations - ranging from
about 5 to 35 µg/m3 - across which linearity in health impacts and absence
of threshold to effects has repeatedly been found (Lepeule et al., 2012; Crouse
et al., 2012; Krewski et al., 2009). These characteristics of the dose-response
function have two implications. Within the above concentrations range: (i)
estimates of health effects for a different level of pollution reduction may be
obtained by simple proportional scaling of results obtained per one unit decre-
ment in ambient PM2.5 concentrations; (ii) RRE can be derived from risk
estimates, that are typically expressed for 4PM2.5 = +10µg/m3, using simple
logarithmic multiplicative scaling (see Appendix C of Chapter 3).
In an effort to encompass all existing relevant evidence and to decrease pa-
rameter uncertainty, risk estimates were preferably sourced from meta-analyses.
In light of the number of studies pertaining to all-cause mortality and lung
cancer development or mortality published in recent years, it was decided to
carry out a systematic review of such studies and two meta-analyses. This was
performed separately in Chapter 6.
To limit extrapolation of epidemiological findings, application of risk esti-
mates in the model sought, to the extent that it was feasible, to be in line with
study subjects’ main characteristics in terms of age and/or health condition.
For instance, the only available piece of evidence on the excess risk of death
associated with PM exposure in COPD patients is based on individuals aged
above 65 years old, identified using hospital discharge data (Zanobetti et al.,
100
2008). As the risk of hospital admission for COPD greatly increases with dis-
ease severity, the study’s risk estimate was applied only to those individuals
aged 65 and above if they were in GOLD 3 or 4 states. In other words, it
was conservatively assumed that individuals with COPD in stages 1 and 2 or
in stages 3 and 4 but aged below 65 faced the same PM-related excess risk
of mortality as the general population. Similarly, the PM-related excess risk
of mortality in individuals with CHD was informed by a study from Tonne &
Wilkinson (2013), based on patients above 25 years of age admitted to hospital
following acute coronary syndrome (ACS). ACS reflects a more severe health
condition than CHD as a whole. Since the risk of ACS linearly increases with
age (Simms et al., 2012), Tonne & Wilkinson (2013)’s risk estimate was only
applied to individuals suffering from CHD if they were aged 75 or above. In-
dividuals with CHD aged below 75 were therefore conservatively assumed to
face the same PM-related excess risk of mortality as the general population.
Table 4.1 links baseline transition probabilities with relevant risk reduction
estimates expressed for a 1 µg/m3 decrement in PM2.5 concentrations. As
lung cancer is very deadly, the impact of PM2.5 exposure on the lung cancer
pathway was restricted to disease development, i.e. no further PM-related
excess risk of death applied to individuals suffering from lung cancer.
Figure 4.2 represents the model’s intervention arm, with RRE associated
with various transition paths. Dotted arrows represent RRE-adjusted transi-
tions, i.e. transitions for which the underlying risk of event is reduced under
pollution reduction, whereas full arrows represent transitions for which the
underlying risk of event is assumed to be unchanged under the intervention.
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Parameter Transition Pop. Risk Reduction Estimates (RRE)
Name Probability age Risk Estimates Mean (95%CI)
PX,Y Definition Source 4PM2.5 = −1µg/m3
RREa PH,COPDi All ORDev.COPD(a) Schikowski et al. (2014) 0.988 (0.918-1.065)
i=GOLD1,..., 3
RREb PH,CHD All HRDev.CHD Cesaroni et al. (2014) 0.976 (0.949-1.004)
RREc PH,LC All HRDev.LC see Chapter 6(b) 0.985 (0.980-0.991)
RREd PCOPDi,D All HRDeathAC see Chapter 6 0.993 (0.991-0.995)
i=GOLD1,...,2
RREe PCOPDi,D < 65 HRDeathAC see Chapter 6 0.993 (0.991-0.995)
i=GOLD3,...,4 ≥ 65 HRDeathAC|COPD Zanobetti et al. (2008)(c) 0.980 (0.976-0.984)
RREf PCHD,D < 75 HRDeathAC see Chapter 6 0.993 (0.991-0.995)
≥ 75 HRDeathAC|CHD Tonne & Wilkinson (2013) 0.982 (0.968-0.996)
RREg PH,D All HRDeathAOC|H Pope III et al. (2002) 0.999 (0.994-1.005)
Table 4.1: Risk reduction estimates for intervention arm.
Abbreviations: PX,Y : age and gender-specific annual probability of developing disease/ experiencing event
“Y”, conditional on being in health state “X”; Dev. = developing; COPD = chronic obstructive
pulmonary disease; CHD = coronary heart disease; LC = lung cancer; H=healthy; D= dead; HR=hazard
ratio; HRY |X : hazard ratio of event “Y” in population with health condition “X”; OR= odd ratio; AC=
all causes; AOC = all other causes.
(a) When events are rare, i.e. with a probability of event occurrence in the unexposed group less than 10%,
which is the case of COPD, OR can be considered equivalent to RR (Sistrom & Garvan, 2004).
(b) In order to be in line with the most recent published work of Hamra et al. (2014), the pooled estimate
of the excess risk of lung cancer associated with PM2.5 exposure used to parameterise the present model
was taken from sensitivity analysis run 3 in Chapter 6, as presented in Figure 6.7.
(c) Results based on PM10 data.
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Figure 4.2: Diagram of the model’s intervention arm.
Abbreviations: COPD = chronic obstructive pulmonary disease; CHD = coronary heart disease; LC =
lung cancer: Yr = year. Risk reduction estimates RREa, ...g are defined in Table 1 and apply to
transitions represented by dotted arrows. Full arrows represent transitions unchanged by the intervention.
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4.5 Parameterising the model for UK case study
4.5.1 Case study definition
The model was developed in order to evaluate an intervention that would
lead to a sustained 1µg/m3 reduction in mean annual population-weighted
concentrations of PM2.5 in England and Wales and in London. This would
represent a 9% and 7% reduction in the annual average concentrations in
respectively England and Wales (11 µg/m3 as at 2008, COMEAP 2010) and
London (14.3 µg/m3 as at 2008, COMEAP 2010).
This amount of pollution reduction was chosen for two reasons. First, it is in
line with the UK Air Quality Strategy’s target to reduce PM2.5 concentrations
at all locations and more especially, to achieve a 15% reduction in PM2.5 levels
at all urban locations by 2020 (DEFRA, 2012). Second, as mentioned in section
4.4.3, estimates of health effects for other reduction levels may be obtained to
a very good approximation by proportional scaling of the estimates obtained
for a 1 µg/m3 reduction.
The lag between exposure decrement and health risk reduction, known as
cessation lag, was assumed to follow the 20-year distributed lag developed
and currently used by the US EPA for its assessment of air pollution control
strategies. The latter assumes that 30% of the risk reduction takes place in
year 1, an additional 12.5% every year between year 2 to year 5 and the final
20% reduction is phased in gradually over year 6 to year 20 (US EPA, 2010).
This assumption was followed in past HIAs of air pollution reduction in the
UK (Miller, 2010; COMEAP, 2010). Whilst the US EPA’s distributed lag was
carefully reviewed by the agency’s science advisory board, it remains never-
theless highly hypothetical due to the large uncertainty surrounding dynamics
in risk reduction following exposure change (Walton, 2010). The sensitivity
of results to the structure of the cessation lag will be assessed in sensitivity
analyses.
Pollution decrement under the intervention was assumed to be immediate.
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While this is unlikely to be realistic, this choice was underpinned by the fact
that the structure of the cessation lag is already largely uncertain.
The target populations of England and Wales and London were defined
as the current adult population aged 40 to 90. Whilst WHO (2013) recently
recommended to apply mortality risk estimates to adults aged 30 and over, the
restriction to individuals aged 40 and above was driven by the availability of
routine disease incidence and prevalence statistics (COPD in particular). Since
the risk of mortality below 40 remains low, this restriction is not expected to
led to a substantial underestimation of the health benefits of air pollution
control.
Individuals were followed until death with a cut-off at 100 years old, as
disease and mortality statistics are typically no longer available beyond this
age. This implies that subjects entering the model at age 40 were followed for
a maximum of 60 years, whereas subjects entering the model at age 90 were
followed for a maximum of 10 years. The two target populations were not
augmented by future generations as doing so would have required additional
assumptions pertaining to future births and would not provide an obvious cut-
off point for ending the follow-up. Instead, results can be scaled, if necessary,
to different population numbers. The analysis time horizon is therefore of 60
years.
For comparability with health care interventions, a discount rate of 3.5%
was applied to health care costs and QALY gains, in line with guidelines for
England and Wales expressed by the National Institute for health and Care
Excellence (NICE, 2013). The sensitivity of results to alternative discounting
structures will however, be assessed.
The model was structured around a yearly cycle length (see section 4.4.2)
and individuals were assumed to move between health states at mid-cycle.
It should nevertheless be underlined that for incremental analyses, as is the
present case, the use of half cycle corrections should have only a small effect
on results (Briggs & Sculpher, 1998).
All the assumptions defining the case study are summarised in Table 4.2.
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Intervention
PM2.5 reduction −1µg/m3 of mean ambient concentrations
Location (i) England and Wales (ii) London only
Timing Immediate and sustained reduction
Lag to health effect US EPA’s 20-year distributed lag
Population
Scope All currently alive adults aged 40 to 90
Follow-up Until death or 100 years old
Analysis
Time horizon 60 years
Discount rate 3.5%
Cycle length One-year with half-cycle correction
Table 4.2: Assumptions underpinning the case study.
4.5.2 Population modelling
Modelling of currently alive adults aged 40 to 90 years old, was based on
a total of 102 age and gender-specific cohorts of 1,000 individuals each (51
one-year age groups for each gender). Results for each age and gender-specific
cohort were then scaled to the numbers of individuals of same age and gender
living in respectively England and Wales and London, as informed by the 2011
census. The model was built and evaluated using the software MATLAB.
4.5.3 Transition Probabilities (TP)
Data were sourced for England and Wales or alternatively the UK (i.e. no
London-specific data were used). Disease prevalence statistics, which represent
the proportion of the population with a disease at a given point in time, were
used to distribute each of the 102 cohorts into the model’s health states at cycle
0, in order to reflect the target populations’ level of health. Annual disease
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incidence statistics, which represent the 1-year probability of developing a
disease, informed cohorts’ transitions from the state “healthy” to each disease
state during each yearly cycle.
For CHD and lung cancer, incidence and prevalence data provided by the
UK Clinical Practice Research Datalink were obtained from the open-access
model DYNAMO-HIA. 1 Disease progression parameters for the COPD path-
way were obtained by combining annual progression probabilities stratified by
smoking status provided by Atsou et al. (2011) with data on the distribution
of COPD patients in England by smoking status from Shahab et al. (2006).
This approach was justified by the lack of strong evidence to date suggesting
that smoking may impact upon individuals’ biological response to air pollu-
tion exposure (Laurent et al., 2007). COPD prevalence statistics by GOLD
stages and 10 year age-group were provided by the UK Department of Health
(2010). However, due to data gaps, the incidence of COPD, or more precisely
the probability of being diagnosed at the different stages of the disease, had to
be estimated. Estimation of diagnosis probabilities was performed separately
in Chapter 5.
Mortality TP were computed using mortality rate data from the UK Office
for National Statistics (ONS, 2011) and reflect the assumption of competitive
risk. The probability of death associated with the CHD pathway - i.e. the
probability of dying from all other causes than COPD or lung cancer condi-
tional on having CHD - was computed by applying hazard ratios of excess
death associated with CHD provided by Whiteley et al. (2005) to the base-
line mortality rates of individuals of the general population who do not suffer
from CHD nor COPD nor lung cancer. The latter were obtained from life-
table computation using ONS data on mortality rates and causes of death.
Similarly, the probabilities of death associated with the COPD pathway were
computed using GOLD-stratified hazard ratios of excess mortality in COPD
patients estimated by Mannino et al. (2006) .
The probabilities of death in lung cancer patients were derived based on age
and gender-specific ratios of relative survival at 1 and 5 years since diagnosis
1DYNAMO-HIA is a European Union-funded generic open-access interface, developed to facilitate health
impact assessments in Europe (Lhachimi et al., 2012). It contains country-level incidence and prevalence
data for a number of common diseases such as CHD and lung cancer.
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(ONS, 2011). The latter are ratios of: (i) the observed survival from all causes
of death among subjects with lung cancer and (ii) the expected survival in
a comparator group of subjects without lung cancer, matched on relevant
covariates (Nelson et al., 2008). Estimation of relative survival ratios at the
other time points (i.e. at 2, 3 and 4 years) was carried out by fitting a Weibull
function to the survival data. Mean results are presented for each gender in
Figure 4.3. Annual probabilities of survival in lung cancer patients after one to
five years since diagnosis were then obtained by multiplying relative survival
ratios by the expected probability of survival in subjects without lung cancer
(nor COPD or CHD due to the competitive risk assumption).
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(a) Females.
(b) Males.
Figure 4.3: Estimated relative survival ratios from lung cancer at 2, 3 and 4 years, by gender
and age-group, using survival data at 1 and 5 years from ONS and LSTM.
4.5.4 HRQoL weights
The EuroQol five dimensional instrument (EQ-5D), which is the most com-
monly used HRQoL metric for cost-effectiveness analysis (De Smedt et al.,
2014) and the preferred measure of the National Institute for health and Care
Excellence (NICE, 2013), was chosen to express the quality of life associated
to each health state.
Age and gender-specific HRQoL scores experienced by “healthy” individu-
als, i.e. individuals without COPD, CHD or lung cancer, were obtained from
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Kind et al. (1999). These values were elicited from a representative sample of
the English population who considered themselves to be generally healthy.
HRQoL scores associated with each condition are presented in Table 4.3
(left-hand side). To reduce parameter uncertainty, scores for COPD and lung
cancer were sourced from meta-analyses (Pickard et al., 2008; Sturza, 2010)
while CHD scores were based on a large patient population (n=7,242) as part
of the EUROASPIRE III study (De Smedt et al., 2014). For lung cancer, the
HRQoL score was based on results for non-small cell cancer, which accounts
for about 90% of all cases of cancer in England (Riaz et al., 2012). The final
HRQoL score for lung cancer was obtained by weighting HRQoL results for
metastatic and non-metastatic non-small cell cancer by respectively 75% and
25%, based on the fact that in England, 75% of non-small cell cancers are
detected at an advanced stage (NHSC, 2010).
Incorporation of HRQoL weights into the model combined two approaches.
As HRQoL values associated with the CHD condition provided by De Smedt
et al. (2014) were stratified by age-groups, a HRQoL decrement was applied
to individuals in the CHD pathway, as a proportion of the HRQoL experi-
enced by the general population, for a given age range and gender. This
approach however, was not deemed suitable for the lung cancer and COPD
pathways due to absence of information on the average age of patients from
which HRQoL scores were obtained for these two conditions. Instead, HRQoL
scores reported for patient populations were directly applied to subjects in the
COPD and lung cancer pathways, while ensuring they were upper-bounded
by the HRQoL scores of the general population for the same age and gender.
The impact of age on HRQoL associated with COPD was however, indirectly
encompassed via the use of HRQoL scores stratified by disease severity (4
GOLD stages), since the distribution of disease prevalence by severity stages
is strongly determined by age (UK Department of Health, 2010). It is worth
reminding that, given the model structure, after a period of five years, HRQoL
scores of lung cancer survivors returned to the age and gender-matched scores
of the general population.
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4.5.5 Health care costs
“Healthy” individuals were assumed not to generate any health care cost,
the implications of which will be discussed in Chapter 8. The average annual
health care cost per patient in each condition is provided in Table 4.3 (right-
hand side). Costs were inflated to 2013 prices, based on the hospital and
community services’ inflation index for the UK NHS (PSSRU, 2013). In the
absence of UK specific data, COPD costs stratified by GOLD stage were based
on a Swedish study (Jansson et al., 2013).
Like for COPD, the costs of CHD also depend on disease severity as the
latter drives the choice of appropriate medical treatment and treatment du-
ration. However, for the reasons exposed in section 4.4.2, the condition was
not modelled by severity levels. Consequently, the average annual cost of a
CHD patient was obtained by scaling the total annual cost of CHD in the UK
(£1.8 billion as of 2009, Nichols et al., 2012), to the number of CHD patients
registered in the UK the same year (n= 2,330,277, British Heart Foundation,
2010). Whilst the obtained annual cost per patient is low (£836), it was
applied from condition onset until death. The annual cost of a lung cancer
patient was provided by the National Cancer Research Institute (NCRI, 2012),
based on patients who have been diagnosed with cancer and are still alive (this
includes newly diagnosed individuals and individuals with stable disease being
followed-up).
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HRQoL scores (EQ-5D) Mean annual cost
Age Severity Value (SE) / patient (2013 prices)
COPD All GOLD 1 0.74 (0.064) £249
GOLD 2 0.74 (0.043) £951
GOLD 3 0.69 (0.046) £2,033
GOLD 4 0.61 (0.084) £4,943
source: Pickard et al. (2008) source: Jansson et al. (2013)(a)
CHD ≤ 40
All
0.85 (0.069)
£83650-69 0.80 (0.079)
≥ 70 0.73 (0.059)
source: De Smedt et al. (2014) source: Nichols et al. (2012) and
British Heart Foundation (2010)
Lung All Non-metastatic 0.85 (0.074)
£9,283
cancer Metastatic 0.57 (0.067)
source: Sturza (2010) source: NCRI (2012)
Table 4.3: Condition-specific HRQOL and health care costs.
(a) Converted in GBP using the average EUR/ GBP exchange rate for 2013.
4.6 Sensitivity analyses
4.6.1 Propagating parameter uncertainty
Joint-uncertainty in parameters can be handled probabilistically by assign-
ing distributions to all parameters, based on their characteristics (Briggs et al.,
2006) and performing Monte Carlo simulations (10,000 draws).
A log-normal distribution was fitted to each of the epidemiological risk
estimate constituting the intervention-effect (see Figure 4.2) as well as to the
excess risk of death associated with each condition.
As no information was available on the variance around disease incidence,
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an interval of +/-25% around mean estimates was used as an estimate of
variation around the incidence of COPD (for each severity stage) and CHD.
Such an approach is in line with current recommendations for uncertainty
analysis in health impact assessment and cost benefit analysis of air pollution
control interventions in Europe (Holland, 2014). For lung cancer, however,
as under-diagnosis or mis-diagnosis of the disease is much more unlikely than
for COPD or CHD, a estimated variation of +/-5% around the mean was
used. Instead of fitting a triangular distribution to incidence data (which
inform the transitions from the state “Healthy to each disease state), the Pert
distribution, which is a special case of the beta distribution, was used. Like the
triangular distribution, the Pert distribution is parameterised with a mode and
a minimum and maximum value but it produces a smooth distribution that
progressively puts greater weight on the most likely value and can provide a
close fit to the normal distribution.
Beta and gamma distributions were fitted to respectively HRQoL weights
and HRQoL decrements and a gamma distribution was fitted to health care
costs. In the absence of information on the variance around health care costs
associated with CHD and lung cancer, it was assumed that the standard error
equaled to half of the mean, as has been done in past economic evaluations
(Briggs et al., 2002).
4.6.2 Sensitivity scenarios
Sensitivity of results pertaining to: (i) dynamics in health risk reduction
following pollution reduction and (ii) the discount rate will be analysed.
Walton (2010)’s thorough review of empirical evidence from cohort, inter-
vention and smoking cessation studies stressed on the level of uncertainty about
patterns of health risk reduction following exposure decrement. The US EPA
considered Ro¨o¨sli et al. (2005)’s exponential decay model as an alternative to
the 20-year distributed lag described in section 4.5.1. However, results were
found to be very sensitive to the choice of time constant for the model and it
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is not clear which source of evidence should inform this parameter (U.S. EPA
- Science Advisory Board and Health Effects Subcommittee, 2009). Exponen-
tial decay will therefore not be considered in the present sensitivity analysis of
time lag. Instead, the two following scenarios, summarised in Table 4.4, will be
evaluated. Scenario “No CL” assumes the absence of a cessation lag, and thus
represents an upper bound to the possible health benefits associated with the
intervention. (ii) As the smoking cessation literature suggests that lung cancer
risk may decrease more slowly than cardiovascular death risk (Walton, 2010;
Rabl, 2003), scenario “Mixed CL” assumes that the decrease in lung cancer
risk is progressive over 40 years, while the change in risks of other health effects
is assumed to follow the US EPA’s 20 year distributed time lag.
For analysis of investments with pay-offs accruing over time-horizons above
50 years, the UK treasury suggests to used staged discount rates (Lowe, 2008).
The two staged discounting structures proposed by the UK treasury, which are
described in Table 4.4, will be used in sensitivity analysis.
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Scenario Cessation lag (CL) Discounting
Base case 20-year distributed lag (a) 3.5% p.a.
Mixed CL
Lung cancer: progressive reduc-
tion over 40 years (b) 3.5% p.a.
Other health impacts: 20-year
distributed lag (a)
No CL Immediate effect 3.5% p.a.
Staged discounting 1 20-year distributed lag (a) Year 1 to 30: 3.5% p.a.
Year 31 to 60: 3% p.a.
Staged discounting 2 (c) 20-year distributed lag (a) Year 1 to 30: 3% p.a.
Year 31 to 60: 2.57% p.a.
Table 4.4: Scenarios of sensitivity analysis against base case.
(a) 30% of risk reduction in year 1, an additional 12.5% every year between year 2 to year 5 and the final
20% being phased in gradually over year 6 to year 20.
(b) i.e. a cumulative decrease in risk at a rate of 2.5% every year.
(c) Excludes the element of pure social time preference.
4.7 Conclusion
Whilst the understanding of air pollution impacts on length and quality of
life is expected to be of particular interest to policy-makers, so far all past
attempts at measuring the QALY gain from air pollution reduction have been
simplistic and inaccurate. In this chapter, it was argued that the Markov-
based simultaneous approach presented in Chapter 3 would enable, for the first
time, to fully capture air pollution’s joint impact on quality and length of life
by encompassing air pollution’s influence on population individuals’ baseline
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quality of life, life expectancy and level of susceptibility to adverse effects. A
Markov model structured around three disease pathways, for which there is
robust epidemiological evidence of association with long-term exposure to fine
particulate pollution, namely chronic obstructive pulmonary disease, coronary
heart disease and lung cancer, was therefore developed.
This chapter focused on the core steps to model construction and param-
eterisation and underlined two distinct data gaps for parameterisation, which
will be addressed in the following two chapters. Chapter 5 develops a frame-
work to estimate the annual probability of being diagnosed at a given stage
of COPD and applies it to the general population of England. Chapter 6 per-
forms a systematic review and two meta-analyses of the association between
long-term exposure to particulate air pollution and respectively all-cause mor-
tality and lung cancer. Modelling results will be presented in Chapter 7. The
limitations of the presently developed model will be discussed in Chapter 8.
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Chapter 5
Estimation of COPD incidence
in England by severity stages
5.1 Introduction
In order to estimate the QALY gain and health care resource impact of air
pollution control in the UK, Chapter 4 developed a Markov model structured
around three disease pathways: CHD, lung cancer and COPD. The latter is a
slowly progressive disease of airflow obstruction.
The transition probabilities that parameterise the model are informed by
mortality and disease incidence (i.e. diagnostic) statistics for England and
Wales. In the case of COPD however, available incidence data suffers from
bias as the disease is largely underdiagnosed, especially in its milder stages. In
England, up to 80% of adults above 30 affected by spirometry-defined COPD
were found to report no respiratory diagnosis (Shahab et al., 2006). Con-
sequently, using primary care data on COPD incidence to parameterise the
model developed in Chapter 4, would seriously underestimate the total pool
of individuals who would benefit from a reduction in the risk of developing
COPD following air quality improvement.
An estimation of the underlying, i.e. “true”, prevalence of COPD by sever-
ity stage in England was, however, carried out by the UK Department of Health
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(2010). The present objective is therefore to develop a coherent probabilistic
framework to estimate the probability of COPD diagnosis in the English popu-
lation at different severity stages of the disease, by exploiting existing estimates
of underlying prevalence and linkages between disease prevalence, incidence,
survival and progression.
The chapter is structured alongside the following sections. In section 2, I
expand upon the key characteristics of COPD and its implications for cost-
effectiveness analysis of preventive interventions such as air pollution control.
In section 3, I outline the linkages between prevalence and incidence, I describe
the approach used by the UK Department of Health to estimate the underlying
prevalence of COPD in England and I further justify the structure of the COPD
disease pathway of the model built in Chapter 4. In section 4, I first describe
an incidence estimation model proposed by Podgor & Leske (1986) for a single-
stage chronic disease and, in a second step, I extend this model to a multi-stage
setting by allowing for disease severity progression and survival stratified by
severity level. In section 6, I apply the developed framework to estimate the
probabilities of COPD diagnosis in England by severity stage. In sections 6
and 7, I present and discuss the results.
5.2 COPD: Key characteristics and implications for cost-
effectiveness analysis of preventive interventions
5.2.1 Key characteristics
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Disease description and classification
COPD is a lung disease of progressive airflow obstruction or limitation,
which is not fully reversible and typically worsen slowly over time (GOLD,
2014). There is clear evidence that health care cost (Jansson et al., 2013),
quality of life decrements (Pickard et al., 2008) and mortality risk (Mannino
et al., 2006) in COPD patients greatly depend on their levels of airflow ob-
struction.
Since anatomical and clinical symptoms may vary between patients, diag-
nosis of COPD is internationally defined by airflow obstruction. The latter is
measured by a set of spirometric criteria, namely forced expiratory flow in 1
second (FEV1) and forced vital capacity (FV C), i.e forced emptying capac-
ity of the lungs. The American Thoracic Society, the European Respiratory
Society, the National Institute for health and Care Excellence in England and
the Global Initiative for Obstructive Lung Disease (GOLD) define COPD as
a reduced FEV1/FV C ratio strictly lower than 70% (Celli et al., 2004; NICE,
2010; GOLD, 2014).
Sub-classification of the disease is based on a third measure known as
FEV1%, which is the ratio of measured FEV1 against predicted FEV1, based
on age, height and gender. In conjunction to a FEV1/FV C ratio lower than
70%, a FEV1% greater than 80% defines “mild” COPD
1, a FEV1% between
50% and 79% defines “moderate” COPD, a FEV1% between 30% and 49%
defines “severe” COPD and a FEV1% lower than 30% defines “very severe”
COPD. “Mild”, “moderate”, “severe” and “very severe” stages are also re-
ferred to as GOLD1, GOLD2, GOLD3 and GOLD4.
Finally, in order to solely account for persistent airflow limitation, there is
global agreement that all spirometric measures should always be taken post
administration of a bronchodilator, i.e. a drug that help alleviate symptoms
of airflow limitation (Celli et al., 2004; NICE, 2010; GOLD, 2014).
1In contrast to the American Thoracic Society, the European Respiratory Society and GOLD, NICE
recommends that symptoms should also be present to confirm diagnosis of the mild stage of the disease
(NICE, 2010).
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Substantial underdiagnosis
In England, based on cross-sectional data on population respiratory health
obtained from the Health Survey for England (HSE) in 2001, Shahab et al.
(2006) found that 80% of individuals aged 30 and over affected by spirometry-
defined COPD reported no respiratory diagnosis.
As the analysis of HSE respiratory data collected in 2010 used a differ-
ent methodology to compute COPD prevalence statistics than in 2001, it is
not possible to evaluate with precision whether COPD underdiagnosis has
decreased over time in England. Indeed, instead of using the fixed ratio of
FEV1/FV C < 70%, in HSE 2010, COPD was defined based on the lower
limit of normal (LLN) values of the FEV1/FV C ratio, with the bottom 5%
classified as abnormal. Whilst each criteria has its pro and cons, LLN values
are highly dependant on reference equations to compare the distribution of
FEV1/FV C values and no scientific evidence to date supports LLN over the
fixed ratio of FEV1/FV C < 70% as best criteria to define COPD (GOLD,
2014).
Nevertheless, analysis of HSE results for the year 2010 greatly confirmed the
magnitude of disease underdiagnosis, whereby less than a third (28% of males
and 27% of females) of individuals with probable airflow limitation reported a
doctor-diagnosis of COPD (Aresu et al., 2011).
Late diagnosis
While COPD is underdiagnosed as a whole, underdiagnosis is less pro-
nounced for individuals in the severe and very severe stages of the disease
(GOLD, 2014). In England, Shahab et al. (2006) reported that 50% of indi-
viduals found to be in the severe and very severe stages of the disease2 were
not diagnosed, whereas across all severity stages underdiagnosis reached 80%.
Indeed, as symptoms worsen alongside disease progression, the disease is more
2as indicated by their spirometric results collected as part of HSE 2001.
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likely to be detected at an advanced stage. Based on HSE (2001) data, the
UK Department of Health (2010) estimated that in England, 95% of the to-
tal underlying (i.e. “true”) cases of GOLD stage 1 were underdiagnosed, as
opposed to 79% for stage 2, 60% for stage 3 and only 7% for stage 4.
5.2.2 Implications for cost-effectiveness analysis
The key characteristics of the COPD disease have three major implications
for the cost-effectiveness analysis of preventive interventions such as air pollu-
tion control.
First, as health care cost, quality of life decrements and mortality risk
greatly depend on the level of airflow obstruction, in order to evaluate most
accurately the impact of an intervention that contribute to alleviate the health
burden of COPD, one should account for the various levels of disease severity
and the speed of disease progression.
Second, since the probabilities to transition between health states are typi-
cally informed by diagnostic statistics (also referred to as incidence) underdiag-
nosis will threaten the accuracy of modelling results. More precisely, disease
underdiagnosis will underestimate the population’s baseline risk of developing
COPD, and thus the total population health gain associated with an interven-
tion that reduces the risk of developing COPD or mitigates its consequences.
Total population health gain is typically irrelevant when assessing whether a
health care technology is cost-effective or not, since the focus of interest is on
the ratio of the incremental cost and health benefit per patient. By contrast,
it is of particular importance when evaluating the cost-effectiveness of an in-
tervention characterised by a large fixed investment cost, as is typically the
case of interventions of air pollution reduction. For these interventions, disease
underdiagnosis will underestimate total population health gain and thus, the
probability of the intervention to be cost-effective.
Third, if the underlying risk of developing the first stage of COPD is un-
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known, despite COPD being a progressive disease, one should account for late
diagnosis in order to avoid underestimating the total population of subjects
with COPD. Late diagnosis is accounted for by allowing for transitions from
the “healthy” state to any stages of the disease. Such an approach was fol-
lowed by Hoogendoorn et al. (2005, 2011) when constructing a Markov model
of COPD applied to the Dutch population, although the rationale for doing so
was not stated.
5.3 Addressing challenges associated with the modelling
of COPD
5.3.1 Linking incidence with prevalence
Relationship between incidence, prevalence and survival
Disease prevalence represents the proportion of the population with a dis-
ease at a given point in time, whereas incidence represents the risk of develop-
ing the disease during a given time period. In a group of individuals in steady
state, prevalence and incidence are linked insofar as prevalence is the product
of incidence and disease duration (Gordis, 2004).
In the case where a disease is treatable but not fully curable, as is the case of
COPD, the only parameter that influences disease duration is disease survival,
i.e. the probability of death conditional on having the disease. It follows that,
under appropriate assumptions, prevalence statistics can be used in combina-
tion with survival data to estimate disease incidence, i.e. the probability of
being diagnosed with the disease.
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Estimates of underlying COPD prevalence in England
The UK Department of Health (2010) computed estimates of the underlying
(i.e. true) numbers of COPD cases in the population, by GOLD severity stage
and 10-year age-groups, for the year 2009 using population projections for year
2009. Estimates were based on lung function measurements gathered from HSE
(2001), which at the time3, provided the most up-to date spirometry results
on the respiratory health of the English population.
HSE (2001) methodology was described in Prior et al. (2003). Briefly, in
2001, 74% (n = 9,373) of households identified via multi-stage probability
sampling agreed to take part to the health survey. From these cooperating
households, 15,647 adults (89% of total adults) were interviewed and 12,404
adults (71% of total adults) saw a nurse who took lung function measures from
11,611 participants, where the most technically satisfactory blow out of five
attempts was selected
As spirometry measurements from HSE (2001) were performed before bron-
chodilator use, in line with current guidelines for COPD diagnosis (see section
5.2.1) the UK Department of Health (2010) adjusted the data so that only the
prevalence of persistent airflow limitation would be captured. This adjustment
for bronchodilator use, known as “post-bronchodilator adjustment”, was per-
formed using data provided by Perez-Padilla et al. (2007). Based on a cluster
sampling of adults representative of five Latin American cities, the authors re-
ported that using spirometric measurements after bronchodilator use, reduced
the overall prevalence of airflow obstruction by 35%. Post-bronchodilator ad-
justment of raw prevalence estimates for England was based on the assumption
that the bronchodilator effect was independent of age and impacted only the
raw prevalence of mild and moderate stages of the disease.
3Whilst HSE cross-sectional studies are carried out on annual basis, survey focus on specific health issues
such as lack of physical activity, cardiovascular disease or respiratory conditions varies from year to year.
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5.3.2 Encompassing COPD characteristics into a Markov model
structure
COPD characteristics were captured in the structure of the COPD disease
pathway of the model developed in Chapter 4 in the following fashion:
(1) COPD was modelled via the GOLD states - numbered 1 to 4 - of disease
severity, which are equivalently referred to as mild, moderate, severe and very
severe states.
(2) Individuals were allowed to enter the COPD disease pathway at several
stages of disease severity in order to allow for “late diagnosis”, as recommended
in sections 5.2.2 and 5.3.1.
(3) Since COPD is a chronic and irreversible disease, the probability to fully
recover from it, or to move to a less severe state, was considered to be null.
Additionally since COPD is a slowly progressing disease it was assumed that,
once individuals entered the COPD disease pathway, they could not jump a
severity stage of the disease, e.g. move directly from stage 1 to stage 3. These
two assumptions are in line with existing Markov models of natural history of
COPD (Hoogendoorn et al., 2005, 2011; Menn et al., 2012; Najafzadeh et al.,
2012).
The resulting structure of the COPD disease pathway of the model devel-
oped in Chapter 4 is represented in Figure 5.1. Its parameterisation requires
three sets of probabilities, pertaining to respectively:
(1) Mortality conditional on health status, i.e. transitions from each four
GOLD states to the “dead” state noted P1,D, P2,D, P3,D, P4,D and from the“healthy”
state to the “dead” state noted PH,D;
(2) Disease progression, i.e. transitions between severity states noted P1,2, P2,3, P3,4;
(3) Disease diagnosis/incidence, i.e. transition from the “healthy” state to each
GOLD state of severity noted PH,1, PH,2, PH,3, PH,4.
The probabilities of disease diagnosis: PH,i, i = 1, ...4 are the focus of the
present study and are underlined in light grey in Figure 5.1.
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Figure 5.1: Markov model structure of COPD pathway and required parameters.
5.4 Incidence estimation in multi-stage chronic diseases
5.4.1 Podgor and Leske (1986)’s framework for a single-stage chronic
disease
As mentioned in section 5.3.1, in a population in steady state, there is an in-
tuitive relationship between incidence and prevalence. Additionally, assuming
the disease is stable over time, one can treat the age-dimension of prevalence
as a time dimension, whereby static age-specific prevalence represents the in-
dividual’s probability of having the disease once reaching a certain age.
Relying on the two assumptions of: (1) stable population, i.e. popula-
tion with stable age composition and (2) stable epidemic, Podgor & Leske
(1986) outlined the relationship between incidence, prevalence and mortal-
ity for an irreversible one-stage chronic disease characterised by differential
mortality. This relationship was modelled via a 3-state closed unidirectional
system, whereby individuals of a population of size N were either healthy (H),
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infected by the irreversible disease (I) or dead (D).
The authors defined the number of “infected” people of age a + t in the
population as the sum of: (i) the number of individuals who were healthy at
age a times the joint-probability PHI that they became infected during the t-
year period and survived and (ii) the number of individuals who were already
infected at age a times the probability PII that they survived during the t-
year period, given that they were infected. Similarly, the number of “healthy”
people of age a + t in the population was defined as the number of people
who were healthy at age a times the joint probability PHH that they did not
become infected nor died during the t-year period. These two relationships are
expressed by equations 5.1 and 5.2:
Na+tΠa+t = Na(1− Πa)PHI +NaΠaPII (5.1)
Na+t(1− Πa+t) = Na(1− Πa)PHH (5.2)
Where Na+t and Na represent the total number of alive individuals of age
a+ t and a at any point in time in the system and Πa+t and Πa represent the
static prevalence of the disease among population individuals of age a+t and a.
Combining equations 5.1 and 5.2 eliminates the population parameters and
provides a single equation with one unknown PHI (5.3).
(1− Πa)Πa+t PHH
(1− Πa+t) = ΠaPII + (1− Πa)PHI (5.3)
PHI represents the joint probability of developing the disease and surviving
during the t-year period given that one is infected, whereas the parameter
of interest is the probability of becoming infected among the total at-risk
population. To derive this parameter, Podgor & Leske (1986) expressed the
joint-probabilities PHH , PHI and the conditional probability PII as a function
of the rates of mortality among respectively those infected and those healthy
and of the rate of disease incidence, assuming that rates followed indepen-
dent exponential distributions. Solving for the rate of disease incidence how-
ever, required a rather sophisticated and computationally-intensive method
(Newton-Raphson method).
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5.4.2 Extension of Podgor and Leske (1986)’s framework to a k-
stage chronic disease
For COPD, the modelling of the relationship between prevalence, incidence
and mortality also need to account for disease progression and the impact of
disease severity on survival. Podgor & Leske (1986)’s model was therefore
extended to a k-stage chronic disease.
To reduce the computational burden associated with probabilities estima-
tion, the extension of Podgor & Leske (1986)’s model was carried out in a
discrete time setting. Importantly the extension of the model is also under-
pinned by the two assumptions of stable population and stable epidemic.
The modelling of the relationship between incidence, prevalence, survival
and disease progression was based on the structural assumptions described in
section 5.3.2. In particular, whilst individuals were allowed to enter the disease
pathway in any state to reflect late diagnosis, once diagnosed with the disease
it was assumed that, during each t-year period they could either: (i) stay in
the disease state they were in or (ii) progress to the next severe state or (iii)
die. The t-year probabilities to transit between severity states i are therefore
of the form Pi,i+1.
To extend the model in a discrete-time setting, PHI , PHH and PII were
expressed in terms of t-year transition probabilities, where PX,Y denotes the
probability of transiting to state Y during a t-year period conditional on being
in state X at age a. It follows that for i = 1, ..., k representing disease stages:
PHH = (1− PH,i)(1− PH,D)
PHI = PH,i(1− Pi,D)
PII = (1− Pi,D)
In a stable population with stable disease, the total number of people aged
a + t who are in stage i of the disease at any point in time is the sum of: (i)
individuals who were healthy at age a and got diagnosed with COPD in stage
i during the t-year period and survived, (ii) individuals who were in stage i
at age a and did not move to the next severe stage nor died during the t-year
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period and (iii) individuals who were in stage i − 1 at age a and moved to
stage i and survived during the t-year period. This relationship is expressed
in equation 5.4, using notations for population size and disease prevalence
introduced in section 5.4.1.
Na+tΠi,a+t = Na(1−
k∑
i=1
Πi,a)PH,i(1− Pi,D)
+NaΠi,a(1− Pi,i+1)(1− Pi,D)
+NaΠi−1,aPi−1,i(1− Pi,D)
(5.4)
For i=1, equation 5.4 simplifies to:
Na+tΠi,a+t = Na(1−
k∑
i=1
Πi,a)PH,i(1− Pi,D) +NaΠi,a(1− Pi,i+1)(1− Pi,D)
For i=k, equation 5.4 equals to:
Na+tΠi,a+t = Na(1−
k∑
i=1
Πi,a)PH,i(1−Pi,D)+NaΠi,a(1−Pi,D)+NaΠi−1,aPi−1,i(1−Pi,D)
Similarly, the number of people aged a + t who are healthy at any point in
time is simply the sum of individuals who were healthy at age a and did not
develop the disease nor died during the t-year period.
Na+t(1− Πi,a+t) = Na(1−
k∑
i=1
Πi,a)(1−
k∑
i=1
PH,i)(1− PH,D) (5.5)
Combining equations 5.4 and 5.5 to eliminate the population size param-
eters Na+t and Na would however, generate an equation with two unknowns:
PH,i and
∑k
i=1 PH,i. To address this issue, the total size of the population of
age a+ t was expressed as a function of: (i) the total size of the population of
age a and (ii) the probabilities of survival for individuals of age a conditional
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on their health status :
Na+t = Na(1−
k∑
i=1
Πi,a)(1− PH,D) +Na
k∑
i=1
Πi,a(1− Pi,D) (5.6)
Substituting the expression for Na+t into equation 5.5 enabled to express
the t-year probabilities for individuals of age a to transit within the closed-
system from the state “healthy” to the each i disease state (i.e. PH,i, i=1,...,k)
as a function of:
(i) t-year death probabilities conditional on health status: Pi,D, i=1,...,k, PH,D
(ii) t-year probabilities of transiting to the next more severe state: Pi,i+1, i=1,...,k−1
(iii) disease prevalence by severity stage for t-year age-groups: Πi,a, Πi,a+t
For i=2,...,k-1:
PH,i =
Πi,a+t[(1−
∑k
i=1 Πi,a)(1− PH,D) +
∑k
i=1 Πi,a(1− Pi,D)]− Πi,a(1− Pi,D)(1− Pi,i+1)
(1−∑ki=1 Πi,a)(1− Pi,D)]
− Πi−1,a(1− Pi,D)(1− Pi−1,i)
(1−∑ki=1 Πi,a)(1− Pi,D)]
(5.7)
For i=1:
PH,i =
Πi,a+t[(1−
∑k
i=1 Πi,a)(1− PH,D) +
∑k
i=1 Πi,a(1− Pi,D)]− Πi,a(1− Pi,D)(1− Pi,i+1)
(1−∑ki=1 Πi,a)(1− Pi,D)]
(5.8)
For i=k:
PH,i =
Πi,a+t[(1−
∑k
i=1 Πi,a)(1− PH,D) +
∑k
i=1 Πi,a(1− Pi,D)]− Πi,a(1− Pi,D)
(1−∑ki=1 Πi,a)(1− Pi,D)]
− Πi−1,a(1− Pi,D)(1− Pi−1,i)
(1−∑ki=1 Πi,a)(1− Pi,D)]
(5.9)
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5.5 Estimating COPD diagnosis probabilities by sever-
ity stage in England
5.5.1 General approach
The framework was applied to the case of COPD in England, in order to
estimate the age-specific t-year probabilities of being diagnosed at each stage
i of the disease, where i = GOLD 1, ..., GOLD 4.
In line with the cycle length chosen for the model developed in Chapter 4,
the t-year period was set to a year. Since the framework considers age as a time
dimension (see section 5.4.2), the period for which diagnostic probabilities were
computed needed to match with the size of the age-groups for which prevalence
data was expressed. Implementation of the framework therefore required three
input parameters:
(i) Annual probabilities of death conditional on health status;
(ii) Annual probabilities to progress to the next more severe disease stage;
(iii) COPD prevalence by severity stage stratified by one-year age-groups.
5.5.2 Input parameter 1: mortality data
The probability of dying if “healthy”, i.e. if without COPD, (PH,D) was
computed using life table analysis.
Information on the excess mortality risk in COPD patients was provided
by Mannino et al. (2006) based on a cohort study of 15,440 American subjects
followed up for 11 years. Hazard ratios, adjusted for age, sex, smoking status,
body mass index, pack-years of smoking, race and educational level, were
stratified by GOLD severity stage but also, by the presence of respiratory
symptoms. Mortality hazard ratios, stratified by GOLD severity stage only,
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were derived by combining Mannino et al. (2006)’s ratios with the proportions
of COPD patients experiencing symptoms in each severity stage, as reported
in the study. The obtained hazard ratios were then applied to age and gender-
specific annual death rates in the general population of England (ONS, 2011)
and resulting mortality rates stratified by GOLD severity stage were converted
into 1-year transition probabilities using equation 5.10:
P = 1− exp−rt , where r is the annual event rate and t is a one-year period
(5.10)
Since hazard ratios of mortality provided by Mannino et al. (2006) were
computed for stages 3 and 4 altogether, age and gender-specific probabilities
of death conditional on being in GOLD 3 or in GOLD 4 were assumed to be
similar.
Figure 5.2 depicts age and gender-specific probabilities of death conditional
on health status. It underlines how the risk of death changes as one moves to
a more severe disease stage.
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(a) Males death probabilities.
(b) Females death probabilities.
Figure 5.2: Input parameter 1: Annual probabilities of death conditional on health status.
Abbreviations: H= healthy; D= dead. Numbers 1 to 4 stand for each GOLD severity stages of COPD.
5.5.3 Input parameter 2: data on severity progression
The annual probabilities to gradually transit from a severity stage to the
next were computed by Atsou et al. (2011) for individuals aged 40 and above,
as a function of age and smoking status. To compute these transition proba-
bilities, the authors combined two data sources. The first consisted of rates of
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progression from the mild to moderate and moderate to severe stages of COPD
by age and smoking status, provided by the analysis of the Framingham Heart
Study cohort from Massachusetts, US. In brief, study participants who had
spirometry data available (n= 583 at baseline) were categorized according to
GOLD stages at the beginning and at the end of 12 years of follow-up, in
order to estimate progression rates between severity stages (Lee et al., 2006).
The second data source was transition probabilities from moderate to severe
and severe to very severe stages by smoking status, but not age nor gender,
reported by Hoogendoorn et al. (2005) for the Dutch population.
As there is currently little evidence supporting a difference in biological
response to air pollution exposure based on smoking habits, disease progres-
sion probabilities were computed for the overall COPD patient population in
England. To do so, Atsou et al. (2011)’s age-specific annual transition prob-
abilities stratified by smoking status were combined with the distribution of
COPD patients in England by smoking status provided by Shahab et al. (2006).
Unlike death probabilities, disease progression probabilities were not stratified
by gender.
Figure 5.3 represents the annual probabilities of progressing to a more severe
stage. It is worth noting that the speed of transition from stage 1 to 2 is slower
than the speed of transition from stage 2 to 3 or from stage 3 to 4 and that
all progression probabilities are a positive function of age.
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Figure 5.3: Input parameter 2: Annual probabilities to progress to the next severe stage of
COPD.
Abbreviations: Numbers 1 to 4 stand for GOLD severity stages.
5.5.4 Input parameter 3: Prevalence data
The UK Department of Health (2010) provided estimates of numbers of
underlying cases of COPD by GOLD stage for 10 year age-bands: 35-44; 45-
54; 55-64; 65-74 and 75+ for the year 2009. The following three manipulations
were performed to the data, so that it could be used as input parameter to the
probabilistic framework developed.
First, the estimated numbers of underlying COPD cases by GOLD severity
stages were compared with population data (2011 census) for England. This
enabled us to compute the distribution of the underlying COPD prevalence in
England by disease severity for 10 year age-bands. Whilst the UK Department
of Health (2010)’s estimates were based on population projections for the year
2009, the use of population census numbers as of year 2011 is not expected to
have any major impact on obtained prevalence results.
Second, as the assumption that the prevalence was uniform across each 10
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year age-groups seemed unrealistic, the estimated prevalence was assumed to
represent the point prevalence at age-group mid-point. For example, preva-
lence for the age-group 35-44 was assumed to represent prevalence at age 40
and so forth. Additionally, in the absence of further information, the last age-
group “75+” was defined as age group 75-94 with mid-point 85 years old. The
resulting estimates of underlying COPD prevalence by severity stage, at each
age-band mid-point, is represented in Figure 5.4a.
Third, disease prevalence was estimated for one-year age-groups by per-
forming a linear extrapolation between each age-band mid-point. Linear ex-
trapolation results are presented in Figure 5.4b.
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(a) COPD underlying prevalence by GOLD severity stage at each age group
mid-point.
(b) COPD underlying prevalence by one-year age-groups obtained via lin-
ear extrapolation.
Figure 5.4: Input parameter 3: underlying prevalence of COPD in the general population
in England, by age and GOLD severity stages, computed using numbers of COPD cases
estimated by the UK Department of Health (2010).
Figure 5.4a shows that the underlying prevalence of COPD in the popula-
tion, across all severity stages, is an increasing function of age. About 4% of
individuals of the general population aged 40 are expected to be with COPD,
as opposed to 11% of those aged 60, 16% of those aged 70 and 25% of those
aged 85. The distribution of prevalence by severity stages is also strongly de-
termined by age, reflecting the fact that COPD is a non-reversible progressive
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disease. Indeed, up to age 50, individuals with COPD are typically expected
to be in stages 1 or 2 whereas, in older individuals, stage 3 becomes increasing
prevalent and represents most of COPD cases in individuals aged 85.
Whilst there are clear age-trends in the estimated underlying prevalence of
COPD, its distribution by severity stages and age nevertheless exhibits some
variations. This resulted in kinked prevalence curves by one-year age-groups, as
shown in Figure 5.4b. Indeed whilst the prevalence of stage 2 increases steadily
as a function of age, the prevalence of stage 3 mostly increases between ages 50
and 60 and, to an even greater extent, between ages 70 and 85. Additionally,
in contrast to the prevalence of stage 2 and 3, the prevalence of stage 1 is
expected to be relatively stable over age-groups, varying from a minimum
of 2% of the general population at age 40 to a maximum of 5% at age 70.
The decrease in prevalence of stage 1 between the ages of 70 and 85 suggests
that: (i) most individuals aged above 70 are expected to have progressed to
more severe stages or to have died (ii) those who get diagnosed at that age
are expected to be diagnosed in more advanced stages. Finally it is worth
underlining that even at a very old age, stage 4 represents only a very small
proportion of the total numbers of COPD cases.
5.6 Results
5.6.1 Results interpretation
PH,i, i=1,...,4, represent the annual probabilities for the general population of
England of being diagnosed with a given stage of COPD, as implied by the
underlying prevalence of COPD and the relationship between disease incidence,
prevalence, progression and survival.
Diagnostic probabilities are also referred to as the annual incidence of
COPD. They are expressed in numbers of annual cases of the disease, by
137
severity stage, per 1,000 individuals of the general population without prior
COPD diagnosis. As only the conditional probabilities of death were strati-
fied by gender, results were very similar across gender and the simple average
across both genders is presented.
5.6.2 Diagnosis/incidence probabilities by severity stage
GOLD stages 1 and 2 incidence
Figure 5.5 shows the expected annual numbers of cases of GOLD 1 and 2
per one-year age-group. In line with the previously described curves of age-
specific prevalence by severity stage (see Figure 5.4b), the annual number of
cases of GOLD 2 increases rather steadily among older age-groups whilst the
number of cases of GOLD 1 remains within a small range of 1 to 4 cases per
1,000 persons per year. There appears to be a small substitution effect between
the incidence of stage 1 and stage 2 around the ages of 50 and 60, which may
reflect estimation error induced by the combination of diverse data sources.
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Figure 5.5: Estimated annual cases of COPD GOLD 1 and GOLD 2 per 1,000 individuals
of the general population, by 1-year age groups.
GOLD 3 incidence
The 1-year probabilities of being diagnosed in stage 3 without previous
diagnostic of the disease were slightly negative (in the order of - 1 case per
10,000 individuals) for individuals aged 40 to 50 and 60 to 70. This is expected
to be the result of the combined effect of a small rate of prevalence increase
between this age points (see Figure 5.4b) and a relatively fast rate of transition
between stages 2 to 3 (see Figure 5.3).
In an attempt to provide stable estimates of age-specific probabilities of
being diagnosed in GOLD stage 3, the analysis was re-conducted for 5-year
time-intervals, based on estimates of underlying prevalence at age 40, 45, 55,
65, 70, 75, 80, 85. Survival and disease progression probabilities were expressed
for a 5-year period by taking the average of 1-year probabilities constituting
each 5-year age-intervals (e.g. 40-44; 45-50 and so forth) and transforming
the obtained results to 5-year probabilities based on equation 5.11, assuming
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a constant rate of incidence over each 5-year intervals.
Pt = 1− (1− P1)t (5.11)
5-year PH,3, for each age-group, were then transformed back to 1-year proba-
bilities using equation 5.12.
P1 = 1− (1− Pt)1/t (5.12)
In order to assess whether performing the analysis using 5-year intervals would
introduce an important loss of accuracy in the estimation of PH,3, a similar
approach was applied to compute cumulative 5-year PH,1 and PH,2 and trans-
form them back to 1-year PH,1 and PH,2 assuming a constant rate of incidence
within 5-year age-groups. 1-year PH,1 and PH,2 estimated using 5-year inter-
vals were of relatively similar magnitude than 1-year PH,1 and PH,2 estimated
using 1-year intervals, which suggests that the loss of accuracy was limited.
Figure 5.6 represents the estimated annual incidence of GOLD 3 cases for
each 5-year age-groups, expressed in annual numbers of GOLD 3 cases per
1,000 individuals. For comparison purposes, Figure 5.6 also shows the annual
numbers of GOLD 1 and 2 cases per 1,000 individuals for the same 5-year
age-groups. Results could not calculated for the last age group (80-85) due to
the lack of information on the prevalence for the next age group (85-90), which
is required for the estimation process (see equation 5.7).
Figure 5.6 shows that the expected annual number of cases of GOLD 3 in the
general population shots up from age 65 onwards. This finding is in accordance
with prevalence trends, where between ages 70 and 85, stage 3 replaces stage
2 as the most likely disease stage of individuals with COPD, and with the
fact that diagnosis of COPD in old age groups tend to be in more advanced
stages of the disease (UK Department of Health, 2010). It is nevertheless worth
underlying that, even in the oldest age groups, the estimated incidence of new
cases of GOLD 3 in the general population is lower than 2% per year.
140
Figure 5.6: Estimated annual cases of GOLD 1, GOLD 2 and GOLD 3 COPD per 1,000
individuals of the general population, by 5-year age groups.
GOLD 4 incidence
1-year PH,4 based on 1-year intervals were quasi all negatives while 1-year
PH,4 computed using 5-year intervals were very small (in the order of 1 to 7 out
of 10,000 individuals) with some age-intervals taking negative values. These
results are not surprising given the very low prevalence of GOLD 4 (see Figure
5.4) and the possibility for individuals to progress from previous stages to stage
4 (see Figure 5.3). They support the assumption that the worst severity stage
at which an individual of the general population of England can be diagnosed
with the disease for the first time is stage 3. Consequently, it is hereafter
assumed that in England PH,4 = 0.
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5.6.3 Distribution of annual incidence by severity stage
Figure 5.7 compares: (A) the presently estimated distribution of COPD
incidence by severity stage, expressed in annual cases per 1,000 individuals
of the general population with (B) the distribution by severity stage of the
underlying prevalence of COPD estimated by the UK Department of Health
(2010), which was used as input parameter to the present framework.
Figure 5.7 provides two main insights. First, like prevalence, the estimated
incidence of COPD is expected to be a positive function of age. Indeed, the
total annual number of COPD cases across all stages, per 1,000 individuals of
the general population in age-group 75-79, is about 10 times as much as the
number of cases in age-group 40-44.
Second, the age-specific distribution of incidence by severity stage is in ac-
cordance with the age-trends that characterise underlying prevalence estimates
outlined in section 5.5.4. For instance, until the age of 49, individuals diag-
nosed with COPD are most likely to be diagnosed in stage 1. This is line with
the fact that up to age 50, most individuals with COPD are in stage 1. Sim-
ilarly, from age 50 up to age 64, individuals diagnosed with COPD are most
likely to be diagnosed in stage 2, while after the age of 70, most new diagnoses
are expected to pertain to stage 3. This is in accordance with the fact that
up to the age of 70, most individuals with COPD are in stage 2, whereas as
from the age of 80, most individuals with COPD are in stage 3. These findings
suggest that the estimation method was sound.
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(a) Distribution of presently estimated age-specific annual COPD incidence by
GOLD severity stage.
(b) Distribution of COPD underlying prevalence by GOLD severity stage at
age-group mid-point Source: UK Department of Health (2010).
Figure 5.7: Distribution of estimated incidence and underlying prevalence of COPD by
GOLD severity stage and age.
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5.6.4 Estimated incidence versus GP registrations-based incidence
Figure 5.6.4 compares the presently estimated “true” annual incidence of
COPD across all stages, against registered incidence data from the UK British
General Practice Research Database (GPRD)4. Comparison is performed across
all four disease stages since GPRD data is not provided by severity stage.
Figure 5.6.4 shows that the difference in incidence results is very high among
young age-groups, with the ratio “estimated incidence” over “GPRD data”
being equal to 7 in age group 40-44. This ratio then decreases with age such
that, for individuals aged 65 and over, presently estimated incidence is about
3 times greater than recorded incidence in general practices.
Whilst these results appear credible given the extent to which COPD is
currently underdiagnosed (see section 5.2.1), their validity is difficult to assess
due to the lack of information on the magnitude of disease underdiagnosis by
age. Nevertheless, in line with the fact that stages 1 and 2 are the most un-
derdiagnosed stages of the disease and that these stages are mostly prevalent
among young individuals (UK Department of Health, 2010), it appears coher-
ent that the discrepancy between the presently estimated incidence and GP
registrations is the greatest for the youngest age-groups.
4UK GPRD data (2007) available from EU-funded open-access model DYNAMO HIA
(http://www.dynamo-hia.eu/)
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Figure 5.8: Estimated annual cases of COPD across all severity stages versus primary care
records (1).
(1) GPRD data for year 2007, obtained from EU-funded open-access model DYNAMO HIA.
5.7 Conclusions
5.7.1 Limitations
Model validation
Whilst diagnostic/incidence estimates are in line with expectations, ideally
the developed framework should be validated, for instance by estimating the
incidence implied by GP-recorded prevalence data and comparing the obtained
result with GP recorded- incidence. Unfortunately this was not feasible since
available primary care data on COPD registrations is not provided by severity
stages.
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The obtained distribution of age-specific annual incidence of COPD by
severity stages could not be compared with estimated incidence data for other
countries. Indeed, although Hoogendoorn et al. (2005, 2011) allowed popu-
lation individuals to transit from the state “healthy” to each severity stages
(as opposed to a single allowed transition from the state “healthy” to stage
1, as commonly assumed in other models of natural history of COPD), they
assumed that the severity distributions of prevalence and incidence were the
same across all age-groups. As both underlying prevalence estimates from
the UK Department of Health (2010) and the presently estimated incidence
are strongly determined by age, a comparison with Hoogendoorn et al. (2005,
2011) data hardly appears appropriate.
Model inputs and assumptions
Firstly, the reliability of the results crucially depends on the validity of in-
put data and in particular, on the estimates of underlying prevalence of COPD
in England provided by the UK Department of Health (2010). Additionally,
parameters of disease progression and survival were obtained by combining dif-
ferent data sources and in particular results from studies performed on COPD
patients in the US. Differences in health care management between the US and
UK may however, influence survival and disease progression outcomes. More
generally, the use of input parameters derived from various data sources is ex-
pected to have introduced some estimation error in output results. Moreover,
as both prevalence data and disease transition parameters were not provided
with confidence intervals, uncertainty around incidence estimates could not be
estimated.
Secondly, the framework is underpinned by the assumption that both the
population and the disease epidemic are stable. While the assumption of sta-
ble population could be relaxed, but at the expense of greatly complicating
the framework, the assumption of a stable epidemic was required in order to
estimate incidence based on results from a single cross-sectional survey.
Finally, in order to substantially reduce the computational burden, the
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framework was developed and solved in a discrete time setting, although dis-
ease development, worsening and death are continuous processes. In order to
reduce the approximation error, the length of intervals for which probabilities
were estimated was set to a year, which appears a reasonable approximation
given that COPD is a slowly progressive disease. However, as explained in sec-
tion 5.6.2, in order to obtain stable estimates of stage 3 incidence, the latter
were computed using a 5-year period. Whilst the annual incidence of GOLD
stages 1 and 2 obtained by using respectively 1-year and 5-year time intervals
was found to be of similar magnitude, inevitably the greater the time-period,
the larger the approximation.
5.7.2 Implication for cost-effectiveness analysis
This chapter provided a coherent framework to estimate the age-specific
annual probability of being diagnosed at a given stage of COPD, implied by
the underlying population prevalence of COPD estimated at a single point in
time and its relationship with disease incidence, progression and survival.
By addressing the issue of underdiagnosis reflected in primary care data
(i.e GP-recorded incidence of the disease), the present estimates of COPD
incidence will enable to model more accurately the total population health
benefits of preventive interventions such as air pollution control that reduce
the risk of developing COPD and COPD patients’ risk of suffering from further
adverse effects.
The framework was applied to the case of England, in order to parame-
terise the model of air pollution impacts developed in Chapter 4. However,
since COPD under-diagnosis is a global issue (GOLD, 2014), the framework
could be applied to estimate COPD incidence by severity stages in other coun-
tries, provided data on the underlying population prevalence of the disease are
available.
It may be argued that only diagnosed cases should be taken into account
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when assessing the intervention’s impact on health care budget. However, the
stages that are the most underdiagnosed, i.e. for which the difference between
recorded and presently estimated “underlying” incidence is the greatest, are
GOLD stages 1 and 2, which are the least expensive stages of the disease
(Jansson et al., 2013). Secondly, estimates of underlying prevalence provided
by the UK Department of Health (2010) aimed to capture the prevalence of
persistent airflow limitation only, thanks to post-bronchodilator adjustment
(see section 5.3.1). It is therefore likely that those undiagnosed individuals may
nevertheless seek health care to treat their symptoms. Obviously as the health
care cost associated with these undiagnosed individuals cannot be related to
the COPD burden, it is not possible to verify this assumption (Hoogendoorn
et al., 2005).
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Chapter 6
Systematic review and
meta-analysis of studies of the
association between long-term
exposure to PM2.5 and all-cause
mortality and lung cancer
incidence or mortality
6.1 Introduction
Mortality in adults of the general population has been one of the health
outcomes most intensively investigated in epidemiological studies of air pollu-
tion. A systematic review and meta-analysis of epidemiological studies of the
association between long term exposure to particulate air pollution (PM) and
mortality, published between 1950 and 2007, was performed by Chen et al.
(2008). However, since publication of this piece of work, additional relevant
epidemiological studies have been released, including results from the extended
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follow-up of two main cohorts in the US: Harvard Six Cities and the American
Cancer Study (see Chapter 2).
The objective of this chapter is therefore to help characterise uncertainty in
the evidence base used to populate the model developed in Chapter 4, by sys-
tematically searching for and synthesising the evidence relevant to the excess
risk of mortality associated with chronic air pollution exposure. More sepcifi-
cally, Chen et al. (2008)’s systematic review and meta-analysis will be extended
for the period 2008-2014, focusing on studies of the association between long
term exposure to particulate air pollution and: (i) all-cause mortality and (ii)
lung cancer incidence or mortality, in adults of the general population.
Pooled risk estimates will be used to parameterise several distinct paths of
the Markov model of the health impacts of air pollution exposure developed
in Chapter 4. First, as mentioned in Chapter 4, individuals with COPD or
CHD, who did not meet specific severity and age conditions, were assumed to
have the same pre-disposition to dying prematurely due to PM exposure as
individuals of the general population. As a result, the pooled risk estimate of
all-cause mortality will be used to model the excess risk of mortality in: (i)
COPD patients of all ages in GOLD stages 1 and 2 (i.e. RREd in Table 4.1 of
Chapter 4); (ii) COPD patients in GOLD stages 3 and 4 aged below 65 years
old (i.e. RREe for age < 65 in Table 4.1); (iii) CHD patients aged below 75
years old (i.e. RREf for age < 75 in Table 4.1). It should be underlined that
the pooled risk estimate of all-cause mortality will not be applied to “healthy”
individuals as the latter are assumed to die from all other causes of death than
CHD, COPD or lung cancer.
Second, the pooled risk estimate of the association between PM exposure
and lung cancer incidence or mortality will be used to model the excess risk
of developing lung cancer in the general population (i.e. RREc in Table 1
and Figure 1 of chapter 4). Indeed, owing to the very high case-fatality rate
for lung cancer, where the net survival rate at 5-year for adults in England is
9.5% (ONS, 2011), mortality and incidence are comparable indicators of the
association between lung cancer and PM exposure and studies informing either
incidence or mortality can be considered altogether.
The chapter is structured alongside three sections. Section 2 focuses on the
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systematic search. It details the search strategy, the screening results and the
key characteristics of the studies identified as relevant. Section 3 consists of the
meta-analysis work. It also provides an assessment of potential sources of bias
and describes the choice of statistical approaches to pooling effect estimates.
Section 4 discusses and concludes.
6.2 Systematic review
6.2.1 Search protocol and strategy
Since Chen et al. (2008)’s search spanned between 1950 and December 2007,
the present systematic search was run from January 2008 to present (April
2014). It was performed using PubMed and Embase databases, which were
the same databases used by Chen et al. (2008).
The search was framed around four main inclusion criteria, described in
Table 6.1.
No particular age restrictions were imposed on the studies subjects, to the
exception of the exclusion of studies based on elderly populations, presently
defined as studies based on adults aged above 65. Additionally, in the absence
of conclusive evidence to date pertaining to gender-related differential suscep-
tibility to air pollution exposure, both gender-specific and all-genders studies
were included.
While the model developed in Chapter 4 focused on the health effects of
fine particulate pollution, i.e. PM2.5, to avoid being over-restrictive, the search
initially considered studies pertaining to both fine and coarse particulate pol-
lution. For the same reason, the search protocol did not include any restriction
on studies’ geographical location. However, since linearity in health impacts
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Population
Adults of the general population
- no focus on elderly subjects
- no occupational studies
Intervention
Change in long-term exposure to particulate air pollution (PM)
- Both PM2.5 and PM10 were initially considered
- Measure of change in PM concentrations: µg/m3 or quantile (a)
Outcomes
- All-cause mortality
- Lung cancer mortality
- Lung cancer incidence
Study design Cohort studies
Search period Jan. 2008 to April 2014
Table 6.1: Inclusion criteria for search protocol.
(a) For statistical analysis, all study estimates will be converted to represent the change in health risk per
10µg/m3 increment in PM exposure, which is the unit of measure commonly used in epidemiological
studies of air pollution.
in response to a change in PM exposure has been validated only in studies
conducted in developed countries (Krewski et al., 2009; Cesaroni et al., 2013;
Lepeule et al., 2012), study location will be later considered in the analysis of
the pool of studies identified as relevant.
The selection of health outcomes was based on the parameterisation needs
of the model developed in Chapter 4 and the choice of study design was de-
termined by the nature of the intervention and the type of health outcomes.
Cohort studies, which link mortality data with long-term cumulative exposure
variables and subject-specific covariates, were selected as the best suited study
design.
Finally, in order to minimise the risk of missing relevant studies, the search
strategy was broadened in the following fashion. First, even though stud-
ies of traffic pollution typically focus on NO2, search terms included “Vehi-
cle emissions” or “Traffic” in case such studies would also consider the ef-
fect of particulate matter alongside NO2. Second, medical subject headings
(MeSH) terms “Cardiovascular Disease/mortality” and “Respiration Disorders
Disease/mortality” were added into the Pubmed query, as some studies some-
times also include all-cause mortality as secondary outcome.
The detailed search queries performed for each database are provided in
Appendix D. Repeated assessment of the validity of the devised queries was
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performed by checking whether they successfully captured publications that
were known to be relevant.
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6.2.2 Systematic search results
Queries in Embase and PubMed, run for the period January 2008 to April
2014, led to the identification of 275 publications in total (including dupli-
cates): 139 articles in PubMed and 136 articles in Embase.
The study selection process is summarised in Figure 6.1. A first screen-
ing based on title and abstract excluded 231 studies which did not meet the
inclusion criteria or were duplicates, thus leaving 44 distinct publications for
full-review. Among these remaining 44 publications, two were based on the
same cohort (the California Teachers study). In such case, in line with Chen
et al. (2008), only the paper associated with the longest follow-up and/or the
largest population study size was selected. In addition, 8 publications were
reviews of literature that did not provide original results. Finally, another 15
publications were excluded based on inclusion criteria. Results were either:
(i) not based on PM as air pollutant, (ii) based on occupational exposure or
on specific populations subgroups, (iii) not derived from a cohort study (1
case-control study).
Out of the pool of 20 remaining publications identified as relevant follow-
ing full-review, one (Beelen et al., 2008) was already included in Chen et al.
(2008)’s review. As the majority of publications pertained to the health effects
of PM2.5 exposure, which tend to be associated with greater adverse health
effects than PM10, it was decided to focus solely on studies of the impact of
PM2.5 exposure, in order to ensure a greater homogeneity in effect estimates.
This led to the exclusion of five studies on PM10. Ultimately, the search
therefore led to the identification of 14 publications.
For the period 1950-2007, Chen et al. (2008) had identified 8 publications
on the association between long-term exposure to PM2.5 and all-cause or lung-
cancer mortality. Three of these studies had been “updated” by studies based
on the same cohort but with longer follow-up and/or population size; two did
not apply to the general adult population; and one (Naess et al., 2007) provided
estimates which could not be reliably converted per 10 µg/m3 increment of
PM2.5. The two remaining relevant publications identified by the authors (for
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the period 1950 - Dec. 2007) were combined with the 14 ones identified by the
present search for the period 2008-2014, providing a final pool of 16 relevant
publications.
Figure 6.1: Flow diagram of search strategy and selection process.
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6.2.3 Identification of the set of relevant risk estimates
One publication (Krewski et al., 2009) provided results for three cohorts:
the American Cancer Study (ACS) national (full cohort) and two derived sub-
cohorts in Los Angeles and New York, for which air pollution assessment and
attribution were different from the national study. Therefore, the 16 publica-
tions identified through the search provided results from 18 distinct studies.
Many of these studies investigated both all-cause and lung cancer mortality as
health endpoints, which gave a total of 15 risk estimates for all-cause mortality
and 13 estimates for lung-cancer mortality or incidence.
The ACS national (full cohort) provided results for two time periods of expo-
sure, respectively 1979-1983 and 1999-2000 (same follow-up length). Since the
risk estimates computed using the most recent exposure period were based on
the largest population size (488,370 study participants, as opposed to 342,521
participants for the older period of exposure), they were selected to represent
ACS national study results. However, since results pertaining to lung cancer
mortality significantly varied between the two time periods of exposure (see
Table 6.2), it was decided to use the risk estimate based on the 1979-1983
exposure period in sensitivity analysis.
6.2.4 Key characteristics of relevant studies
Preliminaries
Table 6.2 provides a summary of the key characteristics of the 18 distinct
studies, which results were provided by the 16 publications identified as rele-
vant to the present research question. In this section, studies are referred to
by their cohort name, with corresponding author information being provided
in Table 6.2.
156
All studies measured the strength of the pollution-mortality association
using hazard ratios, to the exception of Beelen et al. (2014) and Jerrett et al.
(2013) which used relative risks. However, since for rare events such as death,
rates and probabilities are very similar, combining these two measures of effect
in a meta-analysis was considered acceptable. Such an approach was also
followed by Chen et al. (2008).
Methodological differences between studies essentially pertained to: study
follow-up, spatial and temporal assignment of long-term cumulative exposure
to study subjects and adjustment for confounding.
Study follow-up
Whilst most studies were based on population follow-up greater than 10
years, follow-up nevertheless varied greatly between studies. For instance, the
latest analyses of the Harvard Six Cities and American Cancer Society cohorts
relied on a population follow-up of respectively 36 and 18 years, as opposed to
5 years for the English cohort for instance.
Temporal assignment of cumulative exposure
In most studies, exposure was assessed and assigned to subjects solely for
a period of the follow-up, with three studies using 1 to 3-year moving average
of exposure prior to event. In two studies (ASHMOG and Japanese cohorts)
the exposure period was respectively 5 and 10 years before enrolment. The
difference in the temporal resolution of PM2.5 exposure between studies reflects
limited systematic monitoring of fine particulate concentrations until the late
90’s in many countries, as well as the lack of evidence on critical time-windows
of exposure. Whilst some studies suggest that the last few years of exposure
prior to event are the ones most strongly associated with mortality (Lepeule
et al., 2012; Puett et al., 2009; Schwartz et al., 2008), the identification of the
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most influential time windows of exposure has typically proven to be difficult,
due to too small spatio-temporal variations in concentrations.
Spatial assessment and assignment of cumulative exposure
Precision in effects estimation requires sufficient spatial variation in sub-
jects’ cumulative exposure over time. This is harder to obtain when exposure
is assigned to individuals at a coarse scale (Dominici et al., 2003). Conse-
quently, whilst a few studies used the mean of concentrations in the city of
residence at enrolment (e.g. ACS full cohort; Harvard Six Cities) or at the
nearest monitor (e.g. Japanese and US truckers cohorts), most studies used
geographic information systems (GIS)-based statistical methods to account
for small-scale spatial variations in pollution concentrations and obtain finer
spatial contrasts in exposure.
These methods, which can be classified as interpolation methods, land use
regression models or dispersion modelling are described in Jerrett et al. (2005).
Briefly, statistical interpolation produces estimates of pollution concentrations
at un-sampled sites by exploiting spatial dependence in the data (krieging
method) or by relying on deterministic or geometric algorithms such as inverse
distance weighting. By contrast, land use regression models regress pollution
monitoring data obtained from a small number of sampling locations on an
exogenous set of variables (e.g. traffic, land use, altitude), in order to predict
pollution concentrations at other sites. Finally, dispersion models differ from
the first two methods as they rely on monitoring measurements only for model
calibration and validation, i.e. not as input data. Dispersion models generate
estimates of pollutant concentrations based on data on pollutants emissions,
meteorological conditions and topography, assuming these parameters are gov-
erned by deterministic processes.
Although each method has its pros and cons, land use regression models
(used in 8 of the selected studies) have been found to outperform interpolation
methods (used in 3 of the selected studies) (Hoek et al., 2008). The main
drawbacks of interpolation methods is that they are mechanistic, they require
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a relatively dense sampling network to avoid large estimation errors and they
assume that variation is spatially homogenous (Jerrett et al., 2005). The few
studies that have compared land use regression models with dispersion mod-
elling do not suggest that one technique is dominated by the other, rather that
the main strength of dispersion modelling is to assess source-specific concen-
trations of pollutants (Hoek et al., 2008).
Nevertheless, notwithstanding the complexity and refinement of these mod-
elling approaches to exposure assessment, outdoor concentrations are solely a
proxy for individual-level exposure, which is the underlying variable of interest.
Exposure misclassification using outdoor concentrations is therefore inevitable
due to individual-level differences in time-activity patterns, air exchange rate
of outdoor pollutants at home, accommodation type, i.e. high-rise or low-floor
buildings, and so forth (Briggs, 2005; Hoek et al., 2008). Whilst exposure
misclassification is generally expected to be non-differential (i.e. study partic-
ipants have an equal likelihood to be assigned an inaccurate estimate), which
limits the risk of spurious associations, it adversely affects precision in effect
estimation (Raaschou-Nielsen et al., 2013).
Adjustment for confounding
Given the nature of the data, i.e. time to event, all studies used the Cox
proportional hazard model, which links the log of the relative risk to pollution
concentrations. A few studies, namely ACS national, city-scale and regional
sub-cohorts and the Canadian cohort included a random-effect component into
the Cox proportional hazard model, in order to account for spatial clustering of
data at neighbourhood level, i.e. confounding by spatially-varying contextual
factors that are correlated with air pollution.
Studies differed in their adjustment for confounding by lifestyle factors,
smoking in particular. The large majority of studies (15 out of the 18 included
studies) used a set of individual-level covariates to adjust risk estimates for
many risk factors such as diet, body mass index (BMI), active and passive
smoking, alcohol consumption, along with socio-economic status. Neverthe-
159
less, three studies, namely the Rome, Canada and US truckers cohorts, solely
relied on socio-economic status to adjust for lifestyle.
Although there is accumulated evidence on social patterns in smoking and
diet, socio-economic status is only an imperfect measure for lifestyle risk factors
and residual confounding may be an issue if these risk factors are correlated
with air pollution concentrations. All four studies assessed potential corre-
lation between PM2.5 concentration estimates and smoking prevalence, using
health survey samples or cohort subsets for which information on smoking was
available. In the Rome, Olso and US truckers cohorts, no such association
was found, which suggests that smoking was an unlikely residual confounder
in these studies. In the Rome cohort, adjustment for smoking and diet-related
co-morbidities (chronic obstructive pulmonary disease and hypertensive heart
disease) that were recorded on hospital discharges yielded similar or stronger
associations between air pollution exposure and mortality and the inclusion of
smoking habits for a subset of participants (n = 7,845) did not modify the size
of associations.
For the Canadian cohort, analysis by Villeneuve et al. (2011) using estimates
of Crouse et al. (2012) found an inverse association between PM2.5 estimates
and the prevalence of smokers and certain categories of BMI. This is consistent
with the fact that in Canada, individuals with higher socio-economic status
tend to live in more polluted areas. Effect estimates of the association between
PM2.5 and mortality in this cohort increased in magnitude after adjustment
for individual-level socio-economic variables, which suggests that residual con-
founding by lifestyle factors may have led to an underestimation of the air
pollution-mortality effect (Crouse et al., 2012).
Study population
Whilst studies were conducted in geographically-diverse populations, they
were all based in developed countries (12 in North America, 5 in Europe and
1 in Japan).
Study populations had different age and gender composition, with five stud-
160
ies being gender-specific. Participants also had different socio-economic status,
with some studies being based on selected population subgroups such as male
truckers as opposed to female teachers or health professionals.
Finally, studies greatly differed in sample size. Of the 18 included studies,
two had above 1 million participants, six had between 1 million and 100,000
participants; five had between 100,000 and 50,000 participants and five had
below 50,000 participants.
Intervention
Although the levels of PM2.5 concentrations to which study participants
were exposed differed, they are within a rather narrow range (between 5 to
40 µg/m3). This range is in line with concentration levels at which linearity
in impacts and the absence of threshold to effects have repeatedly been found
(Krewski et al., 2009; Crouse et al., 2012; Lepeule et al., 2012; Cesaroni et al.,
2013). The small difference in concentration between studies is therefore not
expected to be problematic with regards to the pooling of risk estimates.
Particulate pollution, however, is a mixture of liquid and solid compounds
emitted by varying sources such as fossil-fuel combustion, industrial processes,
road dust, biomass burning. It is therefore likely that cohort participants have
been exposed to a different mixture of particulates associated with different
levels of toxicity. Nevertheless due to: (i) the lack of evidence on the relative
toxicity of particulate components and (ii) ignorance of the particulate mix of
concentrations in each study, this issue could not be addressed.
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Table 6.2: Summary of relevant studies identified.
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TABLE 6.2. Summary of relevant studies identified (continued).
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TABLE 6.2. Summary of relevant studies identified (continued)
(a) All HR are expressed for 4PM2.5 = +10µg/m3.
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6.3 Meta-analysis
6.3.1 Statistical framework
Two conceptual approaches
Meta-analysis consists in pooling risk estimates from individual studies by
computing a weighted average of effect estimates, using the inverse of esti-
mates’ variance as weights. This allows to give more weight to the more pre-
cise studies, with view to maximise the precision of the pooled effect estimate.
Mathematically,
θ¯ =
∑k
i=1wiθi∑k
i=1wi
with wi =
1
vi
(6.1)
with θ¯ being the pooled estimate and θi and vi representing study-specific
mean effect and variance.
The variance of the pooled estimate is the reciprocal of the sum of study-
specific weights wi, i.e.
V ar(θ) =
1∑k
i=1wi
(6.2)
There are two conceptually different approaches to performing a meta-
analysis known as the fixed-effect model (FE) or the random-effect model
(RE). The FE model assumes that each study generates an estimate of a com-
mon true treatment / intervention effect, subject to sampling error known as
within-study variation. By contrast, the RE model recognises that studies are
heterogeneous in some respect (e.g. they were drawn from populations that
differed from each other), with such differences having an impact on their es-
timated treatment effect (Borenstein et al., 2009). As a result, each study is
assumed to provide a study-specific treatment effect. This introduces another
source of sampling error in the pooled risk estimate known as between-studies
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variance (τ 2). Whilst study-specific effect estimates are not identical, they are
assumed to come from a common distribution - typically taken as the normal
distribution - that is centred at the pooled estimate.
The choice of conceptual approach to pooling each risk estimate has strong
implications on the computation of the pooled estimate. Under the FE model,
the pooled estimate is assumed to provide information about the best estimate
of effect. Consequently, studies with the greatest precision, i.e. with the lowest
within-study variance, will be attributed a much higher weight than the least
accurate studies and will therefore strongly influence the value of the pooled
estimate. By contrast, under the RE approach, the pooled estimate represents
the average intervention effect across different study populations (Borenstein
et al., 2009). This shifts the focus of interest from the estimation of a common
effect to the characterisation of the distribution of effects across studies.
Computation-wise, although effect estimates are weighted by the inverse
of their variance in both models, under the RE-model the variance includes
within-studies and between-studies variance (Sutton et al., 2000). Denoting σi
within-study variance, we obtain the following expressions for study-specific
variance:
vi = σi under the FE model and vi = σi + τ
2 under the RE model (6.3)
Replacing for vi, we obtain the following expressions for study-specific weights:
wi =
1
σi
under the FE model and wi =
1
(σi + τ 2)
under the RE model
(6.4)
The inclusion of between-study variance in the RE model has three con-
sequences. First, the weights assigned to each study will tend to be more
balanced under the RE model than the FE model. Second, since the variance
of the pooled estimate is the reciprocate of the sum of study weights (see equa-
tion (2)), in the presence of between-studies variation, the confidence interval
of the RE-pooled estimate will be larger than the confidence interval around
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the FE-pooled estimate. Third, in line with equations 6.1 to 6.4, if τ 2 equals
to zero, FE and RE models will yield identical results.
Choice of random effect as conceptual model
The studies identified by the present systematic review and those selected
from Chen et al. (2008)’s review were chosen for their similarities in terms of
study population, intervention, health outcomes and study design. Neverthe-
less, as described in section 2.3., studies exhibit some level of heterogeneity
especially with regards their methodology. Therefore, whilst studies are con-
sidered similar enough for the pooling of their effect estimates to be pertinent,
their heterogeneity should be taken into account to avoid pooled estimates
and their confidence intervals to be misleading. The RE model was therefore
preferred.
Interpretation of random effect estimation results in decision modelling
Whilst the random effect model is advocated to incorporate heterogeneity
between studies, the use of random effect meta-analysis results to populate
cost-effectiveness decision models, is open to a number of possible interpreta-
tions about the source of heterogeneity between studies and how the target
setting of the intervention under assessment may potentially differ from the
ones in the studies included in the meta-analysis. (Welton et al., 2015). The
expression of “target setting” presently refers to population characteristics,
intervention definition etc.
Typically, the mean of the random effect distribution is interpreted as the
true effect to be observed in the future. This assumes that the decision target
setting is equal to the average setting of the included studies and that the
pooled estimate is an estimate of the true underlying intervention effect (D)
that has been observed under noisy conditions resulting from random measure-
ment errors (with the bias across studies being centred on zero) (Ades et al.,
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2005; Welton et al., 2015).
Although this common approach was followed when parameterising the
model developed in Chapter 4, it is worth noting that alternative methods
have been suggested to characterise decision uncertainty stemming from vari-
ation in intervention effect. Importantly, this source of decision uncertainty
should be distinguished from parameter uncertainty as it cannot be reduced
by further information.
In the case where the target setting for the decision is assumed to be similar
to the ones in the studies included in the meta-analysis. Ades et al. (2005),
suggested to rely on the predictive distribution of the intervention effect in a
new study. Whilst the predictive distribution will be centred on the mean of
the random effect distribution (i.e. RE pooled estimate), its variance will be
larger as it accounts for uncertainty in parameters (D and τ 2), as well as in
study setting (Welton et al., 2015), namely:
dpredicted ∼ N(D, τ 2) (6.5)
with D being the true underlying effect and τ 2 the between-study variance in
treatment effect.
Alternatively, if the decision target setting is expected to be made up of all
the various target settings of the different studies included in the meta-analysis,
it may be argued that there is not a single effect size but a distribution of
effect sizes. In this case, quantification of the net benefit of intervention would
ideally require to take the expectation of net benefit over the entire random
effect distribution of intervention effect (Ades et al., 2005; Welton et al., 2015).
6.3.2 Checking for potential sources of bias
Publication bias
Before embarking on the meta-analysis, the potential existence of a publi-
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cation bias, which arises when studies reporting non-significant results are less
likely to be published, was assessed. The main consequence of publication bias
in meta-analysis is to produce an over-estimate of the pooled estimate and/or
a too-narrowed confidence interval (Sterne et al., 2008).
The presence of a publication bias seems a-priori unlikely for epidemiolog-
ical studies of air pollution, as both the absence or presence of health effects
from exposure to fine particulate is policy-relevant. Nevertheless, a quick vi-
sual check for bias was performed by creating funnel plots. The latter are
scatter plots of studies’ effect estimates against their precision (i.e. standard
error) on a reversed scale, such that the most accurate estimates are located
at the top of the graph whereas the least accurate ones spread more widely at
the bottom of the graph.
Funnel plots were created for the studies pertaining to respectively all-cause
mortality and lung-cancer incidence or mortality, using the freely available
software Revman 5.2 from the Cochrane Collaboration1. Output results are
provided in Figure 6.2. Since the outcome measure was a hazard ratio, the fun-
nel plots were computed on the log scale, so that effects of the same magnitude
but on different directions are equidistant from unity (Deeks et al., 2008).
In the absence of publication bias, the plots are expected to look like a
symmetrical inverted funnel, with the dotted line at its centre representing
the mean effect estimate. This appears to be the case for studies of all-cause
mortality and lung-cancer incidence or mortality. It should nevertheless be
underlined that the funnel plot is only an informal visual test for publication
bias that may need to be completed by formal statistical tests such as the
Rank correlation test (Sutton et al., 2000). In the present case, this does not
appear necessary, as the symmetry in the funnel plots supports the a-priori
expectation that there is no particular bias affecting the publication of studies
on the association between chronic fine particulate pollution exposure and
mortality.
1http://tech.cochrane.org/revman.
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(a) All-cause mortality.
(b) Lung cancer incidence or mortality.
Figure 6.2: Funnel plots of studies of the association between long-term exposure to PM2.5
and (A) all-cause mortality and (B) lung-cancer incidence or mortality.
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Small-study bias
The presence of small-study bias, which arises when effect size estimates
from small studies are systematically different from the ones of larger studies
(Deeks et al., 2008), was also investigated. Small-study bias is especially prob-
lematic when using the RE model, which puts more weight on small studies
than the FE model in order to characterise the distribution of effects. Ta-
ble 6.2, however, indicates that findings based on small or medium-size study
populations are clearly not systematically different than results from larger
cohorts and small-study bias can therefore be ruled out.
6.3.3 All-cause mortality: results
Main results
Results were obtained using the software Revman 5.2. from the Cochrane
Collaboration. A forest plot in Figure 6.3 summarises meta-analysis results
from the pooling of effect estimates provided by the 15 studies identified as
relevant (see Table 6.2 for further description). In a forest plot, each study
point estimate is marked by a square that is proportional in size to the weight
given to the study, whereas confidence intervals are represented by horizontal
lines. The pooled result is represented by a diamond shape that is centred on
the value of the pooled estimate with the width of the diamond depicting the
95% confidence interval.
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Figure 6.3: Meta-analysis of the association between long-term exposure to PM2.5 and all-
cause mortality
(Random effect model - hazard ratio per 10 µg/m3).
The random-effect pooled estimate is 1.07 with a 95% confidence interval:
1.05 - 1.10. The latter appears uncentered solely due to figures rounding
(figures with more decimals are 1.0713 (1.0473 - 1.0958)). As indicated by its
95% confidence interval, the pooled estimate is statistical significant. This is
corroborated by the very small p-value associated to the Z-test for the presence
of an overall effect, where the Z-statistic is defined as:
Z =
θ¯
SE(θ¯)
and follows a normal distribution under the null hypothesis.
A visual inspection of the forest plot shows the absence of confidence interval
overlap between the Health Professional and Nurses’ Health studies. This
suggests the presence of between study heterogeneity and is confirmed by the
value of the chi-square (χ2) statistic. The χ2 statistic represents the total
variance: it is the weighted sum of the square deviations of each study’s effect
estimates from the pooled estimate, weighted by the inverse of each study
variance. Using similar notations to section 6.3.1, the expression for the χ2
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statistic is:
χ2 =
k∑
i=1
wi(θi − θ¯)2
Under the null hypothesis of no study heterogeneity, which is equivalent to
assuming that each k study estimated the same underlying effect, the statistic
should follow the χ2 distribution with (k-1) degree of freedom. As indicated
by the very small p-value in Figure 6.3, the null hypothesis of no study het-
erogeneity is rejected. This test is however, known to have too much power in
the presence of many studies and alternatively, too little power when only a
few studies are pooled.
A simpler way to assess the presence of heterogeneity is to compare the
value of the χ2 statistic with its degrees of freedom, which represent the ex-
pected value of the χ2 statistic if the only source of variance were within-study
variation (Borenstein et al., 2009). In the present case, the χ2-statistic equals
33, which is clearly much higher than its degrees of freedom (df) equal to
14. This “excess variance” (χ2 − df) is due to between-study variation, i.e.
heterogeneity.
Even with strict inclusion criteria, some level of study heterogeneity appears
inevitable. As a result, it has often been argued that the focus of interest should
not be on the presence of heterogeneity or not but on how much heterogeneity
there is (Higgins et al., 2003). This can be assessed by scaling the “excess
variance” by the total variance, which is referred to as the I2 statistic:
I2 = max[(
χ2 − df
χ2
)100%, 0]
In the present case, I2 equals 58%. This means that heterogeneity between-
studies explains about 58% of the variability in individual effect estimates,
where the rest is the result of sampling error. Whilst there are no clear-cut
guideline on how to interpret the value of the I2-statistic, a 58% value may
be interpreted as moderate heterogeneity between studies (Higgins & Green,
2011).
Finally, it is worth noting that the computation of τ 2, i.e. the between-
studies variance, and the I2-statistic are related. However, while τ 2 is also
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based on the “excess variance” (χ2 − df), it not scaled by the total variance
but by a factor that is a function of within-studies variance. In the present
case, despite positive excess variance, the value of τ 2 appears very small. The
reason is that given the level of inaccuracy in a number of studies i.e. sampling
error, one would anyway expect the effect size to vary across studies. In other
words the variance between studies appears to be essentially explained by the
variance within studies (Borenstein et al., 2009).
Sub-group analysis
As there were too few gender-specific results (5 in total) to perform a sub-
group analysis stratified by gender, alternatively effect estimates of studies
based on respectively: (i) both genders or males only and (ii) both genders or
females only were pooled separately. Results are presented in Appendix E. The
three males studies (ASHMOG, Health Professional and US truckers cohorts,
see Table 6.2 ) only account for a combined 12% of the total weight assigned to
studies pertaining to both genders or males. Similarly, the two females studies
(California teachers and Nurses’ Health cohorts, see Table 6.2 ) only account
for a combined 9% of the total weight assigned to studies pertaining to both
genders or females. As a consequence, the pooled estimate obtained for each
subgroup is equal to the one computed by pooling all 15 available estimates.
Sensitivity analysis
Whilst the presence of moderate study heterogeneity as indicated by the
test statistics supports the choice of the random effect model, analysis under
a fixed-effect model was run, in order to assess the impact of a change of
statistical modelling assumption on the pooled estimate. Results are presented
in Figure 6.4a. The weight assigned to the Rome cohort increased from 18.5%
under the RE model to about 70% under the FE model. As a result, the FE-
pooled risk estimate is extensively drawn towards the effect size estimated in
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the Rome study and equal 1.05 with 95% CI: 1.04 - 1.06. Ignoring between-
studies heterogeneity would therefore misleadingly suggests a much greater
confidence in the precision of the mean of the distribution of effects.
Secondly, although positive residual confounding by smoking in the studies
which did not directly control for this risk factor at individual-level seems
unlikely (see section 2.3.1.), a sensitivity analysis was run (RE model) by
excluding the studies which adjusted for lifestyle solely via socio-economic
status. This led to the exclusion of results from three studies: Rome, Canada
and US Truckers cohorts (see Table 6.2 ). Results are shown in Figure 6.4b.
Whilst the pooled estimate remains the same, its confidence interval is wider
since the Rome and Canada cohorts, excluded in this sensitivity run, provide
rather precise estimates of effect.
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(a) Results under fixed-effect model.
(b) Excluding studies with no direct adjustment for smoking (RE model).
Figure 6.4: Sensitivity-analysis for meta-analysis results for all-cause-mortality (hazard ratio
per 10 µg/m3).
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6.3.4 Lung-cancer incidence or mortality: results
Main results
Although most of the effect size estimates for lung cancer mortality were
drawn from the same cohorts that provided estimates for all-cause mortality,
they have much wider confidence intervals than estimates for all-cause mortal-
ity. This stems from the fact that statistical power is not solely determined by
sample size but also by the number of participants experiencing the event of
interest (Higgins & Green, 2011). In each cohort, counts of lung cancer deaths
were obviously smaller than counts of total deaths, hence the lower precision
in effect estimation. Similarly, although the only risk estimate for lung cancer
incidence was based on a meta-analysis of results from 14 cohorts in Europe
(ESCAPE study), its standard error is nevertheless very large (95% CI: 0.92 -
2.13).
Meta-analysis results are presented in Figure 6.5. Pooling of estimates from
the 13 studies identified as relevant yielded a RE-pooled estimate of 1.13 with
95% CI: 1.07 - 1.20, which is statistically significant. It is worth noting that
this estimate is of greater magnitude than the pooled estimate for all-cause
mortality (1.07, 95%CI: 1.05 - 1.10), though the incertitude about the centre
of the distribution of effects is much greater. Between-studies heterogeneity is
smaller than for studies of all-cause mortality (I2 equal to 34%) but remain
moderate, thus confirming the adequacy of the random effect model.
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Figure 6.5: Meta-analysis of the association between long-term exposure to PM2.5 and lung-
cancer incidence or mortality.
(Random effect model - hazard ratio per 10 µg/m3).
Sensitivity analysis
Two sensitivity analyses were performed. The first sensitivity run consisted
in excluding studies without direct adjustment for smoking, as was previously
done for all-cause mortality. This resulted in the exclusion of two studies:
Rome and US truckers cohorts, which led to an increase in the pooled estimate
to 1.17 with 95% CI: 1.11-1.23 (see Figure 6.6a).
The second sensitivity run consisted in using the risk estimate from the
ACS national study (full cohort) that was estimated based on PM exposure
for the period 1979-1983, as opposed to the period 1999-2000. This sensitivity
run was justified by the fact that the weight assigned to this study in main
analysis is large (21%, see Figure 6.5). Since the excess risk of lung cancer
mortality estimated based on the oldest period of PM exposure is lower than
the one estimated based on the most recent exposure data, its use would yield
a slightly lower pooled estimate: 1.11 with 95% CI: 1.06-1.17 (see Figure 6.6b).
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(a) Excluding studies with no direct adjustment for smoking.
(b) Using ACS national (full cohort) risk estimate based on 1979-1983 years of PM2.5 exposure.
Figure 6.6: Sensitivity-analysis for meta-analysis results for lung-cancer (Random effect
model - Pooled hazard ratio per 10 µg/m3).
* Years of PM2.5 exposure: 1979-1983.
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6.4 Discusssion
6.4.1 Main findings
A total of 18 studies, published from 1950 until April 2014, have been
identified as relevant for informing the association between chronic exposure
to PM2.5 and respectively all-cause mortality and lung cancer incidence or
mortality. Mean effect estimates and 95% confidence intervals obtained by
pooling study-specific results using the random-effect model are respectively:
1.07 (1.05 - 1.10) for all-cause mortality and 1.13 (1.07 -1.20) for lung cancer
incidence or mortality.
Moderate heterogeneity was found between studies, which justifies the use of
the random effect model. Several sources of between-studies heterogeneity were
identified including: (i) varying approaches to spatio-temporal assessment and
assignment of exposure ; (ii) differences in study-population age, gender and
socio-economic status mix and (ii) expected differences in particulates’ chemi-
cal composition and toxicity. A meta-regression of the pooled estimate against
study characteristics was however, not performed for the following two reasons.
First, performing these analyses requires a sufficient number of studies, with
a suggested minimum of ten estimates per characteristic modelled (Higgins &
Green, 2011), which were not available from the present pool of studies. Sec-
ond, since studies are not randomised across potential effect-modifiers, their
findings are problematic to interpret (Deeks et al., 2008).
6.4.2 Comparison with work published most recently
The present results, which take into account the most recent evidence pub-
lished until end of April 2014 are consistent with those previously obtained
by Chen et al. (2008) for the period 1950-2007. The authors reported random
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effect-pooled estimates of respectively 1.06 (1.03 - 1.10) for all-cause mortality
and 1.15 (1.06 - 1.24) for lung cancer incidence or mortality.
Since the start and completion of this piece of work, two meta-analyses on
the association between PM2.5 exposure and respectively all-cause mortality
(Hoek et al., 2013) and lung cancer incidence or mortality (Hamra et al., 2014)
were published (in May 2013 and September 2014 respectively).
Hoek et al. (2013) reported a random effect-pooled estimate of 1.06 (1.04 -
1.08) for all cause mortality, which is very similar to the present findings. The
authors however, only included studies published until January 2013 and as a
consequence, did not encompass results from three cohort studies: ESCAPE,
English cohort and ACS California sub-cohort (see Table 6.2 ). In addition, the
authors encompassed in their scope studies based on elderly populations (Zeger
et al., 2008; Enstrom, 2005), which may further explain the slight difference
with the present result.
Hamra et al. (2014) reported a random effect-pooled estimate of 1.09 (1.04
- 1.14) for lung cancer incidence or mortality, which is smaller than the present
pooled estimate. After careful analysis, it appeared the difference in estimates
was driven by two factors. First, Hamra et al. (2014) used the risk estimate
from the American Cancer Society (ACS) national full cohort based on PM
exposure for the years 1979-1982. By contrast, the present analysis relied on
results based on the 1999-2000 exposure period, which included 42% more
study participants (see section 6.2.3). Unfortunately, Hamra et al. (2014) did
not justify their choice of exposure period. Sensitivity analysis using the risk
estimate based on the 1979-1982 period of PM exposure yielded a slightly lower
pooled estimate (1.11 - 95% CI: 1.06 - 1.17, see section 6.3.4), which is more
in line with Hamra et al. (2014)’s findings.
Second, Hamra et al. (2014) included a result from a cohort study in China
(Cao et al., 2011). This study was excluded from the pool of relevant studies
in the present analysis as it did not provide a risk estimate for particulate air
pollution exposure but only for total suspended particle (TSP). While Hamra
et al. (2014) had similar inclusion criteria and clearly stated that they excluded
studies which did not provide quantitative estimates for particulate matter,
they apparently made an exception for this study - without justification - and
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converted the risk estimate for TSP to a risk estimate of PM2.5 applying a 3:1
ratio. This led to an estimate of 1.07 (95% CI: 1.0 - 1.07). Due to a relatively
small standard error, the weight attributed to the Chinese study in Hamra
et al. (2014)’s meta-analysis was high (21%).
In order to assess the impact of these two factors on the pooled risk estimate
for lung cancer mortality or incidence, a third sensitivity scenario was run
by (i) using the risk estimate from the ACS national full cohort based on
PM exposure for the years 1979-1982 and (ii) adding results from Cao et al.
(2011)’s study. Results are presented in Figure 6.7. In this scenario, the pooled
estimate and its 95% CI exactly match with Hamra et al. (2014)’s findings.
Figure 6.7: Sensitivity-analysis for meta-analysis results for lung-cancer using Hamra et al.
(2014)’s study scope.
(Random effect model - hazard ratio per 10 µg/m3).
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6.5 Conclusion
A systematic review and two meta-analyses of the association between long-
term exposure to fine particulate matter (PM2.5) and respectively all-cause
mortality and lung cancer incidence or mortality were performed. These quan-
titative analyses update past work done by Chen et al. (2008), by including
all the relevant evidence published over the last seven years. These results
are important for public health practitioners and policy-makers who need to
assess air pollution control interventions based on all existing evidence.
Present results are consistent with two meta-analyses published after com-
pletion of this work: Hoek et al. (2013) and Hamra et al. (2014). For lung
cancer incidence or mortality, the difference between the presently obtained
pooled estimate and Hamra et al. (2014)’s results appears to be driven by two
unjustified choices made by the authors and does not put into question the
quality of the present work. Nevertheless, since Hamra et al. (2014) results
were published, they will be used to parameterise the model built in Chapter
4. By contrast, the presently obtained pooled estimate for all-cause mortality,
which closely matches with Hoek et al. (2013)’ estimate, but includes most
up to date evidence and excludes studies on elderly subjects, will be used to
parameterise the model of the health effects of pollution exposure.
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Chapter 7
QALY gain, health care
resources impact and
cost-effectiveness of air pollution
control in England and London
7.1 Introduction
Chapter 4 developed a Markov model of the health effects of air pollution
exposure, in order to fully capture air pollution’s joint effect on quality and
length of life as well as to assess the total health care budget impact of a
reduction in air pollution. The model required a number of parameters, a
subset of which were estimated in Chapters 5 and 6.
This chapter presents the results from the application of the developed
model to the UK case study detailed in Chapter 4. The intervention under-
pinning the case study, hereafter referred to as “the intervention”, consists of
an immediate and sustained 1µg/m3 decrease in population-weighted mean
PM2.5 concentrations in England and Wales and London. This is expected
to represent a decrease by respectively 9% and 7% in current average concen-
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trations. Section 2 provides the total expected health gain and health care
cost impact associated with the intervention, as well as the distribution of
outcomes by age and gender. Section 3 focuses on uncertainty surrounding
outcomes and also evaluates results’ sensitivity to the choice of discount rate
and to dynamics in risk reduction. Section 4 compares the developed Markov
model with the simple life-table approach currently used in health impact as-
sessment (HIA) and contrasts estimates of un-discounted life expectancy gain
with results from past HIAs. Based on case study results, section 5 evaluates
the cost-effectiveness of reducing air pollution in London, whether such an
intervention would be funded by the NHS or through general taxation.
7.2 Total mean health gain, health care cost impact and
associated monetary benefit
7.2.1 Mean outcomes across each target population
Reducing mean PM2.5 concentrations by 1µg/m
3 is expected to generate
more than 60,000 QALYs in London and 540,000 QALYs in England and
Wales, among adult individuals currently aged 40 and above over their re-
maining lifetime, discounting at 3.5% p.a.
The total (i.e. net) health care resource impact of the intervention, which
corresponds to the health care costs from extending the lives of individuals
with a chronic cardio-respiratory condition, net of the health care savings
from a reduction in cases of CHD, COPD and lung cancer, is slightly cost
increasing. It accounts for respectively £24 million in London and £263 million
in England and Wales. It should be reminded that extending the lives of
“healthy” individuals (i.e. individuals without COPD, CHD or lung cancer)
is assumed not to generate any health care cost and that the intervention
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is not expected to impact upon the life expectancy of individuals with lung
cancer (see sections 4.4.3 and 4.5.5 of Chapter 4). Total QALY gain and health
care cost impact under deterministic analysis were slightly lower than under
probabilistic analysis by respectively 1.2% and 2.3%.
7.2.2 Total expected monetary benefit
Valuing QALY gain
As discussed in Chapter 2, the approach to monetizing health gain should
be determined by who will bear the cost of the intervention. If the inter-
vention of air pollution control is funded by the NHS, which has a fixed and
fully allocated budget, the money value of a QALY should represent the cost-
effectiveness of the services to be displaced by the investment (Claxton et al.,
2007). Whilst NICE officially uses a value of £20,000 to £30,000 to assess the
cost-effectiveness of health care technologies (NICE, 2013), recent efforts to
empirically estimate the shadow price of the NHS budget constraint suggest
£13,000 as best estimate (Claxton et al., 2013).
However, if air pollution control is expected to be funded by raising new tax
revenue, it will displace private consumption, as opposed to health care services
from the NHS. In this context, health gain should be monetized based on the
consumption value of a QALY (Ryen & Svensson, 2014). The Department of
Health in the UK recommends to use a willingness to pay (WTP) value of a
QALY of £60,000 in 2009 prices (Glover & Henderson, 2010). Additionally,
Ryen & Svensson (2014)’s recent global review of WTP values for a QALY
found a trimmed mean estimate of e 74,159 (2010 prices), with most estimates
coming from European and US studies. The authors, however, underlined
that estimates vary widely due to differences in methodology (i.e. revealed
vs. elicited method) and perspectives (societal vs. individual) but also, due
to non-proportionality in WTP with regards to the change in QALYs and non
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equivalent valuation of quality and length of life in practice.
Whilst the sensitivity of cost-effectiveness results to the money value of
health will be evaluated in section 7.5, the following values will be used to
monetize QALY impacts:
(i) From the “NHS perspective”, i.e. if the NHS were paying for the interven-
tion, the empirically-based value of £13,000 (Claxton et al., 2013) will be used
to monetize a QALY.
(ii) From the “private consumption perspective”, i.e. if the intervention were
funded by raising taxes, the value of £65,000/QALY will be used. This
value approximately corresponds to the two above cited values of £60,000
and e 74,159 (converted to GBP at the average exchange rate for 2010), when
inflated to 2013 prices.
Valuing health care resource impacts
Health care costs (savings) to the NHS can be expressed as QALY losses
(gains) using the estimate of the shadow price of the NHS budget constraint,
presently assumed to equal £13,000/QALY. From the private consumption
perspective, these “QALY equivalent” will be monetized using the consump-
tion value of a QALY (i.e. £65,000/QALY). This implies that NHS resources
are presently assumed to be worth five times (65/13) their amount of taxes.
The sum of QALY gain and QALY loss (gain) equivalent from health care
resource impacts will hereafter be referred to as net QALY gain. Net QALY
gain results will only be presented for the total target population, as allocating
the consequences of the intervention’s health care cost impact between age-
and gender-stratified population subgroups is outside the scope of the present
work.
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Expected monetary benefit
Table 7.1 provides outcomes summary results, for each target population
and from both payers’ perspectives. Based on an estimate of £13,00/QALY
as the shadow price of the NHS budget constraint, the QALY loss equiva-
lent resulting from net health care costs accounts for solely 2.8% and 3.7%
of the health benefits in respectively London and England and Wales. As
the consumption value of health is five times higher than the estimated NHS
expenditure required to deliver one QALY, and the net health care resource
impact is small, the total monetary benefit of the intervention to private pay-
ers is about five times higher than to the NHS. For London for instance, total
benefits are valued £4 billion from the private consumption perspective, as
opposed to £800 million from the NHS perspective.
Total gain (a)
London England & Wales
Target population size (b) 3,215,975 27,273,400
QALY gain 63,293 541,217
Net health care costs (c) £24 million £263 million
QALY loss equivalent (d) 1,825 20,219
Net QALY gain 61,467 520,998
Total monetary benefit
NHS perspective (d)
£799 million £6,773 million
Total monetary benefit
Private consumption perspective (e)
£3,995 million £33,865 million
Table 7.1: Total net QALY gain and associated monetary benefit of reducing ambient PM2.5
concentrations by 1µg/m3.
(a) 60-year time horizon, applying a discount rate of 3.5 % p.a.
(b) Currently alive adults aged 40 to 90 years old.
(c) Health care costs associated with extending the lives of individuals with a chronic cardio-respiratory
condition net of savings from reduced cases of CHD, COPD and lung cancer.
(d) Using a value of £13,000/QALY as shadow price of the NHS’ budget constraint.
(e) Using a value of £65,000/QALY as consumption value of a QALY.
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7.2.3 Impact distribution by age and gender
At individual level
Figure 7.1a depicts the expected quality-adjusted life day (QALD) gain
associated with the intervention, for each age and gender-stratified individual
of the target population over his/her remaining lifetime. Whilst health gain is
cumulative over a lifetime, the main beneficiaries of the intervention are not
the youngest individuals but those aged around 65 years old. This result is
mainly a consequence of discounting since, as the risk of experiencing adverse
health events increases with age, young individuals are expected to benefit
from the intervention much later in the future than older individuals. The
sensitivity of the age-distribution of health gain to the choice of discounting
rate will be investigated in section 7.3.2.
Figure 7.1a also shows the presence of a substantial gender-gap in health
gain, in particular among young age groups, with the average QALD gain
enjoyed by 40-year old men being nearly a third (28%) higher than the gain
accruing to their female counterparts. This gap reflects gender-differences in
baseline risks of adverse health events, whereby men aged between 40 to 70
in the UK are on average twice more likely to develop CHD and 60% more
likely to die from all causes than women. By having a greater baseline risk of
adverse health events than their female counterparts, young men are expected
to benefit more - in absolute terms - than young women from a given decrease in
risk. Whilst gender-differences in health risks do persist at older ages, there are
smaller. Additionally, gender-differences in baseline health risks have another
smaller opposite effect: by enjoying a greater life expectancy than men, women
are expected to enjoy the intervention’s benefit for a slightly longer time period
than men. Consequently, in old age-groups, the gender-gap in health gain
becomes relatively small.
Figure 7.1b represents the expected health care cost impact per individual
(gender average) from a reduction in both morbidity and premature mortality
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associated with the intervention. It shows that for individuals aged 53 and
above, on average, the health care savings from reducing their lifetime risk of
developing COPD, CHD and lung cancer are more than compensated by the
health care costs associated with extending the lives of those with a chronic
cardiac or respiratory condition.
As will be discussed in section 7.4.2, this finding reflects the expectation,
based on current evidence (see section 4.4.3 of Chapter 4), that individuals with
COPD or CHD - once they reach a given age and/or disease severity level -
are more susceptible to air pollution exposure (i.e. suffer disproportionately)
than individuals of the general population. Consequently, under pollution
decrement, these individuals who are costly to the health care system, are
expected to enjoy a greater lifespan extension (as a proportion of their baseline
life expectancy) than “healthy” individuals.
At population level
Figure 7.2 and Figure 7.3 represent the age- and gender-specific distribu-
tions of respectively the expected QALY gain and the total net health care
cost impact of the intervention for each target population.
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Figure 7.1: Intervention’s average quality-adjusted life day gain (A) and health care cost
impact (B) per person, stratified by age and gender.
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(a) London
(b) England and Wales
Figure 7.2: Distribution of QALY gain by age and gender.
192
(a) London
(b) England and Wales
Figure 7.3: Distribution of total net health care cost impact by age and gender.
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7.3 Uncertainty analysis
7.3.1 Outcomes distributions
Handling uncertainty in non statistically significant risk estimates
As was indicated in Table 4.1 in Chapter 4, out of the seven risk estimates
used to parameterise the “intervention-effect”, three are not statistically signif-
icant at 5% significance level since they include the value of 1, i.e. “no effect”,
in their 95% confidence interval. These three risk estimates are : ORDev.COPD;
HRDev.CHD and HRDeathOAC|H , which were used to derive respectively RREa,
RREb and RREg.
When carrying out Monte Carlo simulations, a random draw of a risk es-
timate value below 1, implies that air pollution reduction will increase the
risk of adverse event. There is, however, general consensus that air pollution
has deleterious effects on health and that reducing it cannot harm population
health (Holland, 2014). On these grounds, recently released European guide-
lines for uncertainty analysis in HIA of interventions of air pollution reduction
(HRAPIE group) recommend to adopt: “a range of +/-100% with a uniform
distribution” for non statistically significant risk estimates (Holland, 2014) (pp
42).
The guidelines have the advantage of getting rid of the improbable possibil-
ity that reducing air pollution may damage public health. However, they are
underpinned by the assumption that the mean effect size is true and that the
variance was wrongly estimated, whilst no evidence supports this. Therefore,
as will be further discussed in section 7.5, they potentially misleadingly re-
duce decision uncertainty. An alternative approach was therefore considered.
It consists in truncating only the left-tail of the original distributions of non
statistically significant risk estimates by assigning a value of 1 to randomly
drawn values below 1. Truncating only the left-tail of risk estimates’ distribu-
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tions, as opposed to truncating both tails as recommended by the guidelines,
will to some extent shift risk estimates mean values and the mean of outcome
measures to the right. On the other hand, this approach has the advantage of
capturing all the information concerning the possible non implausible values
that risk estimates can take.
Another alternative may be to simply get rid of all three non statistically
significant risk estimates. However, the lack of statistical significance does not
necessarily equate with true absence of effects and solely means that we failed
to demonstrate effect for a given - arbitrary - significance level. In light of
the overall body of evidence of positive association between air pollution and
adverse effects on the cardio-respiratory system described in Chapters 2 and
4, ignoring existing evidence based on arbitrary rules of inference (Claxton,
1999) does not appear appropriate.
Table 7.2 summarises the three modelling approaches used to handle uncer-
tainty in the three non statistically significant risk estimates. It should be un-
derlined that A1 (no truncation) is the base case approach to computing mean
estimates. Figure 7.4 compares the distributions of the three risk estimates
obtained under each approach. As the magnitude of risk estimates is relatively
small, for ease of comparison, results are provided for 4PM2.5 = +10µg/m3,
i.e. before rescaling as RRE for 4PM2.5 = −1µg/m3.
Since A2 (guidelines) consists in truncating both tails of the original distri-
butions of non statistically significant risk estimates, the distributions obtained
under A2 remain centred around original mean values, but have a much smaller
standard deviation. Under A3, truncating the left-tail of the original distribu-
tions of HRDev.CHD and HRDeathOAC|H only slightly shifted their mean value.
By contrast, as the left-tail of the original distribution of ORDev.COPD reached
quite below 1, the mean of the obtained distribution for this risk estimate
noticeably shifted from 1.12 to 1.24.
Figure 7.4 clearly shows that by assigning a value of 1 to any draws of values
below 1, as opposed to imposing 1 and “mean effect + 100%” as respectively
the minimum and maximum values that risk estimates can take, A3 allows
for a much larger possibility of no intervention effect than A2 with regards to
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health events “Dev. COPD”, “Dev. CHD” and “Death from AOC”1.
1AOC stands for All Other Causes than COPD, CHD and lung cancer.
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Modelling
approach
Description
A1 (a) Fit a log-normal distribution around original mean and standard error.
Also referred to as: “No truncation”. It is the base case approach used for
computing mean results.
A2 Fit a uniform distribution to a range of values bounded by mean +/-100%.
Also referred to as: “Guidelines”.
A3
Fit a log-normal distribution around original mean and standard error but
assign the value of 1 to random draws of values below 1.
Also referred to as: “Left-tail truncation”.
Table 7.2: Modelling approaches used to assess uncertainty in non statistically significant
risk estimates.
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Figure 7.4: Distribution of risk estimates obtained under each modelling approach
(4PM2.5 = +10µg/m3).
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Obtained distributions of outcomes
Figure 7.5 represents for each target population the distribution of net
QALY gain obtained from Monte Carlo simulations, under each approach to
handling uncertainty in non statistically significant risk estimates as defined
in Table 7.2. As expected, the distribution of net QALY gain is the widest
under A1 and the narrowest under A2.
Under A1, since the original distributions of non statistically significant risk
estimates were left unmodified, the distribution of net QALY gain has a tail
of negative values, which suggests that there is a non-negligible probability
(about 10%) that reducing particulate air pollution could harm health.
As expected, mean outcomes under A2 and A1 are equal. By contrast, mean
net QALY gain under A3 is about 25% greater (27.2% for London; 26.5% for
England and Wales) than under A1 or A2. It is worth noting that about a
quarter of the difference in net QALY gain between A3 and A1 or A2 is due
to health care cost impacts. Indeed, under A3, on average the intervention
is associated with net health care savings (£33 million for London and £195
million for England and Wales), as opposed to net health care costs under A1
or A2 (£24 million for London and £263 million for England and Wales). This
reflects the fact that under A3, the intervention’s capacity to reduce COPD
incidence and thus, to reduce the health care cost burden of the disease, is
expected to be stronger than under A1 or A2 (see Figure 7.4).
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Figure 7.5: Distribution of net QALY gain by modelling approach.
A1: No truncation; A2: Guidelines; A3: Left-tail truncation.
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7.3.2 Sensitivity analyses - cessation lag and discount rate
Table 7.3 and Table 7.4 report results of the analysis of the sensitivity
of mean outcomes to dynamics in risk reduction, known as cessation lag, and
discounting. Sensitivity scenarios were described in Table 4.4. of Chapter 4 and
are briefly restated below. Mean estimates were obtained based on approach
A1 (no truncation). Results are expressed in percentage change against base
case results using net QALY gain as summary metric. The small difference in
results between the two target populations essentially reflects their different
age and gender structures, as previously underlined by Figures 7.2 and 7.3.
Cessation lag
The two scenarios pertaining to the dynamics of risk reduction assessed the
effect of respectively:
(i) no cessation lag (No CL), where the decrease in risk of all adverse health
events under intervention applies fully from time 0;
(ii) a mixed lag (Mixed CL), resulting from a mixture of the US EPA’s 20-year
distributed cessation lag with a lag specific to lung cancer, for which in light
of evidence on smoking cessation, the decrease in risk is expected to be take
place gradually over 40 years;
These two scenarios were assessed against the base case scenario which applies
the US EPA’s 20-year distributed lag to the reduction in all risks of adverse
health events.
In order to assess the influence of the cessation lag independently from
the discounting effect, differences in un-discounted life years gains were also
reported in Table 7.3. Net QALY gain in the “No CL” scenario is 16% larger
than in the base case scenario. By contrast, the difference in outcome between
the base case and the “Mixed CL” scenario is small (3% difference), owing to
the low baseline risk of developing lung cancer, relative to developing COPD
or CHD. As expected, discounting amplifies results’ sensitivity to the structure
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of the cessation lag, whereby for each scenario comparison, the difference in
net QALY gain is greater than the difference in un-discounted life year gain.
Figure 7.6 shows the impact of the cessation lag structure on the average
QALD gain per person (gender-average) for each age group. The shorter the
remaining life expectancy of individuals, the more their health gain is impacted
by the cessation lag structure. Indeed, in the absence of a cessation lag, the
average QALD gain of a 40-year old person would be 10% greater than in the
base case scenario, whereas the average QALD gain of a 70- and a 80-year old
person would be respectively 30% and 50% higher.
The comparison of QALD gain between the base case and “Mixed CL”
scenarios provides a more subtle picture. Whilst the difference in health gain
between the two scenarios initially grows with age, it slowly decreases as from
age 70 since after this age, the risks of other adverse events are increasingly
more prominent than the risk of lung cancer incidence. In other words, dy-
namics in lung cancer risk reduction have progressively less influence on the
overall health gain among older age groups.
Scenarios
No cessation lag
“Mixed”
cessation lag
London
Net QALY gain + 15.9 % - 3.1%
LY gain + 9.0% - 2.3%
England Net QALY gain + 17.3 % - 3.2%
and Wales LY gain + 10.2% - 2.3%
Table 7.3: Sensitivity of results to cessation lag
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Figure 7.6: Impact of cessation lag structure on QALD gain per person
Discount rate
Two alternative scenarios of discounting based on recommendations from
the UK treasury (Lowe, 2008) were used as an alternative to the base scenario,
which applies a 3.5% discount rate p.a. In the “Staged discounting 1” scenario,
a discount rate of 3.5% p.a. was applied in the first 30 years and a lower rate
of 3% p.a. was applied from year 31 to 60. In the “Staged discounting 2”
scenario, which excludes the element of pure social time preference, a discount
rate of 3 % p.a. was applied in the first 30 years and a rate of 2.57% p.a. was
applied from year 31 to 60.
Decreasing the discount rate to 3% p.a. after the first 30 years would lead
to an increase in total net QALY gain by about 7%, whereas decreasing the
discount rate as from year 1 in “Staged discounting 2” would boost net QALY
gain by about 20%. Results for London are slightly more sensitive to the choice
of discount rate than results for England and Wales as the London population
is slightly younger.
Figure 7.7 shows the impact of the choice of discounting structure on the
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average QALD gain per person for each age group. The younger individuals
are clearly the greatest beneficiaries of a lower rate of discounting. In the
“Staged discounting 2” scenario for instance, individuals aged 40 would gain
35% more QALD than in the base case scenario, whereas individuals aged 60
would only benefit from 15% more health gain. Since the “Staged discounting
1” scenario consists in decreasing the discount rate after 30 years only, it would
impact solely upon the health gain accruing to adults currently aged below 65.
Scenarios
Staged discount-
ing 1
Staged discount-
ing 2
London Net QALY gain + 6.9 % + 19.8%
England and
Wales
Net QALY gain + 6.1% + 18.3%
Table 7.4: Sensitivity of results to the choice of discount rate.
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7.4 Comparative analysis
7.4.1 Comparison of methods: life-table vs. Markov modelling
As mentioned in Chapter 4 section 4.1, an alternative methodology used in
past QALY analyses of air pollution control interventions consists in applying
quality of life adjustments to life years gains computed using life-tables. In
addition to the issue pertaining to the correct choice of HRQoL weights, it
was argued that this approach would underestimate interventions’ total QALY
gain by failing to capture the quality of life gain associated with a reduction
in chronic morbidity.
It was also argued that, by ignoring health-related differential susceptibility
to air pollution exposure which drives the distribution of impacts among pop-
ulation subgroups stratified by health status, such a simplistic approach would
not support an accurate estimation of QALY gains. On these grounds, it is of
particular interest to compare the present QALY results, with estimates that
would be obtained using the life-table approach.
The life-table method was described in Chapter 3. It consists in comparing
survival curves, calculated from annual probabilities of death cumulated over
time, under a pollution change as opposed to “business as usual”. The area
between the two curves represents the average life expectancy impact associ-
ated with air pollution decrement (increment). Since it focuses only on life
expectancy effects, the life-table can be represented as a Markov model with
two health states: “Healthy” and “Dead”.
In order to compare the Markov model developed in Chapter 4 and the life-
table approach, a 2-state model was constructed and parameterised with: (i)
the age and gender-specific probabilities of death from all causes in the general
population of England and Wales (ONS, 2011) and (ii) the risk estimates from
all cause mortality estimated in Chapter 6 (i.e. RREd of Table 4.1). Life-table
analysis based on this 2-state model was applied to the exact same case study
presented in Chapter 4 (i.e. 1µg/m3 decrement in PM2.5 concentrations; US
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EPA cessation lag, 3.5% discount rate), using London as a target population.
Life years gain were then multiplied with age and gender-specific HRQoL
weights for England provided by Kind et al. (1999). It should be underlined
that these weights were elicited from a representative sample who considered
themselves to be healthy. Applying those weights to life years gains computed
from life-table analysis will therefore lead to a greater gain than would be
obtained by using weights for the general population of England, in line with
the underlying prevalence of chronic illnesses.
Since the life-table approach does not take into account health-related dif-
ferential susceptibility, the comparison of QALY estimates generated by this
method against the presently developed Markov model was based on two sce-
narios: (i) base case and (ii) a scenario that ignores health-related differential
susceptibility, hereafter referred to as “No Diff. Susc.” scenario. In addition,
as the life-table method cannot link costs to health outcomes except death,
health care cost impacts were not considered in the present comparison.
The difference in mean QALY estimates for London (modelling approach
A1) between the two methods is presented in Table 7.5 for each scenario.
Markov modelling (MM)
Life-table
Difference
Base case
No Diff.
Susc.
(LT)
LT vs. MM
(Base case)
LT vs. MM
(No Diff.
Susc.)
QALY gain
(London)
63,293 41,457 38,463 -39% -6 %
Table 7.5: Markov modelling vs. life-table approach.
Under the scenario of no differential susceptibility, the two methods pro-
vide relatively similar results. Nevertheless, in line with expectations, even
by applying HRQoL weights that overestimate the true level of quality of life
of the general population (since based on healthy subjects), the QALY gain
estimated by the life-table approach is 6% lower than the one estimated by
the present Markov model. This stems from the fact that, as argued in Chap-
ter 4, the life-table approach does not encompass the quality of life gain from
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reduced morbidity.
The principal finding however, is that health-related differential susceptibil-
ity to air pollution drives the difference in outcomes between the two methods.
When encompassing health-related differential susceptibility (i.e. base case
scenario), the total QALY for London obtained from the presently developed
Markov model is 39% higher than the QALY obtained from life-table analysis.
It may be argued that the present model overestimates effects accruing to
those who do not belong to susceptible population subgroups. This, however,
appears to be unlikely. Indeed, the model is structured such that alive indi-
viduals may have either of the following four health status: (i) with CHD; (ii)
with COPD; (iii) with lung cancer; (iv) healthy, i.e. without any of the three
diseases. In light of the age and disease severity conditions that characterised
the subjects in epidemiological studies informing differential susceptibility, the
only population subgroups expected to suffer disproportionally from particu-
late air pollution (PM) exposure are: (i) individuals with CHD above 75 years
old and (ii) individuals with COPD in stages 3 or 4 aged above 65 years old
(see Chapter 4). This leaves: (i) individuals with CHD aged below 75; (ii)
individuals with COPD in stage 1 or 2 (all ages) or in stages 3 and 4 aged
below 65; (iii) individuals with lung cancer and (iv) “healthy” individuals, as
remaining population subgroups. The first two of these subgroups are conser-
vatively assumed to have the same susceptibility to air pollution as the general
population. For the reasons explained in Chapter 4, no PM-related excess risk
of death was applied to individuals with lung cancer.
Finally, the PM-related excess risk of mortality that was applied to “healthy”
individuals pertains only to causes of death excluding cardio-respiratory and
lung cancer causes. To check for the possibility of effects over-estimation in
individuals of the general population, a sensitivity scenario where “healthy”
individuals were assumed not to suffer from any excess mortality risk due to
PM exposure (i.e. HRDeathAOC|H = 1) was evaluated. This scenario was found
to be associated with a small 4% decrease in net QALY gain, which confirms
that the excess risk of mortality in “healthy” individuals does not drive the
health gains associated with the intervention. It can therefore be concluded
that it is unlikely that the present model overestimates effects.
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Comparative analysis therefore shows that, ignoring the current body of
epidemiological evidence on health-related differential susceptibility to air pol-
lution (Zanobetti et al., 2008; Zanobetti & Schwartz, 2007; Tonne & Wilkin-
son, 2013), as is currently done when using the life-table approach, is expected
to substantially underestimate the total health gain of air pollution control.
Importantly, as will be further discussed in section 7.4.3, this finding is not
relevant only for QALY analysis but also for life expectancy impact analysis
as is traditionally performed in HIA.
Since air pollution not only affects people differently according to their
health status, but also impacts upon the risk on entering health-related sus-
ceptible subgroups, the only possible approach to fully handling health-related
differential susceptibility is via “simultaneous modelling” of impacts as advo-
cated in Chapter 3. This finding therefore further demonstrates the inadequacy
of the “separate” approach to quantification currently used in HIA.
7.4.2 Impact of CHD vs. COPD-related differential susceptibility
In order to identify which of CHD or COPD-related greatly susceptibility to
air pollution exposure drives the QALY gain and health care cost impacts of air
pollution reduction, the scenarios of no CHD-related greater susceptibility and
no COPD-related greater susceptibility were evaluated for London. Results are
presented in Table 7.6, alongside results for the base case and the “No Diff.
Susc.” scenarios.
Table 7.6 shows that CHD- and COPD-related greater pre-disposition to
die prematurely due to PM exposure account for respectively 16% and 19% of
the total QALY gain associated with the intervention in the base case scenario.
It is worth noting that, by driving the distribution of life expectancy gain by
population subgroups stratified by health status and thus, by level of cost to the
health care system, health-related differential susceptibility also substantially
influences the total health care cost impact of the intervention. In particular,
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ignoring COPD-related differential susceptibility would lead to a net health
care saving of £44 million, as opposed to a net health care cost of £24 million
in the base case scenario. If both CHD and COPD-related susceptibility were
ignored, the intervention would be expected to yield a net saving to the NHS
of £55 million.
Therefore, the reduction in QALY gain in the “No Diff. Susc.” scenario (-
34%) is partly compensated by health care resource savings. Overall, health-
related differential susceptibility contributes to a quarter (26%) of the net
QALY gain associated with the intervention in the base case scenario.
Base
case
No
CHD-
related
Susc.
% diff.
No
COPD
related
Susc.
% diff.
No Diff.
Susc
% diff.
(a)
QALY gain 63,293 53,180 -16% 50,856 -19% 41,457 -34%
Total HC cost
impact (in £m)
24 11 -53% -44 - 284% -55 -329%
Net QALY gain 61,467 52,326 -15% 54,211 -12% 45,637 -26%
(a) Percentages do not exactly sum up do your rounding.
Table 7.6: Results’ sensitivity to CHD- and COPD-related differential susceptibility.
7.4.3 Comparison with empirical estimates from past HIAs
Since this work represents the first attempt to measure the QALY impact of
air pollution reduction in a UK setting, there are no relevant comparator from
the empirical literature. By contrast, estimates of un-discounted life year (LY)
gain are amenable to comparison with results from past HIAs of interventions
of air pollution control. This metric as the advantage of being independent
of any assumptions regarding the application of HRQoL weights and of the
choice of discount rate.
The un-discounted life expectancy impact of reducing PM2.5 concentrations
in London was investigated as part of the European-funded Aphekom Project
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(Pascal et al., 2013), as well as in a study commissioned by the Greater Lon-
don Authority and carried out by Miller (2010). Evaluation of the effects of
particulate air pollution on mortality in England and Wales was performed
by the Health Protection Agency and communicated under the Committee
on the Medical Effects of Air Pollutants report (COMEAP, 2010). All three
studies relied on the life-table methodology and used the same risk estimate of
all-cause mortality (HRAC = 1.06 for 4PM2.5 = 10µg/m3 estimated by Pope
III et al. (2002)).
As exemplified by the above cited-studies, there are at least three main ways
of expressing life expectancy impacts in a given target population. “Total LY
gain” depends on the size of the target population and the duration of its
follow-up and therefore, is not adequate for comparing results between studies
based on different target populations or follow-up duration, as is presently the
case. The “average life expectancy gain per person of a target population” has
the main advantage of being independent of the target population size and is
typically computed over a person’s a lifetime. This metric will however, be
influenced by the age structure of the target population whereby the younger
the target population is, the greater the average LY gain per person will be.
Finally, “life expectancy at birth or at a given age” has the advantage of
being independent from both the size and the age-distribution of the target
population.
Table 7.7 compares the mean estimates of life expectancy impacts provided
by the presently developed Markov model (modelling approach A1) with re-
sults from past HIAs using: (i) average life expectancy gain per person of the
target population and (ii) life expectancy at 30 or 40 as metrics. Since all three
HIAs relied on the life-table method, they all ignored health-related differential
susceptibility. Consequently, similarly to section 7.4.1, comparison was based
on the base case and the “No Diff. Susc.” scenarios. When necessary, results
were converted to a 1µg/m3 decrement in PM2.5 concentrations and results’
sensitivity to the use of a cessation lag was taken into account.
This comparative analysis is mainly illustrative since the scope of target
population between the HIAs and the present study is not exactly similar.
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For instance Miller (2010) applied PM-related excess risk of mortality to all
currently alive individuals, i.e. aged 1 to 100 years old, whereas as justified
in Chapter 4, the present analysis focused on adults aged 40 to 90. The
primary objective of this comparative analysis is therefore essentially to assess
whether the direction and magnitude of the difference in results are in line
with expectations. For instance, in light of the above discussion on the impact
of the target population age structure on average gain estimates, the present
results are expected to be lower than the ones from Miller (2010). Similarly,
in the absence of discounting, present estimates of life expectancy gain at age
40 are expected to be slightly lower than estimates of life expectancy gain at
age 30 provided by COMEAP (2010) and Pascal et al. (2013).
Un-discounted life day gain/person for 4PM2.5 = −1µg/m3
Lag
(a)
Past HIA results
Present results
(Base case)
Diff.
Present results
(“No Diff Susc”)
Diff.
Yes
20 (age 30) 32.2 (age 40) 61% 22 (age 40) 10%
Young COMEAP (2010)
(b)
Adults
No
24.2 (age 30) 33.1 (age 40) 37% 22.8 (age 40) -6%
Pascal et al.
(2013) (c)
Average
Yes
19.3 (age 1-100) 25.8 (age 40-90) 33% 16.2 (age 40-90) -16%
London
popula-
tion
Miller (2010) (d)
Table 7.7: Comparison of un-discounted life year gain estimates with results from past HIA
studies.
(a) US EPA 20-year distributed cessation lag (US EPA, 2010).
(b) Whilst results were reported as life expectancy at birth for the 2008 birth cohort, risk estimates of
mortality were only applied as from age 30.
(c) Reported results were 2.5 months gain /person aged 30 for 4PM2.5 = −3.1µg/m3.
(d) Reported results were 405,659 life years gain for a target population composed of all currently alive
individuals in London in 2008 (7,673,217 persons).
Table 7.7 provides two main findings. First, under the “No Diff. Susc.” sce-
nario, the difference between present estimates and results from Miller (2010)
and Pascal et al. (2013) is in line with expectations, when one takes into ac-
count age differences in target population (present estimates are respectively
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16% and 6% lower). Against expectations, presents results are higher than
those provided by COMEAP (2010). The latter are, however, substantially
lower (by 17%) than results from Pascal et al. (2013). Whilst these two stud-
ies differ in their application of a cessation lag, sensitivity analysis results
reported in section 7.3.2 showed that the cessation lag has a relatively small
impact on the health gain accruing to young individuals.
Second, base case results, which encompass health-related differential sus-
ceptibility are well above estimates from past HIAs. The difference between
base case results and results from Pascal et al. (2013) and Miller (2010) is of
similar magnitude than the difference found by comparing the life-table method
and Markov modelling when using the QALY as health metric (see section
7.4.1). This finding further underlines that, even for life expectancy analy-
sis, ignoring health-related differential susceptibility by reling on the “sepa-
rate” approach to quantification, is expected to substantially underestimate
the health gain from air pollution control.
7.5 Cost-effectiveness analysis of air pollution abate-
ment in London
7.5.1 Preliminaries
Based on the modelled estimates of net QALY gain associated with a 1
µg decrement in PM2.5 concentrations, this section aims to assess the cost-
effectiveness of investments aimed at curbing fine particulate air pollution in
London.
Section 7.3 underlined a number of sources of uncertainty surrounding the
expected benefits of reducing air pollution. A major source of uncertainty
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is uncertainty around parameter point estimates. Since it is highly improba-
ble that air pollution reduction would harm health, cost-effectiveness analysis
will be performed using the three different approaches to handling parame-
ter uncertainty in the three non statistically significant risk estimates used in
the model (ORDev.COPD, HRDev.CHD and HRDeathOAC|H), described in Table
7.2 of section 7.3.1. Briefly, A1= no truncation of original distributions of risk
estimates; A2= guidelines (both tails truncation) and A3= left-tail truncation.
Secondly, the various possible views of the speed at which the risks of ad-
verse events may decrease following pollution decrement, i.e. shape of cessation
lag, represents a source of structural uncertainty. If the range and likelihood
of possible scenarios of the cessation lag were known, cost-effectiveness eval-
uation could be performed by taking the expectations of net benefit across
the joint-distribution of uncertain parameters and the likelihood of all possible
scenarios of cessation lag (Claxton et al., 2012). However, the scenarios of
cessation lag evaluated in section 7.3.2 were mainly illustrative, as the range
and likelihood of possible lag scenarios remain largely uncertain. As a result,
the present cost-effectiveness analysis will rely on the 20-year distributed lag
(US EPA 2010) that was used in the base case scenario.
Whilst results are also sensitive to the choice of discount rate, this parameter
does not qualify as a source of uncertainty but instead, as a choice that needs
to be made by the decision-maker. The present cost-effectiveness analysis will
rely on a 3.5% discount rate as used in the base case scenario.
In addition, results were found to be strongly influenced by health-related
differential susceptibility to air pollution, whereby ignoring it would lead to
a reduction in net QALY gain by one fourth (see section 7.4.2). Since the
ability to capture health-related differential susceptibility is a key difference
between the Markov-modelling based simultaneous approach to quantification
advocated throughout this thesis and the “separate” approach currently used
in HIA, cost-effective analysis will be evaluated for both the base case and the
“No Diff. Susc.” scenarios. The objective is to assess whether consideration
of health-related differential susceptibility may impact investment decisions in
air pollution control.
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Cost-effectiveness evaluation will be carried out from the two payers per-
spectives set out in section 7.2.2: (i) the NHS perspective, where the invest-
ment is assumed to fall on the NHS budget constraint and (ii) the private
consumption (PC) perspective, where the investment is assumed to be funded
by general taxation.
From the PC perspective, health care cost impacts are converted into QALY
gain (loss) equivalent based on a fixed value of £13,00/QALY that is estimated
to represent the NHS expenditure required to deliver one QALY (see section
7.2.2). By contrast, from the NHS perspective, health care costs impacts are
converted to QALY equivalent based on the same rate at which QALY gains
are monetized. The difference in the computation of the net monetary benefit
(NMB) of intervention between the two perspectives is shown by equations 7.1
and 7.2 .
NMBNHS = (QALY gain ∗ k −HCcosts)− I (7.1)
NMBPC = (QALY gain− HCcosts
13, 000
) ∗ v − I (7.2)
where I stands for investment cost, k represents the value of health to the
NHS and v represents the consumption value of health. When v = k = 13, 000
both approaches are identical.
In line with the case study, cost-effectiveness will be evaluated for an in-
tervention associated with an immediate and sustained 1µg/m3 decrement in
population-weighted mean ambient PM2.5 concentrations in London, which
would represent a 7% decrease in current concentrations.
In order to assess the sensitivity of the cost-effectiveness performance of
such an intervention to the size of investment required, three investment costs
will be assessed: £100 million, £500 million and £1 billion. Investments are
expected to be financed today as a lump-sum payment. Whilst these costs are
hypothetical, they seem plausible when compared to government estimates for
interventions aiming at reducing air pollution, though £1 billion is expected to
be an upper estimate. For example, the UK Department of Transport recently
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pledged to commit a minimum of £200 million to support the early market
for ultra low emission vehicles, in order to help achieve London’s ultra low
emission zone (Department for Transport, 2014).
It should be underlined that, as mentioned in Chapter 4, benefits are ex-
pected to scale linearly to further reduction in concentrations. Therefore,
assuming an absence of economy or diseconomy of scale associated with a de-
crease in emissions, if the intervention costing £1 billion were to reduce PM2.5
concentrations twofold with respect to the intervention costing £500 million,
it would have the same probability of being cost-effective.
For each investment size, cost-effectiveness evaluation will be structured
around the following questions:
(i) “Is the intervention likely to be cost-effective?”;
(ii) “When is the investment expected to break-even?”;
(iii) “Is it recommended to wait for more information before going ahead?”.
7.5.2 Is the intervention likely to be cost-effective?
Cost-effectiveness probabilities and CEAC
For each each random draw from the set of distributions fitted to uncertain
parameters, hereafter denoted by the letter θ, the probability that each invest-
ment is cost-effective (i.e. NMB ≥ 0) can be computed for a specific money
value of a QALY. Expected cost-effectiveness probabilities for a given value of
v or k are then found by averaging probabilities across the joint distribution
of uncertain parameters (θ) and can be represented via a cost-effectiveness
acceptability curve (CEAC) (Barton et al., 2008).
Although the values of k = £13, 000/QALY and v = £65, 000/QALY
underpin the present cost-effectiveness analysis, it is of interest to assess the
214
sensitivity of cost-effectiveness results to the money value of health. Indeed, the
WTP values for a QALY were found to vary greatly (Ryen & Svensson, 2014).
In addition, whilst the shadow price of the NHS budget constraint has been
estimated at £13,000/QALY (Claxton et al., 2013), NICE suggests a threshold
value comprised between £20,000 and £30,000/QALY for cost-effectiveness
assessment of health care technologies (NICE, 2013) and was found empirically,
to use a threshold value around £40,000/QALY (Dakin et al., 2013).
Figures 7.8 and 7.9 depict CEACs according to each approach to handling
parameter uncertainty in non statistically-significant risk estimates (A1 to A3)
from respectively the NHS and the PC perspective. CEACs pertaining to
the “No Diff. Susc.” scenario are presented in Figures 7.10 and 7.11. In
addition, Table 7.8 and Table 7.9 provide: (i) the expected NMB of investment
and (ii) the probability that the investment is cost-effective PINV (CE) for
k = £13, 000/QALY and v = £65, 000/QALY for respectively the base case
and the “No Diff. Susc.” scenario.
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(a) A1 “No truncation”
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(b) A2 “Guidelines”
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(c) A3 “Left-tail truncation”
Figure 7.8: Probabilities that the intervention is cost-effective - Base case scenario - NHS
perspective.
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Figure 7.9: Probabilities that the intervention is cost-effective - Base case scenario - PC
perspective.
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k = £13, 000/QALY v = £65, 000/QALY
£100 m £500 m £1 bn £100 m £500 m £1 bn
A1
Eθ(NMB) (in £m) 699 299 -201 3,895 3,495 2,995
PINV (CE) 0.81 0.64 0.37 0.84 0.81 0.77
A2
Eθ(NMB) (in £m) 696 296 -204 3,881 3,481 2,981
PINV (CE) 1 0.94 0.05 1 1 1
A3
Eθ(NMB) (in £m) 916 516 16 4,981 4,581 4,081
PINV (CE) 1 0.87 0.38 1 1 1
Table 7.8: Cost-effectiveness probabilities and expected net monetary benefit - Base case
scenario.
A1= No truncation; A2= Guidelines; A3= Left-tail truncation.
k = £13, 000/QALY v = £65, 000/QALY
£100 m £500 m £1 bn £100 m £500 m £1 bn
A1
Eθ(NMB) (in £m) 493 93 -407 2,866 2,466 1,966
PINV (CE) 0.73 0.52 0.23 0.76 0.73 0.68
A2
Eθ(NMB) (in £m) 485 85 -414 2,827 2,427 1,927
PINV (CE) 1 0.60 0 1 1 1
A3
Eθ(NMB) (in £m) 697 297 -203 3,886 3,486 2,986
PINV (CE) 1 0.56 0.27 1 1 0.98
Table 7.9: Cost-effectiveness probabilities and expected net monetary benefit - No Diff.
Susc. scenario.
A1= No truncation; A2= Guidelines; A3= Left-tail truncation.
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Figure 7.10: Probabilities that the intervention is cost-effective - No Diff. Susc. scenario -
NHS perspective.
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Figure 7.11: Probabilities that the intervention is cost-effective - No Diff. Susc. scenario -
PC perspective.
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Comparison of CEACs depicted in Figures 7.9 to 7.11 and of cost-effectiveness
probabilities presented in Tables 7.8 and 7.9 provides three main insights.
Impact of modelling approach to parameter uncertainty (A1 to A3) on cost-
effectiveness probabilities
Since under A1, the first decile of the distribution of net QALY gain is
composed of negative values (see Figure 7.5), even when the value of health
becomes very large, cost-effectiveness probabilities never reach the value of 1
and instead, have an asymptote around the value of 0.9. By contrast, since
A2 and A3 reject the possibility that air pollution reduction may harm health,
under both these approaches, the intervention only yields a positive net QALY
gain and CEACs have an asymptote to 1.
By truncating both tails of the original distributions of non statistically
significant risk estimates, approach A2 strongly reduces decision uncertainty,
which translates in very steep CEACs. Indeed, for values of health below
the value λ at which the investment (I) is expected to break-even (see equa-
tion 7.3), cost-effectiveness probabilities are near zero, thus implying that the
probability of error associated with rejecting the investment is negligible. By
contrast, as the value of health becomes greater than λ, cost-effectiveness prob-
abilities quickly reach 1 (i.e. null probability of decision error).
λ =
I
Eθ(MB)
where MB stands for monetary benefit. (7.3)
As was shown in Figure 7.4, A3 allows for a greater probability of no
intervention-effect than A2, with regards to the health events “Dev. COPD”,
“Dev. CHD” and “Death from AOC”. As a result, cost-effectiveness prob-
abilities increase more progressively under A3 than under A2. This explains
why, from the NHS perspective with k = 13, 000/QALY , the guidelines (A2)
suggest a lower probability of error if approving the £500 million investment
(6%), than if one were solely to ignore non plausible risk estimate values (13%,
see Table 7.8). Similarly, guidelines suggest a substantially lower probability of
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error associated with the decision of rejecting the £1 billion investment than
do approaches A1 or A3. Indeed, in this case, decision error equals to 5%
under A2, as opposed to 37% under A1 and 38% under A3 (see Table 7.8). In
conclusion, guidelines appear to systematically underestimate the probability
of error associated with each decision option (namely invest or reject the in-
vestment). This limitation is less visible from the PC perspective, since even
under A3 at v = 65, 000/QALY , the probability of decision error is null.
Cost-effectiveness probabilities from the NHS vs. PC perspectives
From the PC perspective, as v increases above the value of 13,000, the
conversion factor (v/13, 000) at which health care costs (savings) are converted
to QALY loss (gain) equivalent increases and as a result, more weight is put on
health care resource impacts. However since the latter are small in comparison
to health gain, the difference in cost-effectiveness probabilities between the two
perspectives, when using the same value of health, is negligible.
Therefore, what drives the difference in cost-effectiveness performance be-
tween the two perspectives is essentially the choice of money value of health.
Under A3, which unlike A1 rejects the possibility that air pollution reduction
may cause harm but allows for greater uncertainty in outcomes than A2, cost-
effectiveness probabilities for the £100 million, £500 million and £1 billion
investments reach 1 for money values of a QALY equal to respectively £9,000,
£23,000 and £40,000.
It follows that from the PC perspective assuming v = 65, 000/QALY , the
probability of investment decision error is null even for I = £1 billion. By
contrast, from the NHS perspective with k = £13, 000, cost-effectiveness prob-
abilities under A3 equal to respectively 1 if I = £100 million; 0.87 if I = £500
million and 0.38 if I = £1 billion. In other words, whilst an intervention costing
up to £500 million is highly likely to be cost-effective from both perspectives,
the £1 billion would be expected to be cost-effective with high probability,
only from the PC perspective.
The source of funding is therefore expected to have strong implications on
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the optimal level of pollution reduction. Indeed, if the true cost of reducing
ambient PM2.5 concentrations by 1µg/m
3 and 2µg/m3 were respectively £500
million and £1 billion (i.e. assuming no economy of scale), the optional level
of pollution reduction from the NHS perspective would be below 2 µg/m3
whereas from the PC perspective, it would be above 2 µg/m3.
Impact of ignoring health-related differential susceptibility on cost-effectiveness
probabilities
First, under A1, CEACs have an asymptote to 0.8, as opposed to 0.9 for the
base case. In other words, under current evidence, the minimum probability
of error associated with each investment is 20%, as opposed to 10% under the
base case.
Second, for investments above £100 million, cost-effectiveness probabilities
increase much more progressively than in the base case scenario. Under A3,
cost-effectiveness probabilities for the £500 million and £1 billion investments
reach 1 for money values of a QALY equal to respectively £45,000 and £74,000,
as opposed to respectively £23,000 and £40,000 in the base case scenario.
As a result, whilst ignoring evidence of health-related differential suscep-
tibility to air pollution does not affect cost-effectiveness results from the PC
perspective if v = £65, 000/QALY (assuming air pollution reduction cannot
harm health), it strongly impacts upon the probability of decision error from
the NHS perspective. As shown in Table 7.9, under A3 if k = £13, 000/QALY ,
the probability of decision error associated with the £500 million investment
equals to 44%, as opposed to 13% if health-related differential susceptibil-
ity were accounted for. From the NHS perspective, ignoring health-related
differential susceptibility is therefore expected to lead to less ambitious and
potentially sub-optimal strategies for improving air quality.
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7.5.3 When is the investment expected to break-even?
The expected time to break-even is of particular interest when supporting
decision-making with regards to investments characterised with a high up-
front cost, such as air pollution control. First, it helps characterise the level
of investment risk, whereby the sooner the expected time to break-even is,
the lower the investment risk. Second, it helps identify the investments for
which cost-effectiveness performance is expected to be sensitive to the size of
the target population and the analysis time horizon. It indicates whether in-
cluding benefits to future generations, and thus increasing the analysis time
horizon, may substantially affect cost-effectiveness results up to a point where
discounting would make future benefits negligible. A similar reasoning may
be applied to assess cost-effectiveness results’ sensitivity to discount rate. The
shorter the time to break-even, the least cost-effectiveness results will be im-
pacted by the discounting factor, and conversely for investments with a long
time to break-even.
The expected time to break-even t∗ is obtained by cumulating the dis-
counted annual incremental net benefit from investment. It satisfies equation
7.4:
I0 −
t∗∑
t=1
Eθ(MBt)
(1 + r)t
= 0 , where I0 stands for investment cost paid upfront
(7.4)
Figures 7.12 and 7.13 show, from each perspective, interventions’ expected
time to break-even (t∗) under A1 and A3. It should be reminded that: (i)
A1 was the base case approach used to compute mean outcomes estimates and
that mean results under A1 and A2 are equal and (ii) total expected net QALY
gain over the 60-year time horizon is 26% higher under A3 than under A1 (see
section 7.3.1).
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Figure 7.12: Investments’ expected time to break-even - NHS perspective - Base case sce-
nario.
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Figure 7.13: Investments’ expected time to break-even - PC perspective - Base case scenario.
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From the NHS perspective with k = 13, 000/QALY , under A1, investments
of £100 million and £500 million are expected to break-even after respectively
10 and 27 years whereas the £1 billion investment is expected to yield a net
loss. Whilst the choice of modelling approach to parameter uncertainty does
impact upon the total expected net QALY gain, it appears to have a relatively
small impact on the expected time to break-even for investments up to £500
million. For instance, time to break-even for the £500 million investment is
brought forward of only 3 years under A3. By contrast, the choice of modelling
approach does make a substantial difference for the £1 billion investment since
under A3, the latter breaks-even. Break-even however, is expected to happen
only after 50 years. This suggests that for such a large investment, including
benefits to future generations and/or reducing the discount rate is likely to
substantially improve cost-effectiveness performance.
From the PC perspective with v = 65, 000/QALY , under A1, an investment
as large a £1 billion would break-even after solely 16 years (5 and 11 years
for the £100 million and £500 million investments respectively) and time to
break-even is only brought forward of a few years under A3. For each invest-
ment strategy, including benefits to future generations is therefore unlikely to
significantly bring forward the expected time to break-even.
Figure 7.14 shows the impact of ignoring health-related differential sus-
ceptibility on the expected time to break-even from both perspectives, using
approach A1 as a reference for comparative analysis with the base case sce-
nario. The higher the investment cost, the greater the difference in time to
break-even against the base case scenario. From the PC perspective, however,
expected time to break-even would only be postponed for a few years.
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Figure 7.14: Investments’ expected time to break-even - A1 “No truncation” - Both payers’
perspectives - “No Diff. Susc.” scenario.
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7.5.4 Is more information required?
Necessary versus sufficient conditions for investment
The decision to invest should be made simultaneously to the decision of
whether further research should be carried out (Claxton, 1999). Indeed, whilst
a necessary condition for investment is that the expected NMB is greater than
zero, a sufficient condition for investment typically cannot be solely based
on cost-effectiveness rules. For instance, if adopting reduces the prospect of
further research being conducted, a sufficient condition for investing needs to
take into account the value of information that will be foregone (Griffin et al.,
2011). In addition, if the investment is associated with irreversible costs, the
loss to be incurred if the decision were to be reversed ought to be taken into
account (Eckermann & Willan, 2008; Palmer & Smith, 2000).
Investments in air pollution control strategies are unlikely to affect further
research, rather they could contribute to the body of epidemiological evidence
as was done by past natural experiment studies. Air pollution control invest-
ments are however, expected to be largely irreversible.
If an investment is irreversible, further information only has value if one
can delay the commitment (Eckermann & Willan, 2008). Consequently, in the
present case, the two possible courses of action are:
(i) Invest now (INV) or
(ii) Delay commitment, i.e. Do Nothing (DN) and reassess the option to invest
when research reports.
Deciding between these two options requires trading off the opportunity cost of
delay, i.e NMB to be foregone by not investing now, with the expected benefit
from waiting for more evidence to decrease decision uncertainty (Eckermann
& Willan, 2008).
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Expected value of perfect information
A starting point to evaluate the value of getting more evidence is to compute
the expected maximum NMB, if all parameter uncertainty could be resolved,
i.e. under perfect information. It is computed by identifying the option that
yields the maximum net benefit, for each possible realisation of uncertainty and
taking the average across all realisations (Griffin et al., 2011). Mathematically,
the expected maximum NMB under perfect information can be expressed as:
EθmaxjNMB(j, θ) (7.5)
where θ represents the set of all uncertain parameters and j denote decision
options: delay i.e. do nothing (DN) or invest now (INV).
By subtracting to this maximum, the NMB associated with the option that
generates, based on current evidence, the highest expected net benefit among
all other possible options, one obtains the expected value of perfect information
(EVPI) (Griffin et al., 2011). Mathematically, EVPI can be expressed as:
EV PI = EθmaxjNMB(j, θ)−maxjEθNMB(j, θ) with j=DN, INV (7.6)
Since some uncertainty is irreducible and further information will not be
available immediately, the EVPI provides an upper bound to the social value of
undertaking further research. Consequently, the comparison of the maximum
pay-off from further research with the expected cost of research provide a
necessary condition for further research, i.e. the latter is potentially worthwhile
only if EVPI exceeds the cost of research (Claxton, 1999).
The EVPI depends upon the combination of two factors: (i) the prob-
ability of decision error, as previously depicted by the CEACs and (ii) the
consequences of that wrong decision (Barton et al., 2008). The magnitude of
the consequences of making an incorrect decision is clearly a positive function
of the value of health. The probability that a wrong decision is being made
will be the largest at the value of health λ at which the intervention is ex-
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pected to break-even (see equation 7.3). Indeed for values of health below λ,
one can be confident that the intervention will not be cost-effective and thus,
the probability of error associated with “Do Nothing” will be low. Similarly,
for values of health above λ, one can be confident that the intervention will be
cost-effective and thus, the probability of error associated with “Invest now”
will be low.
Figures 7.15 and 7.16 represent the curves of EVPI from both the NHS
and the PC perspectives, according to each approach to handling uncertainty
in non statistically significant risk estimates. It should be underlined that
the present EVPI computations are based on the population and time-horizon
that underpinned the previous benefit computations, i.e. all currently alive
population aged 40 to 90 years followed until death.
231
10 20 30 40 50 60 70 80 90 1000
50
100
150
200
250
300
350
400
QALY value from the NHS perspective (in thousands £)
EV
PI
 (£
 m
illio
n)
 
 
Investment cost = £ 100 million
Investment cost = £ 500 million
Investment cost = £ 1 billion
(a) A1“No Truncation”
10 20 30 40 50 60 70 80 90 1000
10
20
30
40
50
60
70
80
QALY value from the NHS perspective (in thousands £)
EV
PI
 (£
 m
illio
n)
 
 
Investment cost = £ 100 million
Investment cost = £ 500 million
Investment cost = £ 1 billion
(b) A2 “Guidelines”
10 20 30 40 50 60 70 80 90 1000
50
100
150
200
QALY value from the NHS perspective (in thousands £)
EV
PI
 (£
 m
illio
n)
 
 
Investment cost = £ 100 million
Investment cost = £ 500 million
Investment cost = £ 1 billion
(c) A3 “Left-tail truncation”
Figure 7.15: Expected Value of Perfect Information - Base case - NHS perspective.
232
10 20 30 40 50 60 70 80 90 1000
100
200
300
400
500
600
700
Consumption value of a QALY (in thousands £)
EV
PI
 (£
 m
illio
n)
 
 
Investment cost = £ 100 million
Investment cost = £ 500 million
Investment cost = £ 1 billion
Using a value of £13,000/QALY to convert
health care resource impacts into QALY
equivalent
(a) A1“No Truncation”
10 20 30 40 50 60 70 80 90 1000
10
20
30
40
50
60
70
80
Consumption value of a QALY (in thousands £)
EV
PI
 (£
 m
illio
n)
 
 
Investment cost = £ 100 million
Investment cost = £ 500 million
Investment cost = £ 1 billion
Using a value of £13,000/QALY to convert
health care resource impacts into QALY
equivalent
(b) A2 “Guidelines”
10 20 30 40 50 60 70 80 90 1000
50
100
150
200
Consumption value of a QALY (in thousands £)
EV
PI
 (£
 m
illio
n)
 
 
Investment cost = £ 100 million
Investment cost = £ 500 million
Investment cost = £ 1 billion
Using a value of £13,000/QALY to convert
health care resource impacts into QALY
equivalent
(c) A3 “Left-tail truncation”
Figure 7.16: Expected Value of Perfect Information - Base case - PC perspective.
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Comparison of EVPI results further underlines the impact of each modelling
approach on decision uncertainty, as previously discussed in section 7.5.2. All
EVPI curves exhibit a maxima at k or v = λ, where the probability of error
is the largest. Under A1, however, as the value of health keeps on increasing,
EVPI starts increasing again. The reason is that, based on current evidence,
under A1, cost-effectiveness probabilities have an asymptote to 0.9 which re-
flects the view that air pollution reduction may harm health. Consequently, as
the value of health increases, the combination of a non-null error probability
with growing consequences of error leads to an increasing EVPI. By truncat-
ing both tails of the original distributions of non statistically significant risk
estimates, A2 substantially reduces decision uncertainty and thus, the EVPI.
Since decision uncertainty is greater under A3 than under A2 (due to a greater
possibility of no intervention effect with regards to endpoints “Dev. COPD”,
“Dev. CHD” and “Death from AOC”), the EVPI is larger under A3 than
under A2. For instance, from the NHS perspective for I= £500 million, max
EVPI equals to £42 million under A2, as opposed to £115 million under A3.
It can also be noted that since Eθ(NMB) under A3 is greater than under A1
or A2, the value at which EVPI reaches a maximum is slightly lower under A3
than under A1 or A2.
CEACs previously showed that, assuming air pollution reduction cannot
harm public health, the decision error attached to each three investment is
null for values of health above £40,000/QALY. Consequently, under A2 and
A3, from the PC perspective, the EVPI associated with each investment equals
to zero. By contrast, from the NHS perspective with k = £13, 000/QALY , un-
der A3, EVPI equals to respectively £0 for I= £100 million (cost-effectiveness
probability = 1), £9.2 million for I= £500 million (cost-effectiveness prob-
ability = 0.87) and £192 for I= £1 billion (cost-effectiveness probability =
0.38).
Finally, whilst the difference in cost-effectiveness results between the PC
and the NHS perspectives, for a same money value of health, is relatively
small, EVPI curves from each perspective are slightly different under A1. The
fall after the local maxima is smaller from the PC perspective than from the
NHS perspective since, for values of v >> 13, 000, a substantial weight is put
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on health care cost impacts, which pushes up the consequences of error. This
feature can barely be seen under A2 or A3 as the probability of error under
these approaches quickly falls to zero, though not to the same speed.
Figures 7.17 and 7.18 show the EVPI curves associated with the “No Diff
Susc” scenario. Both the value of health at which the EVPI reaches a maxi-
mum, and the magnitude of this maximum, are higher than in the base case
scenario. In addition, since cost-effectiveness probabilities increase much more
progressively than in the base case scenario, the EVPI decreases more slowly
than in the base case scenario (under A2 and A3). This is especially flagrant
for the £1 billion investment for which under A3, EVPI falls below £100,000
at a value of £72,000/QALY, as opposed to £39,000/QALY in the base case
scenario.
As mentioned in section 7.5.2, from the NHS perspective, ignoring evidence
of health-related differential susceptibility strongly impacts upon the proba-
bility of error associated with the £500 million investment. As a result, the
EVPI for this investment at k = £13, 000/QALY jumps to £60 million, as
opposed to £4.7 million in the base case scenario. By contrast, since the prob-
ability of decision error from the PC perspective is unchanged in the “no Diff.
Susc” scenario, the EVPI associated with each three investment strategies at
v = £65, 000/QALY remains low (near zero for the £100 million and £500
million investments).
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Figure 7.17: Expected Value of Perfect Information - “No Diff. Susc.” scenario - NHS
perspective.
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Figure 7.18: Expected Value of Perfect Information - “No Diff. Susc.” scenario - PC per-
spective.
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Sufficient conditions for approval and maximum investment delay
To decide which decision option is optimal, the pay-off associated with re-
spectively “Invest now” or “Delay” (i.e. do nothing until further research
reports) should be compared. The evaluation of the pay-off associated with
delay requires an assessment of: (i) the likelihood that research will be per-
formed (α) and (ii) the timing of when the research will report (τ) (Griffin
et al., 2011).
If the decision maker had the remit and budget to commission research, α
would be equal to one, τ would be known and the pay-off from delay should
account for the cost of research (Griffin et al., 2011). In the present case,
however, it is assumed that the decision maker does not have the remit to
commission research and therefore, the expected pay-off requires an assessment
of both α and τ .
The pay-off from delay can be calculated as the sum of NMB during time
periods 0 to τ and τ to T , with T denoting the investment time horizon.
Before time τ , the pay-off from delay corresponds to the expected NMB of
doing nothing, which equals to zero. After time τ , the pay-off from delay is
the sum of (i) the expected NMB of doing nothing weighted by the probability
(1−α) that research was not conducted and (ii) the expected maximum NMB
under perfect information weighted by the probability α that research was
conducted, assuming the latter resolved all uncertainty.
Mathematically, the pay-off from delay can be expressed as:
piDELAY = Eθ
τ∑
t=1
NMBt(DN, θ)
(1 + r)t
+ · · ·
+ (1 + α)Eθ
T∑
t=τ
NMBt(DN, θ)
(1 + r)t
+ · · ·
+ αEθmaxj
T∑
t=τ
NMBt(j, θ)
(1 + r)t
with j=DN (do nothing), INV(invest now)
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Since Eθ
∑T
t=1
NMBt(DN,θ)
(1+r)t
= 0
piDELAY = αEθmaxj
T∑
t=τ
NMBt(j, θ)
(1 + r)t
with j=DN, INV (7.7)
The pay-off from investing now is simply the expected NMB of the intervention:
piINV = Eθ
T∑
t=1
NMBt(INV, θ)
(1 + r)t
(7.8)
The value of the option to delay can be calculated as the difference between
the pay-offs to delay and to invest now:
Optiondelay = piDELAY (α, τ)− piINV (7.9)
It is worth underlining that, if the intervention is expected to be cost-effective,
when α = 1 and τ = 0, Optiondelay = EV PI.
The pay-off from delay is computed by assuming that all uncertainty will be
resolved at time τ , which is unrealistic. As a result, Optiondelay = 0 provides
a sufficient condition for investing now. Combinations of values of α and τ
can be found for which Optiondelay = 0 for each investment strategy. When
represented in a graph, these combinations represent a boundary line, whereby
any point to the North-East of this line represents a sufficient condition for
approval (Griffin et al., 2011). Alternatively, since Optiondelay > 0 provides a
necessary condition for further research, for a given value of α, one can compute
τ∗, the maximum time to delay the investment while waiting for research to
report that satisfies Optiondelay > 0.
τ∗ values for all three investment costs under each modelling approach (A1
to A3) using k = 13, 000/QALY and v = 65, 000/QALY are reported in
Table 7.10. When Optiondelay was strictly positive for several values of α,
approval boundaries as a function of α and τ values were drawn. Figure 7.19
represents the approval boundaries from the NHS perspective, for investments
of respectively £500 million and £1 billion.
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NHS ( k=13,000) PC (v=65,000)
INV A1 A2 A3 A1 A2 A3
£100 m
2 yrs if α = 0.9
8 yrs if α = 1
0 0 8 yrs if α = 1 0 0
£500 m see Figure 7.19a
2 yrs if α = 0.9
8 yrs if α = 1
0 0
£1 bn Eθ(NMB) < 0
see
Figure
7.19b
6 yrs if α = 0.9;
10 yrs if α = 1
0 0
Table 7.10: Maximum time to delay investment (τ∗) - Base case scenario.
A1= No truncation; A2= Guidelines; A3= Left-tail truncation.
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(b) I = £1 billion
Figure 7.19: Approval boundaries - NHS perspective - Base case scenario.
A1= No truncation; A2= Guidelines; A3= Left-tail truncation. Any point to the North-East of the line
represents a sufficient condition for approval.
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As shown in the left-hand side of Table 7.10, from the PC perspective
under approaches A2 and A3, τ∗=0. In other words, the option to delay
investments as large as £1 billion has no value. This is not surprising since,
under A2 and A3, EVPI for each three investments at v = £65, 000/QALY
equals to zero (see Figure 7.16). Even under A1 which, if one rules out that air
pollution reduction could cause any harm, overestimates decision uncertainty
delay would have value only if one were highly confident that research would
be carried out (α ≥ 0.9) and report within a relatively short period.
From the NHS perspective (right-hand side of Table 7.10), under the as-
sumption that air pollution reduction cannot harm health (A2 and A3), de-
laying to gather further evidence has little value for investments costing up
to £500 million. By contrast, for the £1 billion investment, delay appears
to be valuable under A3, even given a low probability that research will be
conducted. Indeed, under A3, if research were to be performed with a 50%
probability and could resolve all uncertainty, it would be worth delaying the
£1 billion investment up to 20 years.
Results for the “No Diff. Susc.” scenario are reported in Table 7.11. In line
with EVPI results, ignoring health-related differential susceptibility has little
impact on the option to delay from the PC perspective. By contrast, from
the NHS perspective, ignoring health-related differential susceptibility would
bestow more value to delay to collect further information, in particular for the
£500 million investment. This is illustrated by Figure 7.20, which contrasts
the sufficient conditions for approval of this investment under the “No Diff.
Susc.” and the base case scenario.
From the NHS perspective, under A3, ignoring health-related differential
susceptibility would provide support for delaying the £500 million investment
from 8 to 10 years if research were to be performed with a high probability
(α ≥ 0.8), as opposed to maximum two year delay in the base case scenario.
This suggests that if the NHS were paying for air pollution abatement, ignoring
health-related differential susceptibility could lead to population health loss
due to longer investment delay than optimal.
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NHS ( k=13,000) PC (v=65,000)
INV A1 A2 A3 A1 A2 A3
£100 m
4 yrs if α = 0.8;
10 yrs if α = 0.9;
13 yrs if α = 1
0 0
8 yrs if α = 0.9;
12 yrs if α = 1
0 0
£500 m see Figure 7.20b
4 yrs if α = 0.8;
10 yrs if α = 0.9;
13 yrs if α = 1
0 0
£1 bn Eθ(NMB) < 0
4 yrs if α = 0.7;
10 yrs if α = 0.8;
13 yrs if α = 0.9;
15 yrs if α = 1
0 0
Table 7.11: Maximum time to delay investment (τ∗) - “No Diff. Susc.” scenario.
A1= No truncation; A2= Guidelines; A3= Left-tail truncation.
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Figure 7.20: Approval boundaries for I = £500 million - “No Diff. Susc.” vs. base case
scenarios - NHS perspective.
A1= No truncation; A2= Guidelines; A3= Left-tail truncation.
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Prioritizing research and informing future study design
In addition to providing an upper bound to the overall gain from delaying
investment in order to collect further information, the value of information
framework can also be used to prioritise further research. The first step to
prioritisation is to identify the model parameters for which a reduction in
uncertainty would have a substantial impact on decision uncertainty. This is
performed by computing the expected value of perfect information associated
to each uncertain parameter (or each subset of uncertain parameters): EVPPI.
Similarly to EVPI, the EVPPI is simply the difference in net benefit with
perfect information versus current information about the set of uncertain pa-
rameter of interest (θI), which is a subset of all uncertain parameters θ. Com-
putation of the expected net benefit with perfect information about θI requires
two loops of probabilistic simulations. Indeed, one first needs to obtain the
expectations of net benefit across the possible values that the remaining un-
certain parameters (θR) can take conditional on knowing the value of (θI), in
order to then take the expectation of these expected maximum net benefit over
the distribution of θI (Ades et al., 2004). Mathematically:
EV PPIθI = EθImaxjEθR|θINMB(j, θI , θR)−maxjEθNMB(j, θ) (7.10)
With j=DN, INV; θI = set of uncertain parameter of interest and θR is the
complement set of remaining uncertain parameters such that θ = θI + θR .
Like the EVPI, the EVPPI provides an upper-bound to the value of obtain-
ing more information on θI and represents a necessary condition for further
research, i.e. EVPPI needs to be greater than the cost of research. The latter
will however, depend on the type and design of the study required to ob-
tain additional information, e.g. cohort versus case-control study; sample size,
follow-up duration and so forth. In this context, the expected value of sample
information (EVSI) can be used to maximise the efficiency of study design.
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The EVSI is the difference in expected net benefit after sample data D has
been collected versus under current information (Ades et al., 2004). Similarly
to EVPPI calculations, computations of the expected net benefit with sample
data D contains a inner loop within the maximisation process. The first step
consists in averaging over the posterior distribution of the net benefit of each
intervention j, given the sample result D that informs the subset of uncertain
parameters θI . The second step consists in taking the expectation of these
expected maximum net benefit over the distribution of D. Mathematically,
assuming that θI and θR are independent;
EV SID = EDmaxjE(θI |D),θRNMB(j, θI , θR)−maxjEθNMB(j, θ) (7.11)
For a given study design, sample results D will depend on sample size
n. Based on this framework, one could therefore compute EVSI for various
sample sizes n, in order to identify the optimal study size n∗ (e.g. in the case
of air pollution, the number of participants to enrol in a cohort study) that
maximises the difference between EV SIn∗ and the cost of research Cn∗. The
difference between the EVSI and the cost of acquiring sample information is
known as the expected net benefit of sample information (ENBS).
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7.6 Results summary
The methodological contribution of the present study as well as its limita-
tions will be discussed in Chapter 8, which provides an overall conclusion to
the thesis. This section aims at outlining the key findings from the application
of the model developed in Chapter 4 and its implications for the UK air quality
strategy.
7.6.1 Main findings
Expected outcomes and their distributions
Reducing mean population-weighted PM2.5 concentrations by about 7% in
London and 9% in England and Wales (1µg/m3 decrement) is expected to
yield respectively 63,293 and 541,217 QALYs to adults aged 40 and above
over their remaining lifetime, when discounting at 3.5% p.a. By reducing
morbidity but also extending the lives of individuals with a chronic cardio-
respiratory condition, the intervention is expected to increase health care costs
(£24 million in London and £263 million in England and Wales). However,
when converted to QALY loss equivalent at a value of £13,000/QALY, health
care costs only account for 3% of total health benefits.
As a result, the intervention is expected to generate to the NHS a total of
61,467 net QALYs in London and 520,998 net QALYs in England and Wales.
Based on a WTP value of a QALY of £65,000, which is in line with recommen-
dations from the UK Department of Health (Glover & Henderson, 2010) and a
recent review of WTP estimates (Ryen & Svensson, 2014), the intervention’s
total monetary benefit from the private consumption perspective amounts to
£4 billion in London and £34 billion in England and Wales.
The distribution of outcomes obtained from Monte Carlo simulations de-
pends on the approach chosen to handle uncertainty in three non statistically
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significant risk estimates used to parameterise the “intervention-effect” (out
of a total of 7 risk estimates). Three approaches were assessed: (A1) where
parameters’ original distributions were left unchanged, which was the base
case approach used to compute mean estimates; (A2) which follows European
guidelines for uncertainty analysis in HIA of air pollution control and consisted
in attributing a range of +/- 100% of mean effect and assuming equal likeli-
hood within the assigned value range (Holland, 2014); (A3) where a value of 1
was assigned to any random draw value below 1 from risk estimates’ original
distributions. By leaving unchanged the original distributions of non statisti-
cally significant risk estimates, A1 allows for the highly improbable possibility
that air pollution could harm health. Consequently, under A1, the distribution
of net QALY gain has a left-tail of negative values, whereas under A2 and A3
QALY gains are always positive. Whilst mean outcome results are equal under
A1 and A2, they have a much smaller standard deviation under A2. Under
A3, the mean of non statistically significant risk estimates is shifted to the
right (ORDev.COPD in particular), which pushes the expected net QALY gain
by a quarter.
Cost-effectiveness analysis
Cost-effectiveness analysis was based on an intervention that reduces PM2.5
concentrations in London by 1µg/m3 and which cost equals to respectively
£100 million, £500 million or £1 billion, to be fully paid upfront. Cost-
effectiveness was evaluated from two perspectives, whereby the investment
cost would either (i) fall on the NHS budget constraint (NHS perspective) or
(ii) be funded by general taxation (private consumption “PC” perspective).
The analysis was underpinned by three questions.
(i) “Is the intervention likely to be cost-effective?”
Analysis showed that current European guidelines to uncertainty analysis
in HIA of air pollution control interventions, that were followed in approach
A2, systematically underestimate the probability of decision error. In contrast,
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approach A3 offers the advantage of rejecting the highly improbable possibil-
ity that air pollution reduction may harm health while allowing for greater
uncertainty in outcomes than A2.
The difference in investments’ cost-effectiveness performances between the
NHS and PC perspectives is essentially driven by the choice of the value of
health. From both the PC and the NHS perspectives, an intervention costing
up to £500 million is highly likely to be cost-effective (max probability of
decision error equal to 13% under A3). By contrast the £1 billion investment
is expected to be cost-effective with high probability from the PC perspective
only. This shows that the source of funding is likely to influence the optimal
level of air pollution reduction.
(ii) “When will the investment break-even?”
From the NHS perspective with k = 13, 000/QALY , investments of £100
million and £500 million are expected to break-even after respectively 10 and
27 years under A1. For these investments, although the choice of modelling
approach to parameter uncertainty (A1 to A3) impacts upon the total expected
net QALY gain over the 60-year analysis time horizon, it has a relatively small
impact on the expected time to break-even. By contrast, whilst the £1 billion
investment is expected to yield a net loss under A1, it slightly breaks-even
after 50 years under A3. For such a large investment, including benefits to
future generations and/or reducing the discount rate is likely to substantially
improve cost-effectiveness performance.
From the PC perspective with v = 65, 000/QALY , an investment as large
a £1 billion would break-even after solely 16 years under A1. Under A3, time
to break-even is brought forward of a few years only.
(iii) “Is it recommended to wait for more information before going ahead?”
The comparison of EVPI results corroborates the finding that European
guidelines underestimate decision uncertainty, whereby the EVPI for each three
investment is much lower much under A2 than under A3. For instance, for
I= £500 million and k = 13, 000/QALY , max EVPI equals £42 million under
A2, as opposed to £115 million under A3.
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Assuming that air pollution reduction cannot harm public health (A2 or
A3), from the PC perspective with v = 65, 000/QALY , the probability of
decision error attached to each investment is null, and so is the EVPI. As a
result, there is no value in delaying investments costing up to £1 billion. From
the NHS perspective, whilst delaying to gather further evidence has little value
for investments costing up to £500 million, under A3 delay appears valuable
for the £1 billion investment, even given a low probability that research will
be conducted. For instance, if research were to be performed with a 50%
probability and could resolve all uncertainty, it would be worth delaying the
£1 billion investment for up to 20 years to wait for research findings.
7.6.2 Sensitivity analyses
Discount rate and cessation lag
If the intervention’s effect on the risk of adverse health effects would be
immediate, i.e. no cessation lag, the intervention’s total net QALY gain would
increase by 16%. Applying a staged discount rate that excludes the element
of pure time preference (“Staged discounting 2” scenario using 3 % p.a. in the
first 30 years and 2.57% p.a. afterwards), would boost total net QALY gain by
20%. Cessation lag and discounting have opposite effects on the distribution
of health gain across age -groups. Young individuals are clearly the greatest
beneficiaries of a lower rate of discounting, whereas older individuals would
benefit the most from an immediate reduction in the risks of adverse health
events. In the “Staged discounting 2” scenario, individuals aged 40 would
gain 35% more QALD than in the base case scenario, as opposed to only 15%
additional gain for individuals aged 60. By contrast, an immediate reduction
in health risks would increase the average QALD gain of an 80-year old person
by 50%, as opposed to an increase by 30% for a 70-year old person and by 10%
for a 40-year old person.
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Health-related differential susceptibility
The present Markov-modelling based QALY estimates are 39% higher than
estimates that would be obtained using the life-table method. The difference
in results stems from Markov modelling’s capacity to capture health-related
differential susceptibility to air pollution exposure and to a much lesser extent,
quality of life gains from reduced morbidity. In the case of London, accounting
for evidence of CHD and COPD-related greater pre-disposition to die prema-
turely due to PM exposure (Zanobetti et al., 2008; Zanobetti & Schwartz, 2007;
Tonne & Wilkinson, 2013) represents a 34% difference in the expected QALY
gain of air pollution control and a 26% difference in QALY gain net of health
care cost impacts. Similarly, health-related differential susceptibility was found
to explain most of the difference between present estimates of un-discounted
life expectancy gain and results from past HIAs in a similar setting. It follows
that, by ignoring interactions between morbidity and mortality mediated via
health-related differential susceptibility to air pollution, the life-table method
which underpins the “separate” approach to impact quantification currently
used in HIA, substantially underestimates the total health gain of air pollution
reduction.
From the PC perspective if v = 65, 000/QALY , ignoring evidence of health-
related differential susceptibility does not affect the probability of decision error
nor the EVPI or the delay option value associated with each three investment
strategies. By contrast, from the NHS perspective if k = 13, 000/QALY ,
ignoring health-related differential susceptibility has a non negligible impact
on cost-effectiveness probabilities for investments above £100 million. Under
A3, the probability of error if the NHS makes the £500 million investment
equals to 44% (as opposed to 13% in the base case scenario) and the EVPI
jumps to £69 million (as opposed to £9.2 million in the base case scenario).
In this context, if research were to be performed with a high probability, it
may be optimal to delay the £500 million investment 8 to 10 years, as opposed
to a maximum two-year delay in the base case scenario. Therefore, from the
NHS perspective, ignoring health-related differential susceptibility may lead to
population health loss by supporting a sub-optimal reduction in air pollution
and/or extending the delay period of cost-effective investments.
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Chapter 8
Conclusion
The present chapter concludes the thesis. Its aims are fourfold: (i) to
restate the overall structure of the thesis; (ii) to underline the contributions of
the work undertaken; (iii) to highlight its limitations and (iv) to outline some
avenues for further research.
8.1 Thesis overview
Chapter 2 was a review that presented the body of epidemiological evi-
dence on the health effects of air pollution exposure and highlighted several
research opportunities in the economic evaluation of interventions of air pollu-
tion control, in particular with regards to the approach to quantifying health
benefits.
Chapter 3 demonstrated that the current quantification approach tradition-
ally used in health impact assessments (HIA) of environmental policies, where
each health effect is computed separately, has major limitations. It advocated
encompassing interactions between mortality and morbidity impacts, by quan-
tifying effects simultaneously using Markov modelling as a quantification tool.
Chapter 4 described the construction and parameterisation of a Markov
model of the health impacts associated with chronic exposure to particulate
air pollution. The objective of this model was twofold: (i) to refine the un-
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derstanding of air pollution adverse health effects by evaluating quality of life
impacts alongside life expectancy effects using the QALY as health metric
and (ii) to assess the total health care budget impact of air pollution control
that would capture the joint impact of a reduction in chronic morbidity and
premature death.
Chapters 5 and 6 consisted in estimating a subset of parameters required to
parameterise the model developed in Chapter 4. Chapter 5 developed a prob-
abilistic framework to estimate the age-specific probability of being diagnosed
with COPD at different stages of the disease. In a context where COPD is
severely underdiagnosed, the rationale for developing this framework was to
estimate the true size of the population subgroup expected to benefit from a
reduced risk of developing COPD following improvement in air quality.
Chapter 6 performed a systematic review and two meta-analyses of the
risk estimates quantifying the association between long term exposure to fine
particulate pollution and respectively all-cause mortality and lung cancer inci-
dence or mortality. It aimed to encompass all relevant epidemiological evidence
to date and to decrease parameter uncertainty.
Chapter 7 presented and analysed the QALY gain and health care resource
impact associated with a sustained 1µg/m3 decrement in population-weighted
mean PM2.5 concentrations in respectively England and Wales and London.
Based on these results, the cost-effectiveness of reducing particulate air pollu-
tion in London, whether such an intervention would be paid by the NHS or
funded through general taxation, was evaluated for a range of three hypothet-
ical investment costs.
8.2 Contributions
This thesis provides a number of methodological and empirical contributions
to the economic evaluation of air pollution control.
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8.2.1 Methodological contributions
Demonstration that the current approach to quantifying health benefits from
air pollution reduction leads to substantially biased estimates.
The present work demonstrated that the approach to quantification cur-
rently used in HIA of environmental policies, where morbidity and mortality
impacts are evaluated separately using static health impacts functions and
the life-table method, seriously threatens the internal validity of estimates of
health gain associated with air pollution control.
By ignoring interactions between morbidity and mortality effects, this “sep-
arate” approach was found to be associated with two major limitations. First,
it systematically overestimates the change in number of morbidity cases asso-
ciated with pollution increment or decrement. The size of the overestimation
bias is not negligible, especially over long time-horizons as typically used in
assessments of air pollution control interventions. Over a 60-year time horizon
for instance, the “separate” approach was found to lead to an overestimation
by one fifth of the number of CHD cases expected to be avoided following
pollution abatement in London.
Second, the “separate” approach cannot characterise the distribution of
impacts by causal pathways and between population subgroups stratified by
their level of health. It is therefore inappropriate to support health care budget
impact assessments and distributional analysis and also, to quantify health
effects using summary measures of population health. This explains why the
few past attempts at measuring the QALY gain from air pollution control either
failed to encompass the quality of life gain from reduced chronic morbidity, or
departed from the QALY by no longer allowing a linear substitution between
quality and quantity of life.
More importantly, this second limitation was found to lead to a substantial
underestimation of the life expectancy gain, be it quality-adjusted or not, from
air pollution reduction. Indeed since the “separate” approach cannot charac-
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terise the distribution of impacts by health-stratified population subgroups, it
fails to encompass existing evidence that individuals with CHD and COPD,
once they reach a certain age and/or severity level, are expected to face a
greater excess risk of death under pollution exposure than individuals of the
general population. This is problematic since the present analysis found that
accounting for the current evidence of health-related differential susceptibility
has a large impact on the expected health gain and health care cost impact of
air pollution abatement. In the case of London, it represents a 34% difference
in expected QALY gain and a 26% difference in expected QALY gain net of
health care resource impacts.
Development of a Markov model that addresses all the limitations of the “sep-
arate approach” and represents a step forward to the cost-effectiveness analysis
of air pollution control interventions
The thesis developed the first Markov model of health impacts from long-
term exposure to air pollution that addresses all the limitations of the “separate
approach”, by capturing interactional effects between morbidity and mortality
impacts. The model indeed makes it possible to encompass for the first time:
(i) air pollution’s influence on individuals’ quality of life and life expectan-
cies at baseline and (ii) dynamics in individuals’ susceptibility to air pollution
exposure as a consequence of a degraded health condition, be it related to
cumulative air pollution exposure or not. Thanks to these two features, the
model fully captures the lifetime impact of air pollution exposure on individ-
uals’ quality and length of life. The model is also of particular relevance for
health care budget impact analysis as it captures the joint budget impact of
a reduction in both chronic morbidity and premature death. Consequently,
the methodology proposed and the model developed are expected to repre-
sent a step forward to the cost-effectiveness analysis of air pollution control
interventions.
The model follows adult individuals’ health trajectories over time from the
states “healthy” to “dead” across three diseases that aim to represent the
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overall body of epidemiological evidence on the cardio-respiratory effects of
long-term exposure to particulate air pollution: chronic obstructive respira-
tory disease, coronary heart disease and lung cancer. Whilst the model was
applied to a UK case study its structure, which accounts for COPD and lung
cancer characteristics in terms of severity and survival pattern over time, as
well as its thorough use of available epidemiological evidence could be easily
replicated to quantify the health benefits of air pollution control elsewhere. In
a context of increasing interest for the chronic morbidity impacts of long-term
air pollution exposure, as exemplified by large-scale epidemiological projects
such as ESCAPE1 in Europe and MESA Air2 in the US, the model developed
in this thesis is expected to be of particular interest to HIA practitioners. It
should nevertheless be reminded that the model is parameterised using risk es-
timates from epidemiological studies performed in developed countries, where
linearity in health effects in response to a change in air pollution concentra-
tions has been found. Application of the model to assess air pollution control
interventions in developing countries should therefore take into account poten-
tial non linearity in effects, as suggested by existing attempts at extrapolating
concentration-response functions at high concentration levels (Pope III et al.,
2011; Burnett et al., 2014).
Demonstration that the current European guidelines for uncertainty analysis in
HIA of air pollution control underestimate decision uncertainty
Notwithstanding the recommended use of a triangular distribution for a
number of parameter (Holland, 2014), which in reality is difficult to parametrize
correctly since it is not linked to the data estimation process (Briggs et al.,
2006), current European guidelines3 to handling uncertainty in non statisti-
cally significant risk estimates of health effect were found to underestimate
decision uncertainty.
Since it seems indeed implausible that curbing air pollution could harm
1European Study of Cohorts for Air Pollution Effects.
2Multi-Ethnic Study of Atherosclerosis and Air Pollution.
3from the HRAPIE (Health Risks of Air Pollution In Europe) group.
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health, in the case where the risk estimates used to compute the expected
health benefits of air pollution reduction are non statistically significant, guide-
lines recommend to attribute a range of +/- 100% of mean effect and assuming
equal likelihood within the assigned value range. In others words, they suggest
to truncate both tails of the original distributions of parameters, thus assuming
that their mean value was correctly estimated but not their variance.
In this thesis, these guidelines were contrasted with an alternative approach
which truncated only the left-tail of original distributions, by assigning a value
of 1 to any value below 1 randomly drawn from risk estimates’ original distri-
butions. Comparative analysis showed that the probability of decision error
and thus, the EVPI and the option value to delay associated with investments
in air pollution reduction, were systematically significantly lower when follow-
ing the guidelines than under the alternative approach which solely ignored
non-plausible risk estimate values. It follows that, by suggesting greater cer-
tainty in outcomes than is the case, current European guidelines for uncertainty
analysis may misguide decision-making for air quality improvement.
Development of a framework to estimate COPD incidence by severity stages
The thesis developed a framework to estimate the age-specific annual prob-
ability of being diagnosed with COPD at a given severity stage, implied by the
underlying population prevalence of the disease estimated at a single point in
time and its relationship with disease incidence, progression and survival. By
addressing the issue of underdiagnosis embedded in primary care data, this
framework helps support the estimation of the total population health gain
associated with a primary prevention intervention that would reduce the risk
of developing COPD, or COPD patients’ risk of suffering from further adverse
effects. The framework was applied to the case of England in order to parame-
terise the model of air pollution impacts and to support cost-effectiveness eval-
uation of air pollution control in England and Wales and London. However,
since COPD underdiagnosis is a global issue (GOLD, 2014), the framework
could be applied to estimate COPD incidence by severity stages in other coun-
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tries, provided data on the underlying prevalence of the disease is available.
8.2.2 Empirical contributions
Supporting the UK air quality strategy
In addition to showing that existing estimates of life expectancy gain from
air quality improvement are likely to be seriously underestimated, and thus
to lead to suboptimal levels of air pollution reduction, this thesis provides the
first estimates of QALY gain and health care budget impact associated with
particulate air pollution control in England and Wales and London. Estimates
were computed for a unit decrement in PM2.5 and can be linearly rescaled to
a decrement of a different magnitude. These estimates which are summarised
in section 6 of Chapter 7, alongside with the analysis of levels of uncertainty
surrounding them, provide a concrete basis to support the UK air quality
strategy.
More specifically, modelling results underline the strong public health im-
plications of air pollution reduction. In London, reducing air concentrations
of fine particulates by 1µg/m3 (i.e. by 7%) is expected to generate to the cur-
rent population of adults aged above 40 more than 60,000 QALYs over their
lifetime. As a result, investing up to £500 million to achieve this level of pol-
lution reduction is highly likely to be cost-effective (less than 10% probability
of decision error), whether the investment is funded by the NHS or through
general taxation.
For larger investments, however, the source of money value of health em-
bedded in the funding mechanism, namely NHS resources or general taxation,
strongly influences cost-effectiveness results as consumer willingness to pay
for a QALY is much higher than the estimated NHS expenditure required to
deliver one QALY. It follows that the identification of the optimal level of
257
pollution reduction, as well as the decision about whether and for how long
to delay investments to gather further evidence, is expected to depend on the
choice of funding mechanism.
Evidence synthesis
At the time when the model was being developed, there was a gap in ev-
idence synthesis pertaining to the association between long term exposure to
fine particulate pollution and respectively all-cause mortality and lung cancer
development. This gap was filled by the work of Chapter 6, which results were
found to be consistent - or if a difference were found it could be fully explicated
- with meta-analyses published after completion of the present work.
First estimates of underlying incidence of COPD by severity stage in England
Application of the framework developed in Chapter 5 to the case of England,
provides the first estimates of the underlying incidence of COPD by GOLD
severity stages in England. These estimates could be used to support economic
evaluations of preventive interventions targeted at reducing the incidence of
COPD in this country, or to support analyses of budget impact and population
EVPI associated with health care technologies aimed at treating this disease.
8.3 Limitations
The Markov model of the health impacts of long-term exposure to par-
ticulate air pollution and its application to a UK case study, which are core
components of this thesis, present a number of limitations.
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First the model only builds on the linkages between concentration reduction
and health impacts, whilst the chain of impacts from intervention to health
effects is more complex. Indeed, reducing concentrations of air pollutants will
typically require a portfolio of sector-specific interventions targeting various
sources of emissions, e.g. transportation, industrial facilities, housing, which
impact on concentrations over time will be uncertain. As a result, the total
level of uncertainty surrounding the health and health care cost impacts of
particulate air pollution abatement is presently underestimated.
Second, Chapter 7 placed particular emphasis on uncertainty analysis and
in particular, on the value of reducing parameter uncertainty. However, as
underlined in Chapter 2, the impact of parameter uncertainty on decision un-
certainty is mediated by structural uncertainty, i.e. is conditional on the chosen
structure of the model. Scenarios analysis was performed for three different
approaches to handling risk estimates that were non statistically significant at
the conventional 5% level and according to two approaches to encompassing
health-related heterogeneity in susceptibility (namely by excluding or includ-
ing existing evidence related to heterogeneity). Whilst scenarios analysis shows
how cost-effectiveness results would change under different assumptions, it is
important to underline that not all sources of structural uncertainty are rep-
resented in these scenarios. In particular, whilst it was argued that excluding
evidence solely based on the conventional - but arbitrary - rules of statistical
inference would lead to bias, as mentioned in Chapter 4, the body of epidemio-
logical evidence on the association between air pollution exposure and COPD
is currently incomplete (Schikowski et al., 2013). Therefore, ideally, the un-
certainty as to whether to include or not COPD as relevant health endpoint
should also be investigated. An approach to addressing this specific issue and
more generally, to appropriately characterising structural uncertainty, will be
discussed in section 8.4.
Third, the model applies to adult individuals and thus, ignores effects in
children. It should, however, be underlined that documented adverse impacts
in children tend to be subclinical (Shannon et al., 2004; US EPA, 2009; Peled,
2011). These impacts are therefore expected, to some extent, to be captured
into a greater risk of developing chronic morbid conditions later in life. In-
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deed, it is generally accepted for instance, that chronic respiratory impacts
in adults partly derive from the worsening over time of subclinical conditions
developed since childhood (Eisner et al., 2010). It follows that the excess risk
of developing chronic morbid conditions at adult age may, at least in part,
be a consequence of subclinical symptoms associated with exposure during
childhood and/or adverse birth outcomes associated with exposure in utero.
On these grounds, whilst focusing on chronic clinical conditions developed at
adult age may not capture all potential benefits from air pollution reduction,
it has the advantage of avoiding potential double counting of effects. It should
also be noted that translating into QALY loss the adverse birth outcomes as-
sociated with air pollution exposure in utero, such as low birth weight and
pre-term birth, would require a certain number of assumptions that would
further contribute to uncertainty around outcomes.
Fourth, a source of uncertainty when assessing the impacts from pollution
abatement pertains to the time profile of the reduction in risks of experiencing
adverse effects following exposure decrement, which is known as the cessation
lag. This model uses the 20-year distributed cessation lag developed by the US
EPA, which assumes 30% of the risk reduction in year 1, an additional 12.5%
every year between year 2 to year 5 and the final 20% of risk reduction being
phased in gradually over year 6 to year 20 (US EPA, 2010). Although this lag
was carefully elaborated in light of empirical evidence from cohort, natural ex-
periments and smoking cessation studies, it remains largely uncertain (Walton,
2010). In addition, this lag was developed only to characterise dynamics in
mortality risk reduction. Indeed so far morbidity impacts (to the exception of
chronic bronchitis) have only been quantified with regards to acute exposure,
for which the change in risk may be assumed to be immediate. Nevertheless,
repeated cross-sectional analyses suggest that PM-related excess risks of mor-
bid events are also expected to be reversible in a short to middle time-horizon
following improvements in air quality (Downs et al., 2007; Schindler et al.,
2009; Schikowski et al., 2010).
Fifth, whilst the model accounts for COPD and lung cancer characteristics
in terms of severity levels and survival pattern over time, the CHD condition is
modelled via a single state. As a result, the modelling of CHD-related greater
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susceptibility to air pollution involved some level of extrapolation. Indeed,
the study informing differential susceptibility associated with CHD (Tonne &
Wilkinson, 2013) was based on patients aged 25 and above, who had an acute
coronary event. This endpoint represents a more severe health condition than
CHD as a whole. However, in light of evidence that the risk of acute coronary
event is a positive function of age (Simms et al., 2012), the risk estimate
estimated by Tonne & Wilkinson (2013) was only applied to individuals with
CHD aged 75 or above, which considerably restricted the subset of susceptible
individuals. The risk of potential overestimation of health benefits accruing to
individuals with CHD is therefore expected to be limited.
Sixth, the model does not consider effects from acute exposure. Whilst the
latter are irrelevant when considering life expectancy impacts (which are fully
captured in the risk estimates of excess mortality from chronic exposure), acute
effects are relevant for the quality of life dimension but also when assessing
health care cost impacts. It follows that the incorporation of acute effects, such
as asthma or COPD exacerbations for instance, would contribute to further
improve the model.
Seventh, the model does not assign any health care costs to “healthy” indi-
viduals - i.e. those without CHD, COPD or lung cancer - although the latter
will also cost to the health care system. Consequently, the health care costs
associated with air pollution reduction are presently underestimated. Never-
theless it should be underlined that the health benefits of air pollution control
are an order of magnitude higher than the QALY loss from health care cost
impacts. Indeed, based on an estimate of £13,000 as the NHS expenditure re-
quired to deliver one QALY, the QALY loss resulting from net health care costs
accounts for solely 2.8% and 3.7% of the health benefits in respectively London
and England and Wales. As a result, the underestimation of health care cost
impacts is unlikely to substantially affect the cost-effectiveness performance of
interventions that improve air quality.
Eighth, the model is built on the assumption of competitive risk between
disease pathways, which is partly challenged by the fact that COPD is a multi-
component systemic disease that is associated with a greater risk of cardio-
vascular events and lung cancer (GOLD, 2014). However, since the model’s
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estimates of un-discounted life years gain per person are in line with results
from past HIAs (when ignoring health-related differential susceptibility), the
assumption of competitive risk is not expected to have led to a substantial
underestimation of the total life expectancy impact.
Ninth, this thesis and the model developed focus on particulate air pollu-
tion. Particulate matter results from the release of a number of pollutants and
is therefore considered to be a good proxy for air quality (US EPA, 2012). In
addition, it is estimated to adversely affect population health more than any
other air pollutant (WHO, 2014). Nevertheless, effects from other air pollu-
tants such as nitrogen dioxide, may also need to be considered when considering
the benefits of improving air quality.
8.4 Further research
There are a number of avenues to extend the present work. First, it would
be of particular interest to combine the presently developed model of the health
impacts from air pollution exposure with dispersion modelling of air pollutants
emissions. This would enable the overall uncertainty associated with each link
of the chain of effects starting from the implementation of a specific interven-
tion (e.g. low emissions zone, bus retrofitting) to final health impacts to be
captured, as opposed to solely focusing on the uncertainty in health outcomes
following a reduction in concentrations.
A second extension of the present work would be to apply a more structured
approach to characterising structural uncertainty. Jackson et al. (2011) rec-
ommend to encompass all plausible structures of the model in a global model
and to express them via additional model parameters. To inform these pa-
rameters, the authors suggest two alternatives. The first consists in relying on
conventional methods used for choosing between statistical models, in order
to derive weights to apply to the expected costs and benefits associated with
each plausible model structure (for EVPI weights would have to be applied
to each simulated value as opposed to the model-specific expected cost and
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benefits across simulations). Akaike’s Information Criterion (AIC) was sug-
gested as a mean to derive those weights and is straightforward to apply if
structural uncertainty pertains to the inclusion/exclusion of a parameter for
which a p-value is available. The second alternative draws on expert elicita-
tion, whereby experts’ beliefs are translated into probability distributions for
uncertain parameters.
In the presently developed model, a combination of both approaches may be
applied with regards to the inclusion of: (i) COPD as relevant health endpoint
and (ii) health-related heterogeneity in susceptibility to air pollution expo-
sure. Indeed, both sources of uncertainty are informed by epidemiological risk
estimates, based on which one can easily derive differences in AIC between
a model structure that includes the effect of interest and one that excludes
it. Deriving model weights based on a single study may, however, not always
be the most appropriate, especially in the case of COPD where the overall
body of evidence include a number of studies pertaining to related respiratory
symptoms and subclinical conditions. In this case, AIC-based weights may be
combined with prior expert opinion in a Bayesian framework.
Third, the present finding that the identification of the optimal level of
pollution reduction and the decision to delay investments are expected to be
driven by the source of financing could be further explored. In particular, in
the present context of budget devolution whereby some NHS funds are to be
transferred to local authorities (as is to be the case of Greater Manchester
in April 2016), it would be of interest to investigate the impact on local air
quality strategies associated with the use of local governments’ budgets to fund
investments in emission reduction. Alternatively, if the intervention were to be
funded through taxation, cost-effectiveness analysis may be further refined by
accounting for the deadweight loss of taxation, i.e. the economic loss resulting
from inefficient activities undertaken as a result of tax introduction (Kay,
1980). A typical example of allocative inefficiency is the inefficient substitution
of taxed paid work for untaxed leisure.
Fourth, a topic of particular relevance to “Healthy Public policy”, which
was only touched upon in Chapter 3, pertains to the distributional analysis of
benefits of air pollution control among subgroups stratified by socio-economic
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status and the associated impacts on socio-economic related health inequal-
ity. Three main factors are expected to drive the socio-economic distribution
of impacts: (i) differential exposure, which is also linked to the issue of en-
vironmental justice when concentration levels are positively associated with
levels of deprivation; (ii) the existence of a socio-economic gradient in health
outcomes that impacts on individuals’ baseline risks of experiencing adverse
health events and (iii) differential susceptibility, i.e. systematic differences in
relative risks between socio-economic subgroups for which however, existing
epidemiological evidence to date remains inconclusive (Laurent et al., 2007).
It should be underlined that accounting for differential exposure to air pollu-
tion by socio-economic status would require to link the presently developed
model of health effects with dispersion modelling, as previously suggested.
Finally, an additional promising extension of the present work would consist
in considering health effects in children (without double-counting), as well as
wider societal effects than health care costs such as impacts on productivity,
school absenteeism and pension costs. Air pollution is expected to impact
productivity via two mechanisms: (i) premature exit of the job market due to
the development of chronic illnesses and (ii) work loss days due to exacerbations
of chronic morbid conditions following acute exposure. School absenteeism is
expected to be essentially linked to acute exposure, e.g. asthma exacerbations.
Consequently, in order to thoroughly encompass wider societal effects, health
effects from acute exposure in both children and adults would need to be
encompassed alongside effects from chronic exposure.
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Appendix A
Adjustment of mortality risk
estimates
General method
The following method is proposed to estimate the excess risk of mortality
from all other causes of death than cause x. The method is outlined for hazard
ratios which are rate ratios.
The hazard ratio of all cause mortality, HR4h,DeathAC , is defined such that:
HR4h,DeathAC =
h(t)e(DeathAC)
h(t)ne(DeathAC)
(A.1)
where h(t)e(DeathAC) and h(t)ne(DeathAC) denote the instantaneous mortal-
ity rate from all causes (AC) per period t in respectively the exposed and
non-exposed groups and 4h is the difference in hazard exposure between the
two groups.
Assuming death from cause x (denoted Deathx) and death from all other
causes than x (denoted DeathAOC) are mutually exclusive events, we obtain:
HR4h,DeathAC =
h(t)e(DeathAOC) + h(t)e(Deathx)
h(t)ne(DeathAC)
(A.2)
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This implies that:
h(t)e(DeathAOC) = HR4h,DeathACh(t)ne(DeathAC)− h(t)e(Deathx) (A.3)
where:
h(t)e(Deathx) = HR4h,Deathxh(t)ne(Deathx) (A.4)
Dividing expression A.3 by h(t)ne(DeathAOC) yields:
HR4h,DeathAOC = HR4h,DeathAC
h(t)ne(DeathAC)
h(t)ne(DeathAOC)
−HR4h,Deathx
h(t)ne(Deathx)
h(t)ne(DeathAOC)
(A.5)
Therefore, the hazard ratio of mortality from all other causes than x, can
be expressed as a function of:
(i) the hazard ratio of mortality from all causes;
(ii) the hazard ratio of mortality from cause x;
(iii) death rates (death from x, death from AOC, death from AC) in the
non-exposed group, which may be proxied by baseline mortality rates in the
target population of the intervention under assessment.
Adjustment for evaluating the case study
One parameter required for the modelling was the hazard ratio (HR) of
mortality from all causes of death than CHD. The adjustment was performed
using:
1- The central value of hazard ratios of: (i) mortality from all-cause and (ii)
mortality from CHD from Pope III et al. (2002).
2- Population-weighted average annual rates of death in the population of
England aged 40 and above, provided by the UK Office for National Statistics.
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Plugging-in the corresponding values into equation A.5, we obtain:
HR4h,DeathAOC|CHD = 1.07
0.000330
0.000278
+ 1.11
0.000052
0.000278
= 1.05 (A.6)
where 4h represents an increment in PM2.5 concentrations by 10µg/m3 and
AOC stands for all other causes of death than CHD.
(For 4h = −1µg/m3, HR4h,DeathAOC|CHD = 0.995 - see section C)
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Appendix B
Risk estimates: original values
and rescaling
Rescaling of risk estimates (RE) to a decrement in PM2.5 concentration of
1µg/m3 was performed using logarithmic multiplicative scaling, based on the
fact that risk estimates were obtained using log-linear statistical models. As
shown in Chapter 2, this implies that :
RE4PM2.5 = exp(β ×4PM2.5)
⇒ RE4PM2.5=−1µg/m3 = (RE4PM2.5=xµg/m3)
−1
x
The original values of risk estimates taken from the epidemiological litera-
ture are provided in Table B.1.
Parameter Source Values (95% CI) 4PM2.5
RRDev.CHD Gan et al. (2011) 1.02(1.0− 1.05) +1.38µg/m3
HRDeathAC Pope III et al. (2002) 1.06(1.02− 1.11) +10µg/m3
HRDeathAC|CHD Zanobetti and Schwartz (2007) (a) 1.34(1.27− 1.52) +10µg/m3
Table B.1: Risk estimates original values.
(a) Study population was individuals aged 65 years old and above.
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Appendix C
Distribution of London adult
population (40+) by age groups
and gender
Distribution of London adult population (40+) by age groups and gender, based on 2011
census.
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Appendix D
Systematic search: database
queries
271
Figure D.1: Pubmed search query. Data 26/04/2014.
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Figure D.2: Embase search query. Data 26/04/2014.
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(a) Studies focusing on females or both gender
(b) Studies focusing on males or both gender
Figure D.3: Sub-group analysis by gender for the association between long-term exposure to
PM2.5 and all-cause mortality (Random effect model - Pooled hazard ratio per 10 µg/m
3).
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Appendix E
Meta-analysis: sub-group
analysis by gender
275
(a) Studies focusing on females or both gender
(b) Studies focusing on males or both gender
Figure E.1: Sub-group analysis by gender for the association between long-term exposure to
PM2.5 and all-cause mortality (Random effect model - Pooled hazard ratio per 10 µg/m
3).
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